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ABSTRACT 
Autism Spectrum Disorders among Adults: Burden of Healthcare Services’ 
Utilization and Expenditures 
Rini Vohra 
STUDY 1 
Background: Individuals with ASD have extensive comorbidities which affect their health related quality of life. 
The current literature lacks documentation of prevalence of different types of comorbidities and their association 
with healthcare utilization and expenditures among adults with ASD as compared to adults without ASD.  
Aim: To determine: 1) the differences in prevalence of psychiatric, non-psychiatric comorbidities, other health 
conditions, healthcare utilization, and expenditures among adults with and without ASD; and 2) the association of 
type of comorbidity with healthcare utilization and expenditures of adults with ASD. 
Method: A retrospective cohort study using claims data from three state Medicaid Analytic eXtract was conducted. 
Adults aged 22-64 years with ASD (ICD9-CM code: 299.xx) with at least one inpatient or two outpatient claims on 
separate service dates who were continuously enrolled between January 1, 2000 to December 31, 2008 were 
identified.  ASD cases were matched to no ASD controls by age, sex, and race using propensity score matching 
(1:3).  Baseline and outcome differences across cases and controls were examined using bivariate analyses for 
categorical (chi-square) and continuous independent variables (t-tests).  All cause health care utilization (outpatient 
visits, inpatient hospitalizations, emergency room, and prescription drug use), and associated health care costs were 
assessed during the follow-up year. Multivariate multinomial logistic regressions for healthcare utilization and 
generalized linear models with gamma distribution for expenditures were conducted to compare healthcare 
utilization and expenditures among adults with and without ASD.  Association of type of comorbidity with 
healthcare utilization (binary and multinomial logistic regressions) and expenditures (generalized linear models with 
gamma distribution) were also analyzed among adults with ASD.  Multivariate regression analyses were adjusted for 
state, identification year, patient socio-demographics, baseline prescription drug use, and county characteristics.  
Results:  
Comorbidities: Around 80% of adults with ASD (n = 1,772) had a psychiatric comorbidity as compared 41% of 
adults without ASD.  Prevalence of a non-psychiatric comorbidity was significantly lower among adults with ASD 
(40%ASD vs. 45%noASD). Almost 70% of adults with ASD had comorbid intellectual disability. Adults with ASD 
had higher rates of anxiety (12.2% ASD vs. 5.6% noASD), attention deficit disorders/attention deficit hyperactivity 
disorders (ADD/ADHD) (8.2% ASD vs. 0.7% noASD), schizophrenia (16.6% ASD vs. 11.1% noASD), and 
gastrointestinal disorders (12.6% ASD vs.11% noASD) as compared to adults without ASD.  
Rates of other health conditions that were significantly higher among adults with ASD as compared to adults 
without ASD were: epilepsy (22%ASD vs. 5%noASD), thyroid disease (5%ASD vs. 1%noASD), lipid metabolism 
disorders (5%ASD vs. 3%noASD), other endocrine/nutrition disorders (11%ASD vs. 4% noASD)  hematological 
disorders (7%ASD vs. 5%noASD), genito-urinary disorders (10%ASD vs. 8% noASD), infections (22%ASD vs. 
15% noASD), skin disorders (21%ASD vs. 9% noASD), and paralysis (6%ASD vs. 3% noASD).  Adults with ASD 
also had higher prevalence rate of other disabilities such as blindness (5%ASD vs. 4% noASD) and hearing 
impairments (19%ASD vs. 4% noASD).  
Healthcare utilization and expenditures: The mean number of OT visits (32ASD vs. 8noASD) and Rx claims 
(51ASD vs. 24noASD) per year were significantly greater for adults with ASD as compared to adults without ASD.  
The mean average length of stay was also higher for adults with ASD (10ASD vs. 8noASD days).  Adults with ASD 
exhibited higher mean annual OT ($4,375 ASD vs. $824 noASD), ER ($15,929 ASD vs. $2,598 noASD), Rx 
($6,067 ASD vs. $3,144 noASD) and total expenditures ($13,700 ASD vs. $8,560noASD).  
  
Adults with ASD were two times more likely to have >=4 OT visits per year as compared to adults without ASD 
(AOR = 2.73, 95% CI = 2.31-3.22), five times more likely to have >=18 Rx claims than adults without ASD (AOR 
= 4.79, 95% CI = 4.09-5.60).  The likelihood of  >1 IP visit (AOR = 0.70, 95% CI = 0.51-0.96) or >1 ER visit (AOR 
= 0.76, 95% CI = 0.61-0.93) in a year was 30% and 24% lower among adults with ASD as compared to adults 
without ASD. Among users, the expenditures for adults with ASD were significantly higher for OT visits, ER visits, 
and Rx claims as compared to adults without ASD after adjusting for selected characteristics. Adults with ASD had 
additional $824 OT expenditures, $8,932 ER expenditures, and $1,499 Rx expenditures per year as compared to 
adults without ASD.  The average adjusted total Medicaid expenditures (sum of OT, RX, and IP) were $1,159 
higher per year for adults with ASD as compared to adults without ASD, even after controlling for type of 
comorbidity. On an average, presence of a psychiatric and a non-psychiatric comorbidity among adults with ASD 
costed an additional $4,952 and $5,084 per year. 
Conclusion:  
Psychiatric comorbidities such as intellectual disabilities, anxiety, ADD/ADHD, and schizophrenia are very 
common among adults with ASD and non-psychiatric comorbidities such as gastrointestinal disorders are also 
highly common. Other than major comorbidities, other health conditions such as epilepsy, thyroid, lipid metabolism 
disorders, genito-urinary disorders, skin disorders, and infections are also highly prevalent in adults with ASD as 
compared to adults without ASD. Adults with ASD exhibit excess healthcare utilization in form of higher number of 
outpatient visits and prescription drug claims in a year and annual total Medicaid expenditures as compared to adults 
without ASD.  Medicaid coverage of healthcare services for adults with ASD is substantial and state programs bear 
high costs of such services.  
STUDY 2 
Background: The use of emergency department (ED) visits among adults with psychiatric needs is known to be very 
high, yet there are no comprehensive studies that have characterized ED use among adults with autism spectrum 
disorders (ASD). Due to the lack of clarity on adult ASD treatment guidelines and possible delayed/foregone care in 
outpatient settings, adults with ASD may be at a substantial risk of high ED use and costs.  
Objectives: 1) To examine the trends in ED visits and mean total ED charges for adults with ASD over a period of 6 
years; 2) To examine and compare the types of ED use (psychiatric, non-psychiatric, and injury) among adults with 
and without ASD.  
Methods: A cross-sectional study using discharge level data from the Nationwide Emergency Department Sample 
(NEDS; 2006-2011) was conducted to the examine trends and characteristics of ED visits among adults aged 22-64 
years, with and without ASD (ICD9-CM code: 299.xx).  ASD cases were matched to no ASD controls by age and 
gender using propensity score matching (1:3). Trends are presented as annual weighted rates and mean total charges 
for all, psychiatric (principal diagnosis of a psychiatric disorder), non-psychiatric (principal diagnosis of a non-
psychiatric disorder), and injury (any) visits among adults with ASD.  Chi square analyses and t-tests were 
conducted to examine sub group differences in socio-demographic, hospital, and patient disposition characteristics 
across adults with and without ASD. Weighted rates of psychiatric, non-psychiatric, and injury visits were compared 
between adults with and without ASD.  Multivariate adjusted logistic regressions were run to examine the likelihood 
of a psychiatric, non-psychiatric, and an injury visit among adults with ASD as compared to adults without ASD. All 
analyses adjusted for the NEDS complex survey design. 
Results: Around 0.4% (n = 25,527) of ED visits were associated with an adult ASD diagnosis in the unmatched 
sample. The rates of ED visits among adults with ASD more than doubled from 2006 to 2011 (10,047 to 23,992 per 
100,000 admissions).  Around one-third of the ED visits among adults with ASD led to an inpatient hospitalization. 
The rates of specific ED visits among adults with and without ASD were: psychiatric (15%ASD vs. 4.2%noASD), 
non-psychiatric (16%ASD vs. 14%noASD), and injury (24%ASD vs. 28%noASD). Most common ED visits 
associated with adults with ASD were: epilepsy (8.8%), falls (6.5%), schizophrenia (3.8%), and respiratory 
disorders (3.8%).  Adults with ASD were found to be more likely to have a psychiatric visit (AOR = 2.63, 95% CI = 
2.41-2.88), a non-psychiatric visit (AOR = 1.07, 95% CI = 1.01-1.14), and an injury visit (AOR = 1.10, 95% CI = 
  
1.04-1.16) as compared to adults without ASD.  Mean total ED charges for adults with ASD were 2.3 times higher 
than adults without ASD. 
Conclusion: Rates of ED visits among adults with ASD are on the rise. Adults with ASD use ED for different 
reasons which are not restricted to psychiatric needs, but also extend to non-psychiatric needs and injuries. ED visits 
among adults with ASD are also associated with significantly greater hospitalization rates as compared to adults 
without ASD.  Mean total ED charges for adults with ASD are almost twice as high as charges for adults without 
ASD. Prevalence, risk factors, and burden of ED utilization among adults with ASD is understudied and future 
studies should examine the reasons and impact of such ED utilization on long term healthcare costs. 
STUDY 3 
Background: Lack of absolute gold standard ASD treatment, approved guidelines, and strong evidence based 
treatments lead to greater off label prescribing with no information on the long term effects of high prescription drug 
use among individuals with ASD. Extent of general (six or more drug classes in a year) and psychotropic (three or 
more psychotropic drug classes within a period of 90 days) polypharmacy among adults with ASD has not been 
studied till date.  
Aim: 1) To examine and compare the types of prescription drug use and rates of general and psychotropic 
polypharmacy among adults with and without ASD; 2) To examine predictors of polypharmacy among adults with 
ASD.  
Method: A retrospective cross sectional study using claims data from three state Medicaid Analytic eXtract was 
conducted. Adults aged 22-64 years with ASD (ICD9-CM code: 299.xx) who were continuously enrolled between 
January 1, 2000 to December 31, 2008 were identified. ASD cases were 1:3 matched to no ASD controls by age, 
sex, and race using propensity score matching. Rates of different prescription drug classes, general polypharmacy, 
and psychotropic polypharmacy among adults with and without ASD were compared using chi-square tests. T-tests 
were conducted to examine the differences in mean annual number of claims for specific drug classes between 
adults with and without ASD. Multivariate multinomial logistic regressions were run to examine the likelihood of 
general and psychotropic drug polypharmacy among adults with ASD as compared to adults without ASD, after 
adjusting for identification year, patient socio-demographics, county characteristics, and number of comorbidities.  
Results: Almost 70% of adults with ASD had more than 25 prescription drug (Rx) claim in the identification year as 
compared to 28% of adults without ASD. Around 85% of adults with ASD used psychotropic drugs as compared to 
42% of adults without ASD. The rates of specific psychotropic drug classes were: antipsychotics (66%ASD vs. 
20%noASD), anticonvulsants (59%ASD vs. 20%noASD), antidepressants (37%ASD vs. 26%noASD), 
anxiolytics/hypnotics/sedatives (21%ASD vs. 11%noASD), and CNS stimulants (1.9%ASD vs. 1%noASD). Around 
half of adults with ASD used six or more Rx classes per year as compared to one-third of adults without ASD.  
Among adults with ASD who used six or more Rx classes per year, the most common classes were: antipsychotics 
(78%), anticonvulsants (75%), antimicrobials (67%), dermatologic agents (64%), respiratory agents (59%), and 
gastrointestinal agents (52%). A substantial proportion of adults with ASD (19%) also engaged in psychotropic 
polypharmacy as compared to adults without ASD (6%). After adjusting for selected characteristics, adults with 
ASD were 17% more likely and 40% more likely to engage in general and psychotropic polypharmacy, respectively, 
as compared to adults without ASD.   
Conclusion: Prescription drug use, general polypharmacy, and psychotropic polypharmacy is significantly and 
substantially higher among adults with ASD than adults without ASD. Half of adults with ASD use six or more drug 
classes in a year and 19% of them use three or more psychotropic drug classes within a 90 day period. Higher 
prescription drug use among adults with ASD was not restricted to psychotropic drugs, but extended to prescriptions 
alleviating other medical needs including dermatologic agents, respiratory agents, cardiovascular agents, 
gastrointestinal agents, antiparkinsonian agents, and many others. The study highlights considerable pharmaceuticals 
use by adults with ASD as well as practice of off-label prescriptions for adults with ASD by healthcare providers. 
Even though various clinical trials have provided with off-label options for pharmacological treatment of adults with 
  
ASD, such treatments should still be administered based on case by case analysis with due consideration for risk-
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Autism Spectrum Disorders (ASD) is a lifelong neuro-developmental disability 
associated with impaired functioning skills and restricted, repetitive, and stereotyped patterns of 
behavior (American Psychiatric Association, 2000). Even though diagnostic statistical manual V 
(2013) provides a single definition of ASD with three levels of severity, in our study we define 
ASD as anyone with  autistic disorder, Asperger’s syndrome, pervasive developmental disorders 
– not otherwise specified (PDD-NOS), and other rare PDDs (ICD9-CM code: 299.xx). This is 
because the study period for our three part research is restricted till the year 2011, when the new 
diagnostic criteria were not in effect.  Many individuals with ASD experience multiple 
challenging behaviors (Jang, Dixon, Tarbox, & Granpeesheh, 2011; Matson & Rivet, 2008; 
Murphy et al., 2005) and intellectual disabilities (Kraijer, 1999; La Malfa, Lassi, Bertelli, 
Salvini, & Placidi, 2004; Morgan et al., 2002) which hamper their communicating, social, and 
learning capabilities (Harris & Handleman, 1990; Kanner, 1943; Tonge & Brereton, 2011).  In 
addition to the core symptoms of ASD, individuals with the condition are also affected by 
extensive psychiatric (Hofvander et al., 2009a; Leyfer et al., 2006; Lugnegard, Hallerback, & 
Gillberg, 2011a; van Steensel, Bogels, & de Bruin, 2013) and non-psychiatric comorbidities 
(Buie et al., 2010; Fombonne, 2003; Horvath, Papadimitriou, Rabsztyn, Drachenberg, & Tildon, 
1999).  Prevalence of Autism Spectrum Disorders (ASD) has increased considerably over the 
past few decades in the Unites States (Developmental Disabilities Monitoring Network 
Surveillance Year 2010 Principal Investigators & Centers for Disease Control and Prevention 
(CDC), 2014) as well as in other countries (Lazoff, Zhong, Piperni, & Fombonne, 2010).  
Among children, every 1 in 68 children have ASD in the US States (Developmental Disabilities 
Monitoring Network Surveillance Year 2010 Principal Investigators & Centers for Disease 




unknown in the US, every 1 in 100 adults are known to suffer from this condition in the UK 
(Brugha et al., 2011). 
Individuals with ASD have considerable healthcare needs and exhibit greater use of 
healthcare services and costs as compared to individuals without ASD (Autism Speaks, 2012; 
Bitsko et al., 2009; Gurney, McPheeters, & Davis, 2006; Knapp, Romeo, & Beecham, 2009; 
Liptak, Stuart, & Auinger, 2006; Ruble, Heflinger, Renfrew, & Saunders, 2005; Siklos & Kerns, 
2006; Wang & Leslie, 2010a). The burden on caregivers/families of individuals with ASD is also 
known to be extremely high, adversely affecting caregiver health related quality of life and other 
family health outcomes (Cidav, Lawer, Marcus, & Mandell, 2013; Johnson, Frenn, Feetham, & 
Simpson, 2011; Khanna et al., 2011; Kogan et al., 2008; Wang & Leslie, 2010b). 
Need for Research on Adults with ASD 
 Autistic features persist into the adulthood and continue to manifest symptoms of 
diagnostic autism (Billstedt, Gillberg, & Gillberg, 2007; Seltzer et al., 2003). Similar to children, 
adults with ASD also have greater healthcare needs (Billstedt, Gillberg, & Gillberg, 2005; 
Magiati, Tay, & Howlin, 2014). Previous research has mostly focused on assessing healthcare 
and economic outcomes for children with ASD (Cidav et al., 2013; Croen, Najjar, Ray, 
Lotspeich, & Bernal, 2006; Mandell et al., 2008a).  A systematic review (Mukaetova-Ladinska, 
Perry, Baron, Povey, & Autism Ageing Writing Group, 2012a) found that most of the research 
studies concerning ageing in autism have been restricted to case reports and review articles 
which have discussed problems with diagnosis of autism in older adults (van Rooijen, 2005), 
clinical symptomatology of autism in older individuals (Lugnegard, Hallerback, & Gillberg, 




(Lugnegard et al., 2011b; Unenge Hallerback, Lugnegard, & Gillberg, 2012), and clinical 
presentations and assessments of elderly cases with autism (van Niekerk et al., 2011).  
With a substantial number of children with ASD transitioning to adulthood and more 
number of individuals receiving their “first ever” adult ASD diagnosis than ever before 
(American Psychiatric Association, 2012; MESIBOV & HANDLAN, 1997; Vanbergeijk, Klin, 
& Volkmar, 2008), very little is known about the healthcare needs, healthcare services’ use and 
expenditures among adults with ASD. Therefore, studies that investigate the patterns of 
healthcare use, extent of healthcare utilization, and healthcare expenditures among adults with 
ASD are required to understand the healthcare needs of this population (Lunsky et al., 2009; 
Mandell, 2008; Mouridsen, Bronnum-Hansen, Rich, & Isager, 2008; Tsakanikos, Costello, Holt, 
Sturmey, & Bouras, 2007).  
In addition to the tremendous gap in literature about healthcare needs and services use 
among adults with ASD (Shattuck et al., 2012), there are several other reasons for examining the 
healthcare and economic outcomes of adults with ASD:  
a) Adult ASD is a complex issue because of constantly changing diagnosis criteria (Huerta, 
Bishop, Duncan, Hus, & Lord, 2012). There are a certain proportion of individuals who 
receive ASD diagnosis later in adulthood. (Marriage, Wolverton, & Marriage, 2009) 
reviewed medical charts to examine differences in adult ASD functioning by age of 
diagnoses (diagnosed as a child, youth, or adult). The study found that adult functioning 
is more variable and difficult to predict due to the changing evaluation criteria which may 
lead to varying healthcare outcomes for adults as compared to the younger groups, due to 




b) Many studies have shown that healthcare providers (physicians, psychologists, 
psychiatrists, and mental health specialists) report lack of self-perceived competency and 
diagnostic abilities when treating adults with ASD (Bruder, Kerins, Mazzarella, Sims, & 
Stein, 2012; Golnik, Ireland, & Borowsky, 2009; Oskoui & Wolfson, 2012). Also, there 
is a lack of clarity in appropriate adult ASD treatment and referral guidelines in the US 
making the prognosis complex and difficult for both the patients and the providers 
(Bruder, Kerins, Mazzarella, Sims, & Stein, 2012; Golnik, Ireland, & Borowsky, 2009; 
Heidgerken, Geffken, Modi, & Frakey, 2005; Oskoui & Wolfson, 2012). In such an 
environment, studies on adults with ASD that establish the healthcare needs of this 
population are needed to help deliver better behavioral and social outcomes earlier in 
their lifespans. Such health outcomes may include improved activities of daily living and 
employment opportunities, alleviated core symptoms, diminished social difficulties, and 
burden for caregivers, and consequently lower healthcare costs to society and individuals 
with ASD.  
c) There is lack of evidence base and absence of robust clinical trials for pharmacological 
treatment and interventions for adults with ASD (Broadstock, Doughty, & Eggleston, 
2007; Brugha, Doos, Tempier, Einfeld, & Howlin, 2015). Variations in symptomatology 
(Rumsey, Rapoport, & Sceery, 1985) imply that pharmacological studies of children are 
not directly transferable to older populations, and vice versa. Therefore, making 
intervention and treatment decisions for adults with ASD are often dealt on a case by case 





d) Taking care of an individual with ASD is associated with very high expenditures and 
lifetime costs (Chambers, Kidron, Spain, & American Institutes, 2004; Knapp et al., 
2009; Leslie & Martin, 2007; Mandell, Cao, Ittenbach, & Pinto-Martin, 2006; Peacock, 
Amendah, Ouyang, & Grosse, 2012; Wang & Leslie, 2010a). A recent study estimated 
that the cost of supporting an individual with an ASD is $1.4 million in the United States 
and £0.92 million (US $1.4 million) in the United Kingdom (Buescher, Cidav, Knapp, & 
Mandell, 2014). 
e) Adults with ASD report lower satisfaction with their physicians and greater unmet 
healthcare needs as compared to adults without ASD (Nicolaidis et al., 2013; Pellicano, 
Dinsmore, & Charman, 2014). Although very few studies have examined the issue of 
dissatisfaction for adults with ASD with healthcare services, there is a need to identify 
core deficits in provision of services and reasons for higher unmet needs among this 




Three Part Research 
The proposed research work aims to address the aforementioned gaps in the literature by 
examining three aspects of healthcare burden (Figure 1) associated with adults with ASD. We 
will also compare these aspects between adults with and without ASD.  
1) Burden of comorbidities and their impact on healthcare utilization and expenditures: 
describing the prevalence of psychiatric, non-psychiatric comorbidities, and other health 
conditions among adults with and without ASD and their impact on healthcare use and 
expenditures; 
2)  Burden of emergency department (ED) use: describing 6 year ED trends, types of ED 
visits (psychiatric, non-psychiatric, and injury), and associated total ED charges; and 
3) Burden of medication use (general and psychotropic polypharmacy)  




(Utilization & Expenditures) 
Emergency Department 
(Injuries, Psychiatric, and 
Non-Psychiatric Visits) 
Polypharmacy  
(General and Psychotropic) 
Comorbidity 
(Psychiatric, Non-Psychiatric, 




Study 1. The Burden of Comorbidities, Healthcare Utilization, and 
Expenditures in Adult Fee-for-Service Medicaid Enrollees with and without 
Autism Spectrum Disorders (ASD) 
 
Aim: To determine the differences in prevalence of psychiatric, non-psychiatric comorbidities, 
other health conditions, healthcare utilization, and expenditures among adults with and without 
ASD.  To determine the association of type of comorbidity on healthcare utilization and 
expenditures of adults with ASD. 
 
It is well known that individuals with ASD are affected by numerous psychiatric and non-
psychiatric comorbidities that have a negative impact on their health-related quality of life (Buie 
et al., 2010; Khanna et al., 2011; Levy et al., 2010; Lugnegard et al., 2011a; Mandell et al., 2006; 
Maski, Jeste, & Spence, 2011; McElhanon, McCracken, Karpen, & Sharp, 2014).  Such 
comorbidities not only have an adverse effect on core autistic symptoms (Garcia-Villamisar & 
Rojahn, 2013) but also on adult’s healthcare needs and use (Lunsky, Gracey, & Bradley, 2009) 
such as extended length of stays in the hospital (Palucka & Lunsky, 2007).  However, to the best 
of our knowledge, no study in the literature has outlined the comorbidity distribution and 
differential associations of comorbidity types with healthcare utilization and expenditures among 
adults with ASD.   
Our study will examine the prevalence of psychiatric and non-psychiatric comorbidities 
among adults with ASD as compared to adults without ASD.  A psychiatric comorbidity will be 
defined as any co-occurring diagnosis of psychiatric disorders such as adjustment disorders, 
alcohol use disorders (AUD), anxiety disorders, attention deficit disorders & conduct behavior 
disorders (ADD), developmental disorders, mood disorders including depressive disorders and 
bipolar disorder, personality disorders, schizophrenia & other psychotic disorders, substance use 
disorders (SUD).  A non-psychiatric comorbidity will be identified as any co-occurring diagnosis 




gastrointestinal conditions, and respiratory conditions. We will examine the association of these 
comorbidities with healthcare utilization and expenditures among adults with ASD as compared 
to adults without ASD. We hypothesize that adults with ASD will have a significantly higher 
prevalence of both psychiatric and non-psychiatric comorbidities as compared to adults without 
ASD. Both types of comorbidities will also be associated with greater healthcare utilization and 
expenditures for adults with and without ASD.  
Need for Study  
Despite few studies that have described occurrence of specific psychiatric comorbidities 
among adults with ASD (Buck et al., 2014a; Lugnegard et al., 2011a; Lunsky et al., 2009), there 
is a lack of prevalence estimates of other comorbidities such as cardiovascular conditions and 
diabetes which could be equally prevalent and of prime importance among adults with ASD.  In 
addition, other studies concerning comorbidities in adults with ASD have either included very 
restricted sample sizes or specific populations with intellectual disabilities (ID), or included 
specific psychiatry clinic settings with a significant chance of referral bias. The lack of large 
sample sizes and restricted study environments does not allow drawing specific conclusions on 
burden of comorbidities.  
Significance of Study  
A follow up study on patients whose ASD was ascertained in the 1980s as part of 
Utah/UCLA Autism Epidemiologic study was conducted by (Bilder et al., 2013). The authors 
found a relative risk of 9.95 mortality rate among autistic patients in a time span of 20-29 years 
(age range = 27 to 54). Some of the major causes of death were epileptic seizures (6 of 29 
deaths), lethal respiratory events (9 of 29 deaths), and cardiac deaths including myocarditis, 
arrhythmia, and congestive heart failure, and congenital heart disease (5 of 29 deaths). Therefore, 




the needs of this population and address them earlier in life, which will help reduce preventable 
hospitalizations and mortality events among adults with ASD.  Also, since ASD usually is 
considered a psychiatric/neurological condition, most of the psychiatric needs may be met in 
mental health settings but lack of care coordination among different primary and specialty 
healthcare providers may lead to greater unmet medical needs. The current study aims to address 
such shortfall of the current literature. This study will also explain the impact of comorbidities on 
healthcare utilization and expenditures which could be used as a proxy representation of 
healthcare needs of adults with ASD.  Policymakers can use this information to stress the need 
for better case management in primary care and specialty settings to reduce morbidity, poor 
prognosis, and longer length of stays in hospitals among adults with ASD.  
Specific Aims 
Objective 1.1:  To identify the excess healthcare utilization and expenditures (outpatient, 
inpatient, emergency department, and prescription drug use) for adults aged 22-64 years with 
ASD as compared to adults without ASD.  
Hypothesis 1.1: The healthcare utilization and expenditures among adults with ASD will be 
significantly greater as compared to adults without ASD.   
Objective 1.2: To examine and compare the prevalence of psychiatric and non-psychiatric 
comorbidities among adults with and without ASD.  
Hypothesis 1.2: The prevalence of both psychiatric and non-psychiatric comorbidities will be 




Objective 1.3:  To examine and compare the impact of psychiatric and non-psychiatric 
comorbidities on healthcare utilization and expenditures for adults with and without ASD (Total, 
outpatient, inpatient, emergency department, and prescription drug use).  
Hypothesis 1.3:  Both psychiatric and non-psychiatric comorbidities will have a greater impact 
on healthcare utilization and expenditures associated with adults with ASD as compared to adults 
without ASD.  
Data Collection 
We will examine the prevalence of comorbidities, healthcare utilization, and expenditures 
among adults with and without ASD using three state Medicaid administrative claims data (IL, 
NY, and TX; 2000-2008). Medicaid is the single largest payer for individuals with ASD (Ruble 
et al., 2005) and utilization of Medicaid provided healthcare services among individuals with 
ASD is only expected to increase (Semansky, Xie, & Mandell, 2011a).  Medicaid provides a 
wide variety of  services to individuals with ASD (Arjun, Hope, Guyer, & Alker, 2011) 
including providing  primary and secondary health insurance coverage for healthcare services, 
home and community based waivers, screening and diagnostic services, behavioral support, in 
home care, skill training/acquisition, respite care, case management, supported employment, 
service coordination, self-directed services, and parent training and education (Mauch, Pfefferle, 
Booker, Pustell, & Levin, 2011).  
Healthcare administrative claims, especially state Medicaid databases have been 
extensively used for ASD research among children with validated algorithms for identification of 
ASD (Khanna, Jariwala, & West-Strum, 2013; Mandell et al., 2008a; Maski et al., 2011; Peacock 
et al., 2012; Spencer et al., 2013).  Knowing that Medicaid serves as a critical healthcare service 




Medicaid claims will help provide a complete picture of healthcare utilization and expenditures 
as well as generate evidence for extensive healthcare needs of this population.  This evidence can 
be used to create better state policies and expand Medicaid healthcare coverage to other essential 
and costly healthcare services for adults with ASD. We selected IL, NY, and TX because of 
lower managed care penetration rates and greater fee-for-service enrollment during the past 





Study 2. The Burden of Emergency Department (ED) Use among Adults with 
and without ASD 
Aim: To examine the trends and types of ED use among adults with ASD as compared to adults 
without ASD over a period of 6 years. To determine the economic burden of ED use among 
adults with ASD as compared to adults without ASD.  
 
The second study will focus on an understudied, yet very critical aspect of healthcare 
services for adults with and without ASD.  ED use is extremely high among patients with 
psychiatric needs (Hazlett, McCarthy, Londner, & Onyike, 2004; Larkin, Claassen, Emond, 
Pelletier, & Camargo, 2005; Mahajan et al., 2009; Sills & Bland, 2002a).  Almost 38% of ED 
visits in the US are associated with a psychiatric disorder. Considering the psychiatric needs of 
individuals with ASD (Simonoff et al., 2008), presence of extensive comorbidities such as 
behavioral disturbance and conduct disorders (Matson & Rivet, 2008), and previous studies 
documenting substantial ED use among children with ASD (Croen et al., 2006; Kalb, Stuart, 
Freedman, Zablotsky, & Vasa, 2012), it is expected that ED use will be substantially high among 
the adult ASD population as well.  
We will examine and compare the trends in rates of ED use and total ED charges for 
adults with and without ASD across a span of 6 years (2006-2011).  We will also compare the 
rates of specific ED visits such as psychiatric, non-psychiatric, and injury visits among adults 
with and without ASD.  A psychiatric ED visit will be identified as any visit with a principal 
diagnosis of a psychiatric disorder such as adjustment disorders, alcohol use disorders (AUD), 
anxiety disorders, attention deficit disorders & conduct behavior disorders (ADD), 
developmental disorders, mood disorders including depressive disorders and bipolar disorder, 
personality disorders, schizophrenia & other psychotic disorders, substance use disorders (SUD).  




disorder such as cancer, cardiovascular conditions, diabetes, epilepsy, gastrointestinal conditions, 
and respiratory conditions. An injury visit will be identified as a visit associated with any injury 
such as: assault, cutting, drowning, fall, fire, machinery, poison, being struck, suffocation, 
suicidal ideation, and self-harm. We hypothesize that ED visit rates will increase over the 6 year 
period for adults with ASD. Adults with ASD will also be more likely to have a psychiatric and 
injury ED visit as well as higher total ED charges as compared to adults without ASD.  
Need for Study  
In the US, at least one-third of ED visits are avoidable/non-urgent/ambulatory care 
sensitive and treatable in primary care settings and over $18 billion dollars are spent annually on 
such avoidable ED visits (Choudhry et al., 2007). Therefore, identifying and examining at high 
risk and frequent ED users will help reduce long term ED costs. Studying the pattern of ED use 
is also equally critical for adults with ASD because increasing age has been found to be 
associated with frequent visits to ED (Pines et al., 2011). Adults with ASD may be frequent ED 
users due to paucity of trained mental healthcare professionals who can meet their specific needs 
outside ED settings at the appropriate time. Adults with ASD may also present a different 
symptomatology and events to the ED as compared to adults without ASD. Hence, examination 
of burden of the ED use in a high needs and growing population of adults with ASD will not 
only address literature gaps, but will also help highlight reasons for ED use, which may reflect 
issues with accessing timely care, lack of trained professionals, and lack of availability of 
appropriate and quality care in an outpatient/primary care setting (Soto et al., 2009; E. R. 
Williams et al., 2001). 
Significance of Study  
If the proportion and costs of ED visits among adults with ASD are found to be 




this information to identify various needs (psychiatric or non-psychiatric) of adults with ASD in 
the primary care settings. For example, identifying psychiatric conditions which can be better 
managed at the outpatient level (primary care or specialty) can help reduce frequent ED visits, 
ED costs, inpatient hospitalizations, and readmissions for adults with ASD.  In addition, we will 
also examine if adults with ASD who may be prone to self-injurious behaviors and conduct 
problems (Kato et al., 2013; Matson & Rivet, 2008) are more likely to have an injury ED visit as 
compared to adults without ASD.  Information on the type of injuries affecting adults with ASD 
will help ED staff and healthcare providers to better prepare for ASD cases entering ED. Lastly, 
our study will also examine the costs associated with the ED use to provide an understanding of 




Objective 2.1: To examine and compare the trends in prevalence rates of all, psychiatric, non-
psychiatric, and injury ED visits for adults with ASD.  
Hypothesis 2.1: The prevalence rates of all, psychiatric, non-psychiatric, and injury ED visits by 
adults with ASD are expected to significantly increase over the 6 year period. 
Objective 2.2: To examine and compare the trends in mean total ED charges (all, psychiatric, 
non-psychiatric, and injury ED visits) among adults with ASD. 
Hypothesis 2.2:  The mean total ED charges for all, psychiatric, non-psychiatric, and injury ED 
visits by adults with ASD are expected to increase over the 6 year period. 
Objective 2.3: To examine and compare the socio-demographic, hospital, patient disposition 




Objective 2.4: To examine the likelihood of psychiatric, non-psychiatric, and an injury ED visit 
among adults with and without ASD by utilizing predictors such as presence of ASD, socio-
demographic, hospital, and patient disposition characteristics. 
Hypothesis 2.4: Adults with ASD will show greater likelihood of a psychiatric, non-psychiatric, 
or an injury ED visit after adjusting for relevant characteristics mentioned above.   
Data Collection 
We plan to use Nationwide Emergency Database Sample (NEDS) 2006- 2011, largest all- 
payer ED database which includes national estimates for hospital based ED data visits created for 
the Healthcare Cost and Utilization Project, Agency of Healthcare and Research Quality 
(Healthcare Cost and Utilization Project (HCUP), 2011). NEDS compiles discharge data 
collected from hospital billing records from both state emergency department databases (SEDD) 
and state inpatient databases (SID). The SID contains information on patients initially seen in the 
ED and then admitted to the same hospital. The SEDD capture information on ED visits that do 
not result in an admission (i.e., treat-and-release visits and transfers to another hospital).  
The NEDS is built using a 20% stratified sample of institutions and collects data from 
951 hospitals located in 30 States with an unweighted 30 million discharges each year. The 
NEDS presents rich information on type of ED visits (psychiatric, injury, etc.) along with up to 
15 diagnoses associated with each visit, geographic information, hospital characteristics, and 
total charges for each ED visit.  Using a data such as NEDS not only helps understand the extent 
and patterns of ED use among adults with ASD but also provides additional information on 
reasons for such ED visits such as type of injuries (which has not been previously reported in any 
study on adults with ASD), primary diagnosis for the ED visit, and the outcome(s) of the ED 




Study 3. The Burden of Medication Use in Adult Fee-for-Service Medicaid 
Enrollees with and without Autism Spectrum Disorders 
 
Aim: To determine the difference in rates of overall and specific prescription drug use along 
with general and psychotropic polypharmacy among adults with and without ASD. To examine 
the predictors of general and psychotropic polypharmacy among adults with ASD.  
 
*General Polypharmacy:  A prescription drug claim for six or more different therapeutic classes 
in the identification year. 
*Psychotropic Drug Polypharmacy:  A prescription drug claim for 3 or more different 
psychotropic classes within a period of 90 days after the first prescription fill date in the 
identification year. 
The third aim of this three part research will determine and compare the burden of any 
prescription drug use and psychotropic drug use among adults (22-64 years) with and without 
ASD. This study will also outline and compare the distribution of specific drug classes within 
these categories among adults with and without ASD.  General polypharmacy may include but is 
not restricted to prescription drug classes such as antipsychotics, anti-diabetes, anti-neoplastics, 
antibiotics, gastrointestinal agents, respiratory agents, and many more. Psychotropic 
polypharmacy includes drug classes such as antipsychotics, antidepressants, CNS stimulants, 
anxiolytics/sedatives/hypnotics, and anticonvulsants. The study will also examine and compare 
the association of polypharmacy use with other healthcare utilization and expenditures among 
adults with ASD. In contrast to the abundant literature on general and psychotropic drug 
polypharmacy use in children with ASD, very few studies have examined the patterns of 
medication use among adults with ASD.  
(Esbensen, Greenberg, Seltzer, & Aman, 2009) examined the use of psychotropic (such 
as antipsychotics and anti-depressants) and non-psychotropic medications (such as anti lipimic, 
GI medications, and other drugs) among adolescents and adults with ASD (average age 21 years) 




medicated (Odds: 15.83). A critical finding of the study was that once a medication was 
prescribed, the discontinuation over a 4.5 year period was very unlikely. (Khanna et al., 2013) 
examined Mississippi Medicaid fee for service claims data to assess the psychotropic medication 
use and costs associated among individuals with ASD. Adults with ASD (22-64 years of age) 
had the highest average number of claims per beneficiary for any psychotropic drug. Using 
literature support of such studies, we hypothesize that adults with ASD will have greater rates of 
general as well as psychotropic drug polypharmacy than those without ASD. This may be due to 
paucity of clinical trials for most prescription drugs among adults with ASD, lack of training of 
healthcare providers in terms of treatment guidelines (Bruder et al., 2012; Golnik et al., 2009; 
Heidgerken et al., 2005; Oskoui & Wolfson, 2012), greater likelihood of adults with ASD using 
psychotropic medications than their younger counterparts (Khanna et al., 2013), and low 
likelihood of discontinuation of a medication once started at a younger age (Esbensen et al., 
2009).  
Need of Study  
Majority of ASD literature has focused on examining the patterns of psychotropic 
polypharmacy among children with ASD. Even though the definition of polypharmacy has 
varied with studies, use of any psychotropic medication has been reported to be as high as 83%, 
with polypharmacy being reported among 10-20% of children with ASD (Coury et al., 2012; 
Frazier et al., 2011; Gerhard, Chavez, Olfson, & Crystal, 2009; Logan et al., 2012; Mandell et 
al., 2008; Oswald & Sonenklar, 2007a; Oswald & Sonenklar, 2007b; Spencer et al., 2013). 
Adults with ASD have received very little attention regarding polypharmacy use, with no 
documentation of the burden of any prescription drug use in this population. Even though 




Anagnostou, 2014; Volkmar, Cook, Pomeroy, Realmuto, & Tanguay, 1999) and helps to 
alleviate symptoms associated with other co-occurring conditions (Baribeau & Anagnostou, 
2014), the evidence base for most of these medications (including FDA approved antipsychotics 
such as risperidone and aripiprazole for ASD) have received a status of only medium to low level 
effectiveness for core symptoms of ASD (Warren et al., April 2011). In addition, use of such 
prescription drugs (e.g. antidepressants, stimulants, antipsychotics etc.) is also associated with 
significant adverse events and side effects such as aggression, suicidal ideation, obesity, and 
sedation (Blankenship, Erickson, Stigler, Posey, & McDougle, 2010; Ching & Pringsheim, 2012; 
Marcus et al., 2009; McCracken et al., 2002; Owen et al., 2009; West, Brunssen, & Waldrop, 
2009; K. Williams, Wheeler, Silove, & Hazell, 2010).  Therefore, a study documenting the 
overall medication burden is needed to underline the varied pharmaceutical uses in this 
population.  
Significance of Study  
Use of polypharmacy increases the possibility of drug-drug interactions which pose 
additional risk of adverse events aggravating the complexities of healthcare management of 
individuals with ASD. The results of this study can be used to describe the prescription patterns 
and utilization of multiple off label medications (lack of FDA approval for most medications 
among adults with ASD), in addition to informing physicians who in most cases report being 
under-trained in pharmacological treatment approaches of patients with ASD (Bruder et al., 
2012; Oskoui & Wolfson, 2012). The findings will identify which prescription drug classes are 
commonly used by adults with ASD and demonstrate a need of pharmacological treatment 
guidelines (Bruder et al., 2012; Golnik et al., 2009; Heidgerken et al., 2005; Oskoui & Wolfson, 
2012) and the needs of clinical trials for drugs commonly prescribed to adults with ASD 






Objective 3.1: To examine and compare the use of different prescription drug classes among 
adults with and without ASD.  
Hypothesis 3.1:  Use of various prescription drug classes will be higher among adults with ASD 
as compared to adults without ASD.  
Objective 3.2: To determine and compare the rates of general and psychotropic drug 
polypharmacy use among adults with and without ASD. 
Hypothesis 3.2:  Adults with ASD will show higher rates of general as well as psychotropic drug 
polypharmacy as compared to adults without ASD.  
Objective 3.3: To determine and compare the likelihood of general and psychotropic drug 
polypharmacy use among adults with and without ASD. 
Hypothesis 3.3: After adjusting for socio-demographics, patient characteristics, county level 
healthcare workforce, and Medicaid eligibility, adults with ASD will be more likely to use both 
general and psychotropic drug polypharmacy as compared to adults without ASD. 
Objective 3.4: To identify the predictors of general and psychotropic drug polypharmacy among 
adults with ASD. 
Data Collection 
Similar to Study 1, we will use three state Medicaid administrative claims data (IL, NY, 
and TX; 2000-2008) to determine the rates of polypharmacy, and its association with other 
healthcare utilization, and expenditures among adults with ASD.  Although, prescription drug 
coverage is an optional benefit under federal Medicaid law, all state Medicaid programs provide 




significant role in prescription drug coverage for individuals with mental health and substance 
abuse issues as well (Schubart et al. 2014). Many studies have utilized Medicaid claims 
databases to examine the rates of psychotropic drug polypharmacy among children with ASD 
(Frazier et al., 2011a; Logan et al., 2012; Mandell et al., 2008b).  Thus, using this database will 





 The three studies proposed in this document will use the modified version of 
Andersen’s socio-behavioral model (Andersen, 1995). Andersen’s model has been previously 
used in plethora of studies and is very useful when the researchers intend to identify the reasons 
for excess healthcare utilization and expenditures among specific group of patients as compared 
to other patient groups.  
 We will use this model to determine the factors that contribute to the anticipated 
excess healthcare utilization and expenditures for adults with ASD as compared to adults without 
ASD. The framework constitutes individual level factors and community level factors which 
determine an individual’s behavior, their healthcare needs, access to services, and consequently 
their healthcare utilization and costs. Individual level factors are divided into: predisposing (e.g. 
patient demographic information such as age, gender, and race), enabling (e.g. urban/rural status 
of place of care/residence, education level, annual household income level, and Medicaid 
eligibility), and need factors (e.g. comorbidities). The community level factors include 
contextual characteristics such as state and region that influence the nature of policies and extent 
of healthcare access to the individuals with and without ASD. For example, healthcare services 
offered under the state Medicaid programs vary substantially from state to state, depending on 
the state funds and other state policies (Mauch et al., 2011).   
 Together these factors will be used to explain differences in outcomes (healthcare 
utilization and expenditures) for adults with and without ASD.  Such outcomes include 
utilization and costs of services such as outpatient visits, inpatient hospitalizations, ED, and 

















Figure 2. Modified Andersen’s Behavioral Model 
  
 









































Significance of three part research 
 The current dissertation research will fill a tremendous gap in the literature about the 
pattern of healthcare use and expenditures associated with adults with ASD. (Buescher et al., 
2014) predicted significantly greater medical costs for adults with ASD as compared to their 
pediatric counterparts. Given the increasing number of ASD cases, there is a growing concern 
about the healthcare utilization and costs associated with the children transitioning to adults.  Our 
research will identify the healthcare needs of adults with ASD by examining the extent of their 
comorbidities, overall prescription medication use and polypharmacy, and burden of ED use.  
The research will highlight the nature of off label prescription drug use and perhaps, 
underline the need of clinical drug trials among adults with ASD. If adults with ASD have higher 
healthcare needs, use greater healthcare services, and have higher expenditures, the findings will 
help autism advocacy groups and policymakers to provide a rationale for expanding and 
improving the quality of healthcare coverage, encouraging ASD awareness and education for 
healthcare providers, and providing early intervention services to reduce long term morbidity and 
poor prognosis among those diagnosed as children. The findings from our study will help reduce 
long term healthcare costs to the payers as well as to the society. It will also help to understand 
the need for improving social outcomes for adults with ASD, who, when provided timely care 
may have better employment opportunities and work productivity.   
 Overall, this research may provide evidence that adults with ASD are in substantial need 
of healthcare services and have higher costs as compared to adults without ASD. Policymakers 
may need such information to create mandates/policies that can serve the specific needs of this 
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Background: Individuals with ASD have extensive comorbidities which affect their health 
related quality of life. The current literature lacks documentation of prevalence of different types 
of comorbidities and their association with healthcare utilization and expenditures among adults 
with ASD as compared to adults without ASD.  
Aim: To determine: 1) the differences in prevalence of psychiatric, non-psychiatric 
comorbidities, other health conditions, healthcare utilization, and expenditures among adults 
with and without ASD; and 2) the association of type of comorbidity with healthcare utilization 
and expenditures of adults with ASD. 
Method: A retrospective cohort study using claims data from three state Medicaid Analytic 
eXtract was conducted. Adults aged 22-64 years with ASD (ICD9-CM code: 299.xx) with at 
least one inpatient or two outpatient claims on separate service dates who were continuously 
enrolled between January 1, 2000 to December 31, 2008 were identified.  ASD cases were 
matched to no ASD controls by age, sex, and race using propensity score matching (1:3).  
Baseline and outcome differences across cases and controls were examined using bivariate 
analyses for categorical (chi-square) and continuous independent variables (t-tests).  All cause 
health care utilization (outpatient visits, inpatient hospitalizations, emergency room, and 
prescription drug use), and associated health care costs were assessed during the follow-up year. 
Multivariate multinomial logistic regressions for healthcare utilization and generalized linear 
models with gamma distribution for expenditures were conducted to compare healthcare 
utilization and expenditures among adults with and without ASD.  Association of type of 
comorbidity with healthcare utilization (binary and multinomial logistic regressions) and 
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expenditures (generalized linear models with gamma distribution) were also analyzed among 
adults with ASD.  Multivariate regression analyses were adjusted for state, identification year, 
patient socio-demographics, baseline prescription drug use, and county characteristics.  
Results:  
Comorbidities: Around 80% of adults with ASD (n = 1,772) had a psychiatric comorbidity as 
compared 41% of adults without ASD.  Prevalence of a non-psychiatric comorbidity was 
significantly lower among adults with ASD (40%ASD vs. 45%noASD). Almost 70% of adults with 
ASD had comorbid intellectual disability. Adults with ASD had higher rates of anxiety (12.2% 
ASD vs. 5.6% noASD), attention deficit disorders/attention deficit hyperactivity disorders 
(ADD/ADHD) (8.2% ASD vs. 0.7% noASD), schizophrenia (16.6% ASD vs. 11.1% noASD), and 
gastrointestinal disorders (12.6% ASD vs.11% noASD) as compared to adults without ASD.  
Rates of other health conditions that were significantly higher among adults with ASD as 
compared to adults without ASD were: epilepsy (22%ASD vs. 5%noASD), thyroid disease (5%ASD 
vs. 1%noASD), lipid metabolism disorders (5%ASD vs. 3%noASD), other endocrine/nutrition 
disorders (11%ASD vs. 4% noASD)  hematological disorders (7%ASD vs. 5%noASD), genito-urinary 
disorders (10%ASD vs. 8% noASD), infections (22%ASD vs. 15% noASD), skin disorders (21%ASD vs. 
9% noASD), and paralysis (6%ASD vs. 3% noASD).  Adults with ASD also had higher prevalence rate 
of other disabilities such as blindness (5%ASD vs. 4% noASD) and hearing impairments (19%ASD vs. 
4% noASD).  
Healthcare utilization and expenditures: The mean number of OT visits (32ASD vs. 8noASD) 
and Rx claims (51ASD vs. 24noASD) per year were significantly greater for adults with ASD as 
compared to adults without ASD.  The mean average length of stay was also higher for adults 
with ASD (10ASD vs. 8noASD days).  Adults with ASD exhibited higher mean annual OT ($4,375 
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ASD vs. $824 noASD), ER ($15,929 ASD vs. $2,598 noASD), Rx ($6,067 ASD vs. $3,144 noASD) and total 
expenditures ($13,700 ASD vs. $8,560noASD).  
Adults with ASD were two times more likely to have >=4 OT visits per year as compared to 
adults without ASD (AOR = 2.73, 95% CI = 2.31-3.22), five times more likely to have >=18 Rx 
claims than adults without ASD (AOR = 4.79, 95% CI = 4.09-5.60).  The likelihood of  >1 IP 
visit (AOR = 0.70, 95% CI = 0.51-0.96) or >1 ER visit (AOR = 0.76, 95% CI = 0.61-0.93) in a 
year was 30% and 24% lower among adults with ASD as compared to adults without ASD. 
Among users, the expenditures for adults with ASD were significantly higher for OT visits, ER 
visits, and Rx claims as compared to adults without ASD after adjusting for selected 
characteristics. Adults with ASD had additional $824 OT expenditures, $8,932 ER expenditures, 
and $1,499 Rx expenditures per year as compared to adults without ASD.  The average adjusted 
total Medicaid expenditures (sum of OT, RX, and IP) were $1,159 higher per year for adults with 
ASD as compared to adults without ASD, even after controlling for type of comorbidity. On an 
average, presence of a psychiatric and a non-psychiatric comorbidity among adults with ASD 
costed an additional $4,952 and $5,084 per year. 
Conclusion:  
Psychiatric comorbidities such as intellectual disabilities, anxiety, ADD/ADHD, and 
schizophrenia are very common among adults with ASD and non-psychiatric comorbidities such 
as gastrointestinal disorders are also highly common. Other than major comorbidities, other 
health conditions such as epilepsy, thyroid, lipid metabolism disorders, genito-urinary disorders, 
skin disorders, and infections are also highly prevalent in adults with ASD as compared to adults 
without ASD. Adults with ASD exhibit excess healthcare utilization in form of higher number of 
outpatient visits and prescription drug claims in a year and annual total Medicaid expenditures as 
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compared to adults without ASD.  Medicaid coverage of healthcare services for adults with ASD 
is substantial and state programs bear high costs of such services.  
  




Comorbid conditions occurring among individuals with autism spectrum disorders (ASD) 
adversely affect their core autistic symptoms (Garcia-Villamisar & Rojahn, 2013), activities of 
daily living, and health related quality of life (Kamp-Becker, Schroder, Remschmidt, & 
Bachmann, 2010). Specifically for adults with ASD, the reported rates of comorbidities have 
varied substantially due to the variations in study designs, data sources, study period, type of 
ASD examined, and sample sizes.  (Croen et al., 2015) used electronic health records of adults 
with ASD (n = 1,507) who were enrolled in Kaiser Permanente (KP) Northern California health 
insurance program from 2008 to 2012 and found very high rates of comorbid psychiatric as well 
as non-psychiatric conditions. Such comorbidities included depression (26%), anxiety (30%), 
gastrointestinal disorders (35%), epilepsy (12%) and diabetes (8%).  In addition, a few other 
studies have outlined the prevalence rates of comorbidities among adults with ASD using limited 
sample sizes and restricted hospital and/or community settings  with a high chance of referral 
bias (Buck et al., 2014a; Lugnegard et al., 2011a; Lunsky et al., 2009).  (Buck et al., 2014a) 
investigated comorbid psychiatric disorders among 129 adults with ASD ascertained during 
childhood in a 1980's statewide Utah autism prevalence study, and found that comorbid anxiety 
disorder had the highest current (39.5%) and lifetime prevalence (52.7 %) in this group of adults.  
(Lugnegard et al., 2011a) examined the prevalence of psychiatric comorbidity in young adults 
diagnosed with Asperger’s syndrome (mean age = 27 years; 26 men and 28 women).  In this 
study, major depression was shown to be as high as 70%, followed by anxiety disorder (56%), 
attention deficit hyperactivity disorder (ADHD; 30%), substance dependence disorder (11%), 
bipolar disorder (9%), and obsessive compulsive disorder (OCD; 7%).  
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It is also well documented in the literature that children with ASD have higher healthcare 
resource utilization such as greater number of outpatient (OT) visits, inpatient hospitalizations 
(IP), length of stays, emergency room (ER) use, and medication (Rx) use and higher healthcare 
costs as compared to children without ASD (Croen et al., 2006; Lokhandwala, Khanna, & West-
Strum, 2012; Mandell, 2008a).  For example, (Croen et al., 2006) examined KP medical care 
program 2003-2005 and found that children with ASD aged 2-18 year olds had a higher annual 
mean number of total clinic (5.6 vs 2.8), pediatric (2.3 vs 1.6), and psychiatric (2.2 vs 0.3) 
outpatient visits as compared to children without ASD.  In addition, a higher percent of children 
with ASD also experienced inpatient hospitalizations (3% vs 1%) and were nine times more 
likely to use psychotherapeutic medications. Also, the mean annual member costs for 
hospitalizations ($550 vs $208), clinic visits ($1373 vs $540), and prescription medications 
($724 vs $96) were significantly higher for children with ASD as compared to children without 
ASD.  Since adults with ASD have similar autistic symptoms (Baker, 2013; Billstedt et al., 2007) 
and exhibit high healthcare needs (Cidav et al., 2013; Howlin, Goode, Hutton, & Rutter, 2004; 
Lunsky et al., 2009; Mukaetova-Ladinska, Perry, Baron, Povey, & Autism Ageing Writing 
Group, 2012b), it is important to establish their healthcare utilization and expenditures using real 
world settings. 
Studies have also shown that comorbidities play a significant role in elevating the risk of 
using additional healthcare resources and increased healthcare expenditures among individuals 
with ASD (Ahmedani & Hock, 2012; Buescher et al., 2014; Croen et al., 2006; Mandell et al., 
2006; Mandell, 2008b; Peacock et al., 2012; Wang, Mandell, Lawer, Cidav, & Leslie, 2012). 
Such studies have established that comorbidities along with ASD are specifically associated with 
higher medication use (Buck et al., 2014a; Mandell et al., 2008a; Mandell, 2008a), greater 
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hospitalization rates, higher expenditures (Peacock et al., 2012) and extremely high lifetime 
support costs per individual with ASD (ASD alone = $1.4 million and ASD+ Intellectual 
disability =$2.4 million in US) (Buescher et al., 2014).  Thus, it is critical to examine not only 
the burden of prevalence of comorbidities among adults with ASD, but also their ramifications 
on healthcare utilization and expenditures of adults with ASD.  Given the recent studies which 
have established that individuals with ASD not only have psychiatric comorbid conditions but 
also non-psychiatric conditions (Buie et al., 2010; Croen et al., 2015; Esbensen et al., 2009; 
McElhanon et al., 2014), we include examining the rates of non-psychiatric disorders among 
adults with ASD as one of our study aims.  
Even though the current literature indicates a high occurrence of specific comorbidities 
(mostly focusing on psychiatric) among adults with ASD (Buck et al., 2014a; Lugnegard et al., 
2011a; Lunsky et al., 2009; Unenge Hallerback et al., 2012), there is a gap in the literature 
regarding how different these prevalence rates are from adults without ASD.  The study by 
(Croen et al., 2015) is the first study that used a large sample of adults with ASD who were 
enrolled in KP Northern California to estimate and compare the prevalence rates of 
comorbidities among adults with and without ASD.  Despite being a significant addition to the 
literature with a comprehensive understanding of prevalence rates of comorbidities among adults 
with ASD, this study was restricted to KP members in Northern California. In addition, the study 
also did not report the impact of each type of comorbidity among adults with ASD on their 
healthcare utilization and expenditures, which is of prime importance to policymakers as ASD 
related costs are predicted to increase substantially in the next few years (Buescher et al., 2014). 
The current study will: 1) Examine the rates of specific types of psychiatric and non-
psychiatric comorbidities among adults with and without ASD; 2) Compare the healthcare 
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utilization (OT, IP, ER, and Rx) and associated healthcare expenditures among adults with and 
without ASD; and 3) Determine the association of psychiatric and non-psychiatric comorbidity 
among adults with ASD with their healthcare utilization and expenditures. A psychiatric 
comorbidity is defined as any co-occurring diagnoses of psychiatric disorders such as adjustment 
disorders, alcohol/substance use disorders (AUD/SUD), anxiety disorders, attention deficit 
disorders & conduct behavior disorders (ADD), developmental disorders, mood disorders 
including depressive disorders and bipolar disorder, personality disorders, and schizophrenia & 
other psychotic disorders.  A non-psychiatric comorbidity is defined as any co-occurring 
diagnoses of physical disorders such as cancer, cardiovascular conditions, diabetes, 
muscoskeletal disorders, gastrointestinal conditions, and respiratory conditions. We expect that 
adults with ASD will have a higher prevalence of both psychiatric and non-psychiatric 
comorbidities as compared to adults without ASD. Since autistic features persist into adulthood 
and continue to manifest symptoms of diagnostic autism (Billstedt et al., 2007; Seltzer et al., 
2003), we also anticipate that adults with ASD will have greater use of healthcare services and 
have greater healthcare expenditures as compared to adults without ASD similar to findings of 
other studies among children with ASD (Ahmedani & Hock, 2012; Buescher et al., 2014; Croen 
et al., 2006; Mandell et al., 2006; Mandell, 2008b; Peacock et al., 2012; Wang et al., 2012). 
 For the current study we used data from three state Medicaid (IL, NY, and TX) fee for 
services enrollees during the study period of 2000-2008. Medicaid is an ideal data source for 
several reasons. It is the single largest payer for individuals with ASD (Ruble et al., 2005) and 
utilization of Medicaid provided healthcare services among individuals with ASD is only 
expected to increase (Semansky et al., 2011a).  Medicaid provides a wide variety of  services to 
individuals with ASD (Arjun et al., 2011) including providing  primary and secondary health 
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insurance coverage for healthcare services, home and community based waivers, screening and 
diagnostic services, behavioral support, in home care, skill training/acquisition, respite care, case 
management, supported employment, service coordination, self-directed services, and parent 
training and education (Mauch et al., 2011). Healthcare administrative claims, especially state 
Medicaid databases have been extensively used for ASD research among children and will help 
address similar questions for adults with ASD as well (Khanna et al., 2013; Mandell, 2008b; 
Maski et al., 2011; Peacock et al., 2012; Spencer et al., 2013). 
   
  




Study Population and Design 
A retrospective matched cohort study among adults aged 22-64 years with and without 
ASD was conducted. Adults with any ASD (at least one inpatient or two outpatient claims on 
separate service dates with an ICD9-CM code: 299.xx in any position) and continuously enrolled 
in a fee for service program from 2000-2008 were matched (1:3) to adults without ASD by age, 
gender, and race using propensity score matching method with GREEDY (1 to 8) algorithm. 
Adults without ASD were included if they had at least two claims on separate dates of service 
(either inpatient or outpatient).  Other exclusion criteria were:  a) dual Medicaid/Medicare 
eligible; b) Managed care enrollees; and c) died during the observation period. The baseline 
characteristics (patient’s socio-demographic information, comorbidities, and baseline drug use) 
were extracted from the identification year (first medical claim year with any ASD diagnosis) 
and the outcomes (healthcare utilization and expenditures) were measured in the follow up year 
(year after the identification year). 
Data 
Administrative health insurance claims data from three state Medicaid programs (IL, NY, 
and TX) were extracted from the 2000-2008 Centers for Medicare and Medicaid Services 
Medicaid analytic eXtract (MAX) data files. We selected IL, NY, and TX because of lower 
managed care penetration rates and greater fee-for-service enrollment during the study period 
(The Henry J Kaiser Family Foundation, 2013). The MAX files provide diagnosis codes, service 
use, demographic characteristics, and state of residence. Separate files received from CMS can 
be linked based on beneficiaries’ unique identification number.  
For the current study we used the personal summary file (provides information on 
Medicaid eligibility, enrollment type, and demographics), other therapy file (provides 
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information on two possible diagnoses, utilization of outpatient services such as clinical services, 
physician services, procedures, home health, and lab services), inpatient file (provides 
information on nine possible diagnoses, hospitalizations, procedures, and length of stays), and 
the prescription drug file (national drug codes (NDC), prescription fill date, and days of supply).  
County level variables were obtained from the area resource file (ARF) (Quality Resource 
Systems, 2006) which provides information on type of health facilities, number and type of 
health professions, resource scarcity measures, health status, economic activities, health training 
programs, and socioeconomic and environmental characteristics. The Medicaid files were linked 
with ARF files with five digit county identification variable.   
Variables 
Healthcare utilization and expenditures  
 Our outcome measures were all cause healthcare utilization and expenditures in the 
follow up year.  We counted the number of outpatient visits (OT), inpatient hospitalizations (IP), 
emergency use (ER), and any prescription drug claims (Rx) on separate dates of service. OT 
services included all encounters and claims for services that were rendered in a doctor’s office, 
hospital OT facility, ER, or other OT facility services.  We defined the OT visits as any 
physician/other practitioner’s/ clinic visits using MAX type of service codes.  ER services were 
identified using revenue codes (450-452, 456, 459, 981), procedure codes (99281- 99285), and 
place of service codes (23) provided in the MAX OT and IP file.  Rx use included claims for 
prescriptions filled at retail and mail order pharmacies that were billed to the Medicaid’s 
pharmacy benefits. In addition to visits, we included average length of stay for a hospitalization 
as one of the variables in the study.  We also examined and compared the OT, IP, ER, Rx, and 
total expenditures (sum of OT, IP, and Rx expenditures) among adults with and without ASD.  
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Medical care services part of the annual consumer price index (CPI) was utilized to transform 
expenditures to 2008 constant dollars. The CPI was obtained from the Bureau of Labor Statistics 
(Bureau of Labor Statistics, US Department of Labor, 2014).  
Socio-demographic and need characteristics 
 Age (22-40 and 41-64 years), sex (male and female), race (White, African-American, and 
Other), state (IL, NY, and TX), identification cohort (before and after 2004), and Medicaid 
eligibility by cash and medical needs (yes/no) were extracted from the MAX personal summary 
file.  Baseline Rx use (>25 unique Rx claims, <=25 unique Rx claims, and no Rx claims) was 
used as a proxy measure of healthcare needs. 
County Characteristics 
We used various contextual variables from the ARF file such as county metro status 
(urban/rural), primary care shortage area (yes/no), mental health specialist shortage area (yes/no), 
psychiatrist density (high/low), median household income level (quartiles: q1, q2, q3, and q4), 
and high school education and above density which is a measure of county education status 
(quartiles: q1, q2, q3, and q4). These were used as a proxy measure of access to services.  
Comorbidities 
Two main types of comorbid conditions were identified using either one inpatient or two 
outpatient claims on separate service dates with a diagnosis in any position for a psychiatric or a 
non-psychiatric disorder. We used the single level clinical classification software (CCS) 
provided by Agency for Healthcare Research and Quality (https://www.hcup 
us.ahrq.gov/toolssoftware/CCS/AppendixASingleDX.txt) to categorize diagnosis codes to 
clinically meaningful categories. A psychiatric comorbidity included: adjustment disorders (CCS 
code: 650), alcohol/substance use disorders (AUD/SUD; CCS code: 660,661), anxiety disorders 
(CCS code: 651), attention deficit disorders & conduct behavior disorders (ADD; CCS code: 
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652), developmental disorders (CCS code: 654), mood disorders including depressive disorders 
and bipolar disorder (CCS code: 6571,6572), personality disorders (CCS code: 658), and 
schizophrenia & other psychotic disorders (CCS code: 659). A non-psychiatric comorbidity 
included: cancer (CCS code: 11- 37, 39-43, 46, 47) cardiovascular disease (CCS code: 96-108), 
diabetes (CCS code: 49, 50), muscoskeletal disorders (CCS code: 201-212), gastrointestinal 
disease (CCS code: 138-151, 153-155), and respiratory disease (CCS code: 125-128, 132-134). 
Other health conditions included epilepsy (CCS code: 83), headache including migraine (CCS 
code:84), thyroid disease (CCS code:48), other metabolic, nutritional, and endocrine disorders 
excluding diabetes (CCS code:51,58), nutrition deficiencies (CCS code:52), lipid metabolism 
disorders such as hypercholesterlomia (CCS code:53), fluid and electrolyte dysfunctions (CCS 
code:55), jaw and teeth disorders (CCS code:136), hematological disorders (CCS code: 59-64), 
genito-urinary disorders such as tract infections, bladder and urethra disorders, nephritis, renal 
failure, and others (CCS code: 156-163), paralysis (CCS code:82), infections such as 
tuberculosis, bacterial infections, hepatitis, HIV, and others (CCS code: 1-9,135), skin disorders 
such as infections, inflammatory conditions, and others (CCS code:197-200), blindness/other 
vision defects (CCS code:89), and hearing impairments (CCS code:92-94).  
Statistical Analysis 
Bivariate analyses such as chi-square tests of associations for categorical variables and t-
tests for continuous variables were conducted to assess the sub-group and mean differences 
between adults with and without ASD.  Diagnostic tests for count data (OT, IP, ER, and Rx 
visits) were run to examine the feasibility of poisson, negative binomial, and zero inflated 
regressions. However, the dispersion factor for all regressions did not satisfy the distribution 
assumptions and count data were categorized into multinomial categories above and below the 
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median of the sample distributions. For comparison between adults with and without ASD, a 
multinomial logistic regression was conducted to examine the likelihood of >=4 OT visits (vs. <4 
OT visits and no OT visits), >1 IP visit (vs. =1 IP visit and no IP visit), >1 ER visit (vs. =1 ER 
visit and no ER visit), and >=18 Rx claims (vs. <18 Rx claims and no Rx claims) per year. We 
used generalized linear modeling with gamma distribution and log-link function to test for 
differences in Medicaid expenditures (OT, IP, ER, Rx, and total). To account for data with zero 
costs, a two-part model was used (part 1 with logistic regression to examine the association 
between all cause costs from ASD status [>0 vs 0] and part 2 with generalized linear modeling 
with log-link function for positive costs).  For examining the association of type of comorbidity 
(psychiatric and non-psychiatric) with healthcare utilization and expenditures for adults with and 
without ASD, we used interaction terms (ASD*psychiatric comorbidity and ASD*non-
psychiatric comorbidity) in separate regression analyses. We tested the impact of comorbidity 
type in two ways: 1) Effect of comorbidity on differences in healthcare utilization and 
expenditures across adults with and without ASD (ASD with comorbidity vs. No ASD with 
comorbidity); and 2) Effect of comorbidity on healthcare utilization and expenditures of adults 
with ASD (ASD with comorbidity vs. ASD with no comorbidity).  
 Adjusted odds ratios (multinomial regressions) along with 95% confidence intervals, and 
parameter estimates (beta) with standard errors for generalized linear models are reported.  All 
adjusted analyses were adjusted for socio-demographics, county characteristics, baseline Rx use, 
and comorbidities selectively. Variables which were highly collinear with expenditures such as 
association of baseline prescription drug use with Rx and total expenditures (sum of OT, IP, and 
Rx) were excluded from the model. Findings with cell sizes that were 11 or less are suppressed 
in accordance with CMS data user agreement.  All analyses were conducted using SAS v9.4.   




Descriptive Analyses  
Baseline Characteristics (Tables 1 and 2) 
Our sample had 1,772 adults with ASD, most of them being male (71%), aged 22-40 
years, and under a cash assistance program (82%).  Around 70% of adults with ASD had more 
than 25 Rx claims per year as compared to 28% of adults without ASD.  Psychiatric comorbidity 
rates were significantly higher among adults with ASD (81%) than those without ASD (41%).  
Almost 70% of adults with ASD in the sample had intellectual disability, followed by 
schizophrenia (17%), mood disorders (14%), and anxiety (12%).  Rates of non-psychiatric 
comorbidity were modestly lower among adults with ASD as compared to adults without ASD 
(40%ASD vs. 46% noASD). Adults with ASD had significantly higher prevalence rate of 
gastrointestinal disorders (13%ASD vs. 11% noASD) and significantly lower prevalence rate for 
cardiovascular disorders (14%ASD vs. 17% noASD), muscoskeletal disorders (12%ASD vs. 16% 
noASD), and respiratory disorders (15%ASD vs. 19% noASD) as compared to adults without ASD.  
Rates of other health conditions that were significantly higher among adults with ASD as 
compared to adults without ASD were: epilepsy (22%ASD vs. 5%noASD), thyroid disease (5%ASD 
vs. 1%noASD), lipid metabolism disorders (5%ASD vs. 3%noASD), other endocrine/nutrition 
disorders (11%ASD vs. 4% noASD)  hematological disorders (7%ASD vs. 5%noASD), genito-urinary 
disorders (10%ASD vs. 8% noASD), infections (22%ASD vs. 15% noASD), skin disorders (21%ASD vs. 
9% noASD), and paralysis (6%ASD vs. 3% noASD).  Adults with ASD also had higher prevalence rate 
of other disabilities such as blindness (5%ASD vs. 4% noASD) and hearing impairments (19%ASD vs. 
4% noASD).  
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Outcome Measures  
 Most adults with ASD had an OT visit (95%) in the follow up year (Table not shown 
here). Around 14 % had an IP visit, 33.6% had an ER visit, and 95% had at least one Rx claim in 
the follow up year. IP (20%) and ER visits (40%) were much more common among adults 
without ASD as compared to adults with ASD.  Almost 76% of adults with ASD used 
psychiatric OT services as compared to 41% of adults without ASD.  Greater proportion of 
adults with ASD (35%) also used residential OT services as compared to adults without ASD 
(2%).   
The mean number of OT visits (32ASD vs. 8noASD) and Rx claims (51ASD vs. 24noASD) per 
year were significantly greater for adults with ASD as compared to adults without ASD (Table 
3a).  The mean average length of stay was also higher for adults with ASD (10ASD vs. 8noASD 
days).  Adults with ASD exhibited higher mean annual OT ($4,375 ASD vs. $824 noASD), ER 
($15,929 ASD vs. $2,598 noASD), Rx ($6,067 ASD vs. $3,144 noASD) and total expenditures ($13,700 
ASD vs. $8,560noASD).  
Stratification of healthcare utilization and expenditures (Table not shown here) by each 
type of comorbidity showed higher OT and Rx visits per year as well as annual expenditures for 
most categories. Having a psychiatric comorbidity with ASD was associated with significantly 
higher mean OT visits (38ASD vs. 11noASD) and Rx claims (55ASD vs. 32noASD) per year. Having a 
non-psychiatric comorbidity with ASD was also associated with higher mean OT visits (41ASD 
vs. 10noASD) and Rx claims (62ASD vs. 33noASD) per year. A similar pattern was observed for all 
expenditures, where annual OT, ER, and Rx expenditures were higher for the ASD group as 
compared to the no ASD group for all comorbidity groups.   
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Regression Analyses (Tables 4) 
Adults with and without ASD 
 The adjusted odds ratios for all visits and claims were higher for adults with ASD as 
compared to adults without ASD, except for IP and ER visits. Adults with ASD were more likely 
to have >=4 OT visits per year as compared to adults without ASD after adjusting for socio-
demographic, county, and need characteristics (AOR = 2.73, 95% CI = 2.31-3.22).  Adults with 
ASD were five times more likely to have >= 18 Rx claims than adults without ASD (AOR = 
4.79, 95% CI = 4.09-5.60).  Interestingly, the likelihood of  >1 IP visit (AOR = 0.70, 95% CI = 
0.51-0.96) or >1 ER visit (AOR = 0.76, 95% CI = 0.61-0.93) in a year was 30% and 24% lower 
among adults with ASD as compared to adults without ASD.  For healthcare expenditures, we 
conducted two part models to examine expenditure differences in adults with and without service 
use. ASD status, a key independent variable in the study was significantly associated with 
positive expenditures (non-zero) in the two part model. Adults with ASD were more likely to 
have positive expenditures for OT visits (AOR = 3.67, 95% CI = 2.89-4.66), Rx claims (AOR = 
2.24, 95% CI = 1.75-2.87) and less likely to have positive expenditures for IP visits (AOR = 
0.48, 95% CI = 0.41-0.57) and ER visits (AOR = 0.58, 95% CI = 0.51-0.66). Among users, the 
expenditures for adults with ASD were significantly higher for OT visits, ER visits, and Rx 
claims as compared to adults without ASD after adjusting for selected characteristics. On an 
average (exp (intercept) - exp (beta)), adults with ASD had additional $824 OT expenditures, 
$8,932 ER expenditures, and $1,499 Rx expenditures per year as compared to adults without 
ASD.  The average adjusted total Medicaid expenditures (sum of OT, RX, and IP) were $1,159 
higher per year for adults with ASD as compared to adults without ASD, even after controlling 
for type of comorbidity  
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Association of comorbidity with ASD status 
Psychiatric comorbidity: Adults with ASD and a psychiatric comorbidity had significantly 
greater likelihood of having >=4 OT visits per year (AOR = 3.05, 95% CI = 2.49-3.73) and >= 
18 Rx claims per year (AOR = 3.87, 95% CI = 3.23-4.65) as compared to adults without ASD 
but with a psychiatric comorbidity.  Adults with ASD and a psychiatric comorbidity had lower 
likelihood of >1 IP visit (AOR = 0.61, 95% CI = 0.44-0.84) or >1 ER visit (AOR = 0.71, 95% CI 
= 0.56-0.88) as compared to adults without ASD but with a psychiatric comorbidity.  Among 
expenditures, adults with ASD and a psychiatric comorbidity had higher OT (beta = 1.14, SE = 
0.05, p<0.001), ER (beta = 1.42, SE = 0.08, p<0.001), Rx (beta = 0.32, SE = 0.05, p<0.001), and 
total expenditures (beta = 0.19, SE = 0.05, p<0.001). Presence of psychiatric comorbidity among 
adults with ASD significantly increased the OT expenditures by $2,130, ER expenditures by 
$10,532, and total expenditures by $4,952.  
Non- Psychiatric comorbidity: Adults with a non-psychiatric comorbidity had significantly 
greater likelihood of having >=4 OT visits per year (AOR = 2.48, 95% CI = 1.91-3.22) and >= 
18 Rx claims per year (AOR = 5.43, 95% CI = 4.19-7.04) as compared to adults without ASD 
but with a non-psychiatric comorbidity. Adults with ASD and a non-psychiatric comorbidity had 
no differences in likelihood of >1 IP visit or >1 ER visit as compared to adults without ASD but 
with a non-psychiatric comorbidity. Adults with ASD and a non-psychiatric comorbidity had 
higher OT (beta = 1.05, SE = 0.06, p<0.001), ER (beta = 1.58, SE = 0.09, p<0.001), Rx (beta = 
0.54, SE = 0.06, p<0.001), and total expenditures (beta = 0.40, SE = 0.06, p<0.001) as compared 
to adults without ASD but with a non-psychiatric comorbidity.  Presence of a non-psychiatric 
comorbidity among adults with ASD significantly increased the OT expenditures by $443, IP 
expenditures by $1,990, Rx expenditures by $1,160, and total expenditures by $5,084.  








 Our study examined the rates of psychiatric and non-psychiatric comorbidities 
among adults with and without ASD in a 1:3 matched cohort.  We also assessed differences in 
healthcare utilization and expenditures for adults with and without ASD, and examined the 
association of type of comorbidities with their healthcare utilization and expenditures.  With an 
increasing number of adults with ASD (Brugha et al., 2011) and a lack of published studies on 
their healthcare needs, patterns of healthcare services use, and costs, this study fills a critical gap 
in the literature.  
Although the rates of specific comorbidities among adults with ASD in our study are 
significantly different from those found in the recent study by (Croen et al., 2015), the two 
studies do share a common finding: prevalence of most psychiatric and a few non-psychiatric 
comorbidities among adults with ASD that are significantly higher when compared to adults 
without ASD.  In addition, prevalence rates of several other co-occurring health conditions were 
also significantly higher among adults with ASD as compared to adults without ASD. Our rates 
of specific comorbidities as compared to the study by Croen et al. (2015) were much lower. For 
example around 26% and 30% of adults with ASD in the Croen et al. (2015) study had 
depression and anxiety as compared to 15% and 12% rates respectively in our study. We also 
found that rates of non-psychiatric comorbidities such as gastrointestinal disorders (35%Croen vs. 
12.6%) and diabetes (7.6% Croen vs. 3.6%) in our sample were also lower in adults with ASD in 
our study.  There could be many reasons for these differences in prevalence rates between the 
two studies: 1) Croen et al. (2015) focused only on KP members from Northern California, a 
population whose demographics may be inherently different from our three state (IL, NY, and 
TX) Medicaid population; 2) The data in Croen et al. (2015) study was more recent (2008-2012), 
which may represent a period of greater awareness of autism as well as better access to services 
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associated with both mental and physical health needs (Patient Protection and Affordable Care 
Act, 42 U.S.C. § 18001 (2010)); and 3) We used an algorithm of one inpatient or two outpatient 
claims to identify a comorbidity which may have excluded patients with a single claim only. This 
criteria, however, helped to create a more robust definition of a comorbid condition in our study 
along with reducing chances of including coding errors.  
Psychiatric comorbidities (Table 2) 
Similar to children with ASD (Buck et al., 2014; Gorrindo et al., 2012; Maski et al., 
2011; Matson & Shoemaker, 2009), adults with ASD also have very high rates of  psychiatric 
comorbidities. Around 81% of adults with ASD had a psychiatric comorbidity as compared to 
41% of adults without ASD.  This prevalence rate of a psychiatric comorbidity also supports the 
findings from other small sample studies among adults with ASD (Buck et al., 2014a; Lugnegard 
et al., 2011a; Lunsky et al., 2009; Tsakanikos, Costello, Holt, Sturmey, & Bouras, 2007). In our 
study the most common comorbid condition among adults with ASD was intellectual disability 
(ID) with a 70% prevalence rate. This finding is very critical since studies have shown how ASD 
with comorbid ID can increase the lifetime costs of individuals with ASD substantially 
(Buescher et al., 2014; Knapp et al., 2009).  
Other common psychiatric comorbidities that had higher prevalence rates among adults 
with ASD as compared to adults without ASD were anxiety (12%ASD vs. 5.6%noASD) 
ADD/ADHD (8%ASD vs. 0.7%noASD), and schizophrenia (16%ASD vs. 11%noASD).  Interestingly, 
behavioral disorders such as alcohol/substance abuse (2%ASD vs. 18%noASD) were significantly 
less common among adults with ASD as compared to adults without ASD.  Literature has shown 
that usually individuals with ASD are less prone to use of drugs/alcohol, however, higher 
functioning individuals may frequently engage in alcohol consumption to help alleviate the 
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social difficulties they experience (Santosh & Mijovic, 2006; Sizoo, van den Brink, Gorissen van 
Eenige, & van der Gaag, 2009). Since substance use disorder (SUD) is associated with greater 
healthcare resources utilization and worse outcomes (Smith, Stocks, & Santora, 2015), greater 
attention and monitoring may be needed to identify SUD among adults with ASD so that timely 
counseling can be provided.  
Non-psychiatric comorbidities (Table 2) 
 Adults with ASD had a significantly lower prevalence rate of non-psychiatric disorders at 
40% as compared to 46% among adults without ASD. Even though a meta analyses showed 
higher prevalence of gastrointestinal (GI) disorders among children with ASD as compared to 
children without ASD (Buie et al., 2010; McElhanon et al., 2014), our study showed a 
significantly higher yet similar prevalence of GI symptoms among adults with ASD as compared 
to adults without ASD.  The rate of cardiovascular/cerebrovascular disorders was significantly 
lower in adults without ASD (14%) than adults with ASD (17%).  Muscoskeletal disorder 
prevalence rate was lower among adults with ASD (12%) as compared to adults without ASD 
(16%). It was the same case for diabetes rates as well, where around 4% of adults with ASD had 
a comorbid diabetes diagnosis as compared to 5% of adults without ASD. These findings reflect 
that adults with ASD if not higher, have similar extent of non-psychiatric needs as adults without 
ASD which are not usually addressed in the literature.  
Other Health Conditions 
Even though the rates of most non-psychiatric conditions except gastrointestinal disorders 
were much lower in adults with ASD as compared to adults without ASD, the prevalence of 
other comorbid health conditions were higher in the former group. For example, adults with ASD 
had significantly higher prevalence rates of epilepsy (22%) as compared to adults without ASD 
(5%), confirming the evidence on high epilepsy prevalence among individuals with ASD from 
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previous studies (Howlin et al., 2004; Kohane et al., 2012; Maski et al., 2011).  Other health 
conditions which were more common among adults with ASD were thyroid disease (5%), other 
nutrition/endocrine/metabolic disorders excluding diabetes (11%), lipid disorders (5%), 
hematological disorders (6.5%), infections (22%), genito-urinary disorders (10%), and skin 
disorders (22%).  Several of these disorders such as skin disorders have been found to be very 
common among children with ASD (Bakare, Munir, & Kinney, 2011; Schieve et al., 2012). In 
addition, adults with ASD also showed higher prevalence of other impairments such as 
blindness/vision defects (5.4%) and hearing impairments (19%) showing high disability needs in 
this population.  
There are a couple of notable points after examining prevalence rates of psychiatric, non-
psychiatric comorbidities, and other health conditions among adults with ASD. Psychiatric 
disorders such as schizophrenia and ASD have been linked previously in adult populations 
(Hofvander et al., 2009a; Mouridsen, Bronnum-Hansen, Rich, & Isager, 2008).  High rates of 
other psychiatric disorders such as anxiety and ADD should be highlighted in adults with ASD, 
since these disorders not only put the individuals at a greater risk of other disorders such as 
depression, but also are associated with suicide attempts (Kato et al., 2013). In addition many of 
these psychiatric conditions such as ADD/ADHD, mood disorders, and schizophrenia have been 
shown to share similar genetic makeup as compared to ASD in a recent study (Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013). Pharmacotherapy for individuals with 
ASD, which usually includes antipsychotics, antidepressants, stimulants, and anticonvulsants 
have been shown to be associated with increased risk of dyslipidemia, metabolic syndrome, 
obesity, diabetes, and cardiovascular issues (Ji & Findling, 2015; Rojo et al., 2015).  Our study 
showed a high prevalence of lipid disorders which could be attributed to high medication use in 
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the ASD population. Considering that a substantial proportion of adults with ASD diagnosed as 
children continue with these medications for a very long time (Esbensen et al., 2009), their risks 
of developing such conditions later in life are high (Croen et al., 2015). According to a study by 
(Nicolaidis et al., 2013), adults with ASD (n = 209) are more likely to report lower general and 
chronic condition self-efficacy, poor satisfaction rates with  patient-provider communication, 
lower receipt of preventive services, and higher unmet needs as compared to adults without ASD 
(n = 228). This study highlights that there are certain needs of adults with ASD that have not 
been met either due to difficulties in communication or lower access to ASD care. In addition, it 
is quite possible that social impairments may not allow adults with ASD to correctly report 
symptoms that cause discomfort, leading to possibly a missed or delayed diagnosis and foregone 
care.  
Health care utilization and expenditures (Table 3 and 4) 
In addition to assessing the rates of specific comorbidity in our sample, our study also 
examined the differences in use of healthcare services and associated expenditures across adults 
with and without ASD. We found that adults with ASD have significantly greater use of OT 
visits and Rx claims as compared to adults without ASD, regardless of the type of comorbidity 
associated with either group.  The mean number of OT visits were 4 times higher and Rx claims 
were more than 2 times higher for adults with ASD as compared to adults without ASD.  
Surprisingly, IP visits were much lower in ASD group and there were no significant differences 
in the mean number of ER visits among adults with and without ASD despite previous studies 
among individuals with ASD of all ages as compared to individuals without ASD showing a 
higher inpatient burden (Croen et al., 2006; Lokhandwala et al., 2012).  Previous studies have 
shown that individuals with ASD who participate in home and community based (HCBS) 
waivers have significantly lower likelihood of using IP or long term care services (Cidav, 
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Marcus, & Mandell, 2014; Velott et al., 2015). It is quite possible that many individuals with 
ASD in our sample are also participating in HCBS waivers and making their hospitalization rates 
are lower as compared to adults without ASD.   
Adults with ASD also had significantly higher mean total expenditures (sum of OT, IP, 
and Rx expenditures) as compared to total expenditures of adults without ASD. The mean OT, 
ER, Rx, and total expenditures associated with adults with ASD were 5 times, 7 times, 2 times, 
and 2 times higher, respectively than adults without ASD (Table 3). In contrast to lower mean 
number of ER visits among adults with ASD, the corresponding ER expenditures were 
significantly higher than for adults without ASD. After adjusting for selected characteristics, 
adults with ASD had 0.4 times ($1,159 difference; Table 4) the average annual total expenditures 
of adults without ASD.  There are a plethora of studies that have shown that children with ASD 
have high healthcare utilization and expenditures, especially as compared to children without 
ASD (Croen et al., 2006; Kogan et al., 2008; Leslie & Martin, 2007; Liptak et al., 2006; 
Lokhandwala et al., 2012; Mandell et al., 2006; Shimabukuro, Grosse, & Rice, 2008; Wang & 
Leslie, 2010a). Our study is the first among a large sample of adults with ASD identifying the 
excess healthcare utilization and expenditures as compared to adults without ASD.  The reasons 
why the healthcare utilization and expenditures are higher among the ASD group may be 
attributable to the extensive comorbidities among adults with ASD and the lack of knowledge of 
ASD among healthcare providers which leads to delayed care and frequent revisits to the 
outpatient settings, ER, and hospitals (Heidgerken et al., 2005; Imran et al., 2011). 
Our study also contributed to the literature by providing an estimate of the association of 
the type of comorbidity with healthcare utilization and expenditures of adults with and without 
ASD (Table 4).  There was no significant impact of psychiatric comorbidity on likelihood of 
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healthcare utilization per year, where adults with ASD showed significantly higher OT and Rx 
utilization and lower IP and ER utilization as compared to adults without ASD. However, non-
psychiatric comorbidity did have an effect modification on likelihood of higher IP and ER visits, 
where adults with and without ASD were no longer significantly different. This finding could 
mean that non-psychiatric comorbidity contributes significantly to determining the extent of 
hospitalizations and ER visits among adults with and without ASD. In terms of differential 
economic burden due to comorbidities, adults with ASD had consistently higher OT, ER, Rx, 
and total expenditures and lower IP expenditures as compared to adults without ASD, regardless 
of type of comorbidity.  
Presence of comorbidity within adults with ASD did have a significant impact on both 
healthcare utilization as well as expenditures. Presence of psychiatric comorbidity among adults 
with ASD significantly increased the OT expenditures by $2,130, ER expenditures by $10,532, 
and total expenditures by $4,952. Presence of a non-psychiatric comorbidity among adults with 
ASD significantly increased the OT expenditures by $443, IP expenditures by $1,990, Rx 
expenditures by $1,160, and total expenditures by $5,084. (Peacock et al., 2012) established that 
Medicaid enrolled children with ASD have substantially higher healthcare expenditures based on 
the type of comorbid condition. Having ADHD, epilepsy, and intellectual disability was 
associated with 1.3 times, 1.6 times, and 2.7 times higher annual total expenditures for adults 
with ASD as compared to adults with ASD but no comorbidity.  
Implications 
Our study showed that adults with ASD not only suffer from a great deal of comorbid 
pathology but also exhibit high healthcare needs and expenditures. Addressing the core deficit 
areas in adult ASD care is the next step where adults will have a better transition from childhood, 
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are able to communicate their issues to a healthcare provider, and receive well-coordinated and 
quality care for psychiatric, non-psychiatric conditions, and other health conditions. From a 
policy perspective, our study showed that adults with ASD represent a high needs group within 
the Medicaid population. Medicaid coverage provides substantial number of services for adults 
with ASD which also transforms into extremely high costs.  With the recent efforts to reduce 
long term healthcare costs and still maintain quality care, understanding the pattern of healthcare 
utilization and factors influencing the high services use among adults with ASD may draw 
attention to the need for better coordinated care and/or processes to improve communication and 
treatment experiences.  
As noted in many previous studies (Heidgerken et al., 2005; Imran et al., 2011; Liptak et 
al., 2006; Miller, 2015; Piven, Rabins, & Autism-in-Older Adults Working Group, 2011), ASD 
knowledge and training among physicians and other specialty care providers have been reported 
to be low, and there is a lack in self-reported confidence among providers in being able to 
correctly identify ASD, understand their symptoms and pharmacological needs, and provide 
quality care that improves disease prognosis and reduce morbidity.  In a scenario where there is 
no gold standard cure and most medications have medium to low level effectiveness (Warren et 
al., April 2011), greater focus may be needed to provide easy access to early intervention 
services which have been shown to significantly improve prognosis of this condition (Autism 
Speaks, 2013; Bailey, Hebbeler, Scarborough, Spiker, & Mallik, 2004; Reichow, 2012). In 
addition, further studies may be needed to address the poor rating of patient provider 
communication and greater unmet healthcare needs that have been reported by adults with ASD 
(Magiati et al., 2014; Nicolaidis et al., 2013).  




To conduct this study, we used a three state Medicaid dataset (IL, NY, and TX) for the 
period 2000-2008.  Even though these states provided variation in demographics and high 
number of adults with ASD, we did not control for any unobservable bias in the study. The goal 
of the study was to examine the rates of comorbidities and excess healthcare use and 
expenditures among adults with ASD as compared to adults without ASD and our current data 
was sufficient for this purpose. Our identification of ASD and comorbidities using a conservative 
algorithm has not been validated among adults and this study may underestimate the real world 
prevalence of adults with ASD as well as comorbidities in Medicaid data. This was also an issue 
because there are no existing published studies on adults with ASD in the Medicaid population 
which could be used as a reference point. Our study focused on all cause healthcare utilization 
and expenditures, so we did not know what type of diagnoses these outcomes were associated 
with or what were the reasons of such visits. We required adults with ASD to be continuously 
enrolled during the study period to allow capturing their true healthcare utilization and 
expenditures, which could have excluded many individuals with irregular Medicaid enrollment. 
We did not match the ASD cases and no ASD controls on their enrollment period, which could 
have created certain baseline differences in the two groups.  
Strengths 
 The current study is the first study to examine a large number of adults with ASD and 
compare their extent of comorbidities, healthcare utilization, and expenditures to adults without 
ASD within a Medicaid population. Medicaid serves as the largest single payer for individuals 
with ASD (Ruble et al., 2005) and highlighting the healthcare use patterns and expenditures 
associated with this population will help promote better education and development of guidelines 
for healthcare providers on ASD treatment and care.  We also examined the impact of the type of 
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comorbidity on healthcare utilization and expenditures for adults with ASD to provide an 
estimate of how a comorbidity can impact the healthcare use of adults with ASD.  We addressed 
significant observed differences between adults with and without ASD by matching them by age, 
gender, and race.  
Conclusions 
Psychiatric comorbidities such as intellectual disabilities, anxiety, ADD/ADHD, and 
schizophrenia are very common among adults with ASD and non-psychiatric comorbidities such 
as gastrointestinal disorders are also highly common. Other than major comorbidities, other 
health conditions such as epilepsy, thyroid, lipid metabolism disorders, genito-urinary disorders, 
skin disorders, and infections are also highly prevalent in adults with ASD as compared to adults 
without ASD. Adults with ASD exhibit excess healthcare utilization in form of higher number of 
outpatient visits and prescription drug claims in a year and annual total Medicaid expenditures as 
compared to adults without ASD.  Even though comorbidities play a significant role in 
increasing service utilization and expenditures for adults with ASD, they contribute minimally 
towards the differences in healthcare utilization and expenditures between adults with and 
without ASD.  Medicaid coverage of healthcare services for adults with ASD is substantial and 
state programs bear high costs of such services. Care should be directed towards managing both 
psychiatric and non-psychiatric needs of adults with ASD in the primary as well as specialty care 
settings. Future policies should strive for better ASD training and education of healthcare 
providers as well as guidelines for treatment that assure quality and well-coordinated care for 
adults with ASD. 
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Table 1. Description of Sample by ASD diagnoses 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
  ASD No ASD  
    N Col% N Col% Sig. 
ALL   1,772 100.0 5,320 100.0   
Identification year      
 2000 617 34.8 1,851 34.8  
 2001 250 14.1 750 14.1  
 2002 185 10.4 555 10.4  
 2003 162 9.1 486 9.1  
 2004 163 9.2 489 9.2  
 2005 129 7.3 387 7.3  
 2006 92 5.2 280 5.3  
 2007 174 9.8 522 9.8  
State       
 IL 292 16.5 876 16.5  
 NY 1,216 68.6 3,648 68.6  
 TX 264 14.9 796 15.0  
Sex       
 female 506 28.6 1,518 28.5  
 male 1,266 71.4 3,802 71.5  
Age       
 22-40 1,517 85.6 4,555 85.6  
 41-64 255 14.4 765 14.4  
Race       
 White 658 37.1 1,974 37.1  
 African American 364 20.5 1,094 20.6  
 Other 750 42.3 2,252 42.3  
Eligibility     *** 
 Cash 1,456 82.2 3,207 60.3  
 No cash 316 17.8 2,113 39.7  
      *** 
 Medically needy 77 4.3 912 17.1  
 Not medically needy 1,695 95.7 4,408 82.9  
       
Rx claims per year     *** 
 >25 Rx claims 1,230 69.4 1,486 27.9  
 <=25 Rx claims 448 25.3 3,137 59.0  
 no claim 94 5.3 697 13.1  
County Characteristics           
Metro      *** 
 yes  1,450 81.8 4,570 85.9  
 no 322 18.2 750 14.1  
PCP shortage area      
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Table 1. Description of Sample by ASD diagnoses 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
  ASD No ASD  
    N Col% N Col% Sig. 
ALL   1,772 100.0 5,320 100.0   
 yes 1,575 88.9 4,810 90.4  
 no 197 11.1 510 9.6  
    
Mental health specialist shortage area   * 
 yes 1,434 80.9 4,419 83.1  
 no 338 19.1 901 16.9  
Psychiatrists density      ** 
 high 1,322 74.6 4,138 77.8  
 low 450 25.4 1,182 22.2  
 Median household income level    *** 
 q1 286 16.1 440 8.3  
 q2 69 3.9 438 8.2  
 q3 338 19.1 1,053 19.8  
 q4 1,079 60.9 3,389 63.7  
HS education and above     *** 
 q1 1,071 60.4 3,164 59.5  
 q2 80 4.5 483 9.1  
 q3 244 13.8 737 13.9  
  q4 377 21.3 936 17.6   
Note: Based on chi-square estimates for fee for service enrolled individuals aged 
22-64 years with no Medicare coverage and alive in IL, NY, and TX Medicaid from 
2000-2008.ASD: Autism Spectrum Disorders; Rx: Prescription Drug; PCP: Primary 
Care Provider. Col %: Column percentages; ns: not significant at p<0.05 level. Sig.: 
***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. 
  




Table 2. Description of sample baseline characteristics by ASD diagnoses 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
    ASD No ASD   
    N Col% N Col% Sig. 
ALL   1,772 100.0 5,320 100.0   
Psychiatric Comorbidity 1,440 81.3 2,216 41.7 *** 
Adjustment disorders      
 yes 58 3.3 138 2.6  
 no 1,714 96.7 5,182 97.4  
Anxiety      *** 
 yes 216 12.2 299 5.6  
 no 1,556 87.8 5,021 94.4  
ADD/ADHD     *** 
 yes 146 8.2 37 0.7  
 no 1,626 91.8 5,283 99.3  
Intellectual disabilities     *** 
 yes 1,231 69.5 270 5.1  
 no 541 30.5 5,050 94.9  
Mood disorders      
 yes 256 14.4 839 15.8  
 no 1,516 85.6 4,481 84.2  
Personality disorders      
 yes 44 2.5 105 2.0  
 no 1,728 97.5 5,215 98.0  
Schizophrenia     *** 
 yes 294 16.6 590 11.1  
 no 1,478 83.4 4,730 88.9  
Alcohol/Substance use disorders    *** 
 yes 36 2.0 948 17.8  
  no 1,736 98.0 4,372 82.2   
Non-Psychiatric Comorbidity 708 40.0 2,429 45.7 *** 
Cancer      *** 
 yes 21 1.2 149 2.8  
 no 1,751 98.8 5,171 97.2  
Gastrointestinal disorders    *** 
 yes 223 12.6 583 11.0  
 no 1,549 87.4 4,737 89.0  
Respiratory disorders     *** 
 yes 267 15.1 1,010 19.0  
 no 1,505 84.9 4,310 81.0  
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Table 2. Description of sample baseline characteristics by ASD diagnoses 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
    ASD No ASD   
    N Col% N Col% Sig. 
ALL   1,772 100.0 5,320 100.0   
Cardiovascular/Cerebrovascular disorders   ** 
 yes 242 13.7 897 16.9  
 no 1,530 86.3 4,423 83.1  
Diabetes      * 
 yes 63 3.6 250 4.7  
 no 1,709 96.4 5,070 95.3  
Muscoskeletal disorders    *** 
 yes 216 12.2 852 16.0  
  no 1,556 87.8 4,468 84.0   
Other Health Conditions             
Epilepsy      *** 
 yes 403 22.7 257 4.8  
 no 1,369 77.3 5,063 95.2  
Headache/Migraine     *** 
 yes 18 1.0 176 3.3  
 no 1,754 99.0 5,144 96.7  
Thyroid      *** 
 yes 83 4.7 71 1.3  
 no 1,689 95.3 5,249 98.7  
Other endocrine disorders    *** 
 yes 192 10.8 214 4.0  
 no 1,580 89.2 5,106 96.0  
Nutrition deficiencies      
 yes 15 0.8 42 0.8  
 no 1,757 99.2 5,278 99.2  
Lipid disorders     *** 
 yes 84 4.7 131 2.5  
 no 1,688 95.3 5,189 97.5  
Fluid and electrolyte dysfunctions    *** 
 yes 84 4.7 168 3.2  
 no 1,688 95.3 5,152 96.8  
Jaw and teeth disorders     *** 
 yes 184 10.4 155 2.9  
 no 1,588 89.6 5,165 97.1  
Hematological disorders    *** 
 yes 115 6.5 240 4.5  
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Table 2. Description of sample baseline characteristics by ASD diagnoses 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
    ASD No ASD   
    N Col% N Col% Sig. 
ALL   1,772 100.0 5,320 100.0   
 no 1,657 93.5 5,080 95.5  
Genito-urinary disorders    *** 
 yes 168 9.5 423 8.0  
 no 1,604 90.5 4,897 92.0  
Paralysis      *** 
 yes 101 5.7 157 3.0  
 no 1,671 94.3 5,163 97.0  
Infections      *** 
 yes 381 21.5 924 17.4  
 no 1,391 78.5 4,396 82.6  
Skin disorders     *** 
 yes 376 21.2 786 14.8  
 no 1,396 78.8 4,534 85.2  
Blindness/vision defects    ** 
 yes 96 5.4 197 3.7  
 no 1,676 94.6 5,123 96.3  
Hearing impairments     *** 
 yes 328 18.5 210 3.9  
  no 1,444 81.5 5,110 96.1   
Note: Based on chi-square estimates for fee for service enrolled individuals aged 22-
64 years with no Medicare coverage and alive in IL, NY, and TX Medicaid from 
2000-2008. ASD: Autism Spectrum Disorders; Col %: Column percentages; ns: not 
significant at p<0.05 level. Fischer’s exact tests were run for variables with expected 
counts <5. Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. 
  




Table 3a. Healthcare utilization and expenditures by ASD diagnoses 
Mean, medians, and standard deviations for healthcare utilization and expenditures 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
  ASD No ASD Sig. 
 Mean, Median  SD Mean, Median  SD   
Healthcare utilization (number of 
visits, claims in follow up year) 
          
OT 32 ,12 49 8 ,3 17 *** 
IP 0.30 ,0 1 0.46,0 2 *** 
Rx 51 ,45 38 24 ,12 32 *** 
ER 1 ,0 7 1 ,0 3   
Healthcare expenditures (2008 constant dollars)       
OT $4,375 ,$1,092 $7,836 $854 ,$187 $2,751 *** 
IP $3,258 ,$0 $14,130 $4,562 ,$0 $20,368 * 
Rx $6,067 ,$4,925 $5,390 $3,144 ,$625 $6,798 *** 
ER $15,929 ,$0 $38,747 $2,598 ,$0 $13,133 *** 
Total $13,700 ,$9,072 $17,095 $8,560 ,$1,760 $22,534 *** 
Note: Based on t-tests estimates for fee for service enrolled individuals aged 22-64 years with no Medicare coverage 
and alive in IL, NY, and TX Medicaid from 2000-2008. 
ASD: Autism Spectrum Disorders; Rx: Prescription Drug; OT: Outpatient Visits; IP: Inpatient Hospitalizations; ER: 
Emergency Room 
Total expenditures are sum of OT, IP, and Rx expenditures 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. 
  




Table 3b. Healthcare utilization and expenditures by ASD diagnoses among users 
Mean, medians, and standard deviations for healthcare utilization and expenditures 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
          
  N  ASD No ASD   
    Mean, Median  SD Mean, Median  SD Sig.  
Healthcare utilization 
(number of visits, claims in 
follow up year) 
      
OT  5,969 34 ,13 49 10 ,5 18.0 *** 
IP 1,313 2 ,1 2 2 ,1 3.0  
Rx 6,313 54 ,48 37 28 ,16 33.0 *** 
ER 2,741 3 ,2 11 3 ,2 5.0  
ALOS 1,313 10 ,6 17 8 ,4 14.0 * 
Healthcare expenditures (2008 constant dollars)       
OT 5,969 $4,617 ,$1,272 $7,980 $1,059 ,$303 $3,028 *** 
IP 1,313 $22,912 ,$11,812 $30,928 $22,872 ,$10,199 $40,773  
Rx 6,313 $6,388 ,$5,298 $5,342 $3,613 ,$968 $7,170 *** 
ER 2,741 $47,438 ,$15,967 $54,578 $6,441 ,$1,937 $20,073 *** 
Note: Based on t-tests estimates for fee for service enrolled individuals aged 22-64 years with no 
Medicare coverage and alive in IL, NY, and TX Medicaid from 2000-2008. Users represent only those 
individuals who used respective services. 
ASD: Autism Spectrum Disorders; Rx: Prescription Drug; OT: Outpatient Visits; IP: Inpatient 
Hospitalizations; ER: Emergency Room; ALOS: Average Length of Stay 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. 
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Table 4. Odds Ratios, 95% Confidence Intervals, Parameter Estimates, and Standard Errors for Healthcare Utilization and Expenditures 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
Utilization >= 4 OT visits > 1 IP visit >1 ER visit >=18 Rx claims       
    AOR 95% CI AOR 95% CI AOR 95% CI AOR 
95% 
CI       
ASD                 
 yes 2.73*** (2.31,3.22) 0.70* (0.51,0.96) 0.76** (0.61,0.93) 4.79*** (4.09,5.60)   
 no            
ASD*Psychiatric Comorbidity         
 
ASD_psych vs. 
NoASD_psych 3.05*** (2.49,3.73) 0.61** (0.44,0.84) 0.71** (0.56,0.88) 3.87*** (3.23,4.65)   
 
ASD_psych vs. 
ASD_nopsych 3.30*** (2.43,4.49) 1.70 (0.59,4.88) 1.49 (0.91,2.47) 2.08*** (1.53,2.84)   








nonpsych 1.44* (1.08,1.93) 1.57 (0.92,2.68) 1.96*** (1.41,2.72) 1.99*** (1.49,2.66)   
              
Expenditures OT IP ER Rx Total Total $ 
    Beta SE Beta SE Beta SE Beta SE Beta SE   
Intercept 6.28*** 0.11 8.13*** 0.18 7.83*** 0.17 7.75*** 0.11 8.02*** 0.11 $3,048 
ASD (Model 1)            
 yes 0.94*** 0.05 -0.20** 0.08 1.51*** 0.07 0.49*** 0.04 0.32*** 0.04 $4,207 
 no            





NoASD_psych 1.14*** 0.05 -0.26** 0.08 1.42*** 0.08 0.32*** 0.05 0.19*** 0.05 $1,800 
 
ASD_psych vs. 
ASD_nopsych 1.54*** 0.09 0.16 0.23 0.62*** 0.17 0.17 0.09 0.65*** 0.09 $4,952 
PhD Dissertation Chapter 2 
83 
 
Table 4. Odds Ratios, 95% Confidence Intervals, Parameter Estimates, and Standard Errors for Healthcare Utilization and Expenditures 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 








nonpsych 0.18** 0.07 0.45*** 0.13 -0.16 0.11 0.17* 0.07 0.46*** 0.07 $5,084 
 
Note: Based on estimates for fee for service enrolled individuals aged 22-64 years with no Medicare coverage and alive in IL, NY, and TX Medicaid from 2000-
2008.ASD: Autism Spectrum Disorders; Rx: Prescription Drug; OT: Outpatient Visits; IP: Inpatient Hospitalizations; ER: Emergency Room. 
AOR’s represent estimates from multinomial logistic regression analyses respectively after adjusting for cohort (before/after 2004), state, eligibility, county 
characteristics (metro status, median household income,  above high school education, PCP shortage area, mental health specialist shortage area, and psychiatrist 
density), baseline Rx use, psychiatric comorbidity, and non-psychiatric comorbidity. 
Parameter estimates represent results from generalized linear models with gamma distribution and log-link function after adjusting for cohort (before/after 2004), 
state, eligibility, county characteristics (metro status, median household income,  above high school education, PCP shortage area, mental health specialist shortage 
area, and psychiatrist density), baseline Rx use, psychiatric comorbidity, and non-psychiatric comorbidity.      
Model for IP expenditures was also adjusted for average length of stay. 
Model for Rx and total expenditures was not adjusted for baseline prescription drug use due to high collinearity issues.  
Total expenditures represents sum of OT, IP, and Rx expenditures. 
Model 1, 2, and 3 represent separate regressions.  
Total dollar = exponentiated (beta)  
Additional Dollar = exponentiated (intercept) – exponentiated (beta) for each regression. 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. 
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Background: The use of emergency department (ED) visits among adults with psychiatric needs 
is known to be very high, yet there are no comprehensive studies that have characterized ED use 
among adults with autism spectrum disorders (ASD). Due to the lack of clarity on adult ASD 
treatment guidelines and possible delayed/foregone care in outpatient settings, adults with ASD 
may be at a substantial risk of high ED use and costs.  
Objectives: 1) To examine the trends in ED visits and mean total ED charges for adults with 
ASD over a period of 6 years; 2) To examine and compare the types of ED use (psychiatric, non-
psychiatric, and injury) among adults with and without ASD.  
Methods: A cross-sectional study using discharge level data from the Nationwide Emergency 
Department Sample (NEDS; 2006-2011) was conducted to the examine trends and 
characteristics of ED visits among adults aged 22-64 years, with and without ASD (ICD9-CM 
code: 299.xx).  ASD cases were matched to no ASD controls by age and gender using propensity 
score matching (1:3). Trends are presented as annual weighted rates and mean total charges for 
all, psychiatric (principal diagnosis of a psychiatric disorder), non-psychiatric (principal 
diagnosis of a non-psychiatric disorder), and injury (any) visits among adults with ASD.  Chi 
square analyses and t-tests were conducted to examine sub group differences in socio-
demographic, hospital, and patient disposition characteristics across adults with and without 
ASD. Weighted rates of psychiatric, non-psychiatric, and injury visits were compared between 
adults with and without ASD.  Multivariate adjusted logistic regressions were run to examine the 
likelihood of a psychiatric, non-psychiatric, and an injury visit among adults with ASD as 
compared to adults without ASD. All analyses adjusted for the NEDS complex survey design. 
PhD Dissertation Chapter 3 
87 
 
Results: Around 0.4% (n = 25,527) of ED visits were associated with an adult ASD diagnosis in 
the unmatched sample. The rates of ED visits among adults with ASD more than doubled from 
2006 to 2011 (10,047 to 23,992 per 100,000 admissions).  Around one-third of the ED visits 
among adults with ASD led to an inpatient hospitalization. The rates of specific ED visits among 
adults with and without ASD were: psychiatric (15%ASD vs. 4.2%noASD), non-psychiatric 
(16%ASD vs. 14%noASD), and injury (24%ASD vs. 28%noASD). Most common ED visits associated 
with adults with ASD were: epilepsy (8.8%), falls (6.5%), schizophrenia (3.8%), and respiratory 
disorders (3.8%).  Adults with ASD were found to be more likely to have a psychiatric visit 
(AOR = 2.63, 95% CI = 2.41-2.88), a non-psychiatric visit (AOR = 1.07, 95% CI = 1.01-1.14), 
and an injury visit (AOR = 1.10, 95% CI = 1.04-1.16) as compared to adults without ASD.  
Mean total ED charges for adults with ASD were 2.3 times higher than adults without ASD. 
Conclusion: Rates of ED visits among adults with ASD are on the rise. Adults with ASD use ED 
for different reasons which are not restricted to psychiatric needs, but also extend to non-
psychiatric needs and injuries. ED visits among adults with ASD are also associated with 
significantly greater hospitalization rates as compared to adults without ASD.  Mean total ED 
charges for adults with ASD are almost twice as high as charges for adults without ASD. 
Prevalence, risk factors, and burden of ED utilization among adults with ASD is understudied 








The burden of emergency department (ED) use in the US is high and the total number of 
national ED visits in the year 2005 ranged from 109.2 million to 116.3 million (Owens et al., 
2010; Tang, Stein, Hsia, Maselli, & Gonzales, 2010). According to a report by (Choudhry et al., 
2007) on association of community affiliated plans, at least one-third of ED visits were 
avoidable/non-urgent/ambulatory care sensitive and treatable in primary care settings. 
Surprisingly, over $18 billion dollars are spent annually on such avoidable ED visits in the US 
(Choudhry et al., 2007).  Since ED is often the most critical point of healthcare delivery and for 
many individuals the only point of healthcare delivery, it is important to document the extent of 
ED utilization among patients with high healthcare needs and among those who are at high risk 
of frequent returns. 
Even though adults with ASD have considerable healthcare needs (Billstedt et al., 2005; 
Magiati et al., 2014), there is a lack of comprehensive documentation of characteristics and 
patterns of ED use among this group. Previous studies on use of ED services among individuals 
with ASD have been either restricted to pediatric/adolescent population (Croen et al., 2006; Kalb 
et al., 2012; Wharff, Ginnis, Ross, & Blood, 2011) and/or examination of ED use as a part of a 
bigger study with no specific details on types of ED visits (Croen et al., 2006; Kato et al., 2013; 
Nicolaidis et al., 2013).  Nonetheless, such studies have provided insights which corroborate the 
hypothesis that adults with ASD are at high risk of ED use.  Nicolaidis et al. (2013) examined the 
healthcare experiences of adults with and without ASD via an online cross sectional survey and 
found that adults with ASD had greater odds of using an ED as compared to adults without ASD 
(OR = 2.1, 95% CI = 1.8-3.8).  (Kato et al., 2013) compared the characteristics of suicide 
attempts in a hospital emergency room between adults with and without ASD. The authors found 
that about 7.3% of patients with suicidal emergencies had ASD, and those with ASD had a 
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significantly greater prevalence of adjustment disorders (70%) and a longer length of stay in the 
intensive care unit/hospital as compared to adults without ASD. The authors suggested that 
patients with ASD, due to impulsive behavior and aggression tendencies may be more likely to 
choose lethal methods of suicide, and may even be more likely to succeed in their first suicidal 
attempt in cases where stressors are not spontaneous, and when there is a lack of psychiatric 
treatment in the recent past. Despite such studies, there is a need to characterize preponderant ED 
visits among adults with ASD and compare them to adults without ASD because the former has 
various concerns that puts them at a greater risk of worse ED outcomes:  
Comorbidities 
Adults with ASD have extensive comorbidities such as intellectual disabilities, 
depression, anxiety, ADHD, and substance dependence disorder (Hofvander et al., 2009b; 
Lugnegard et al., 2011b) along with core autistic symptoms that present greater challenges in 
care as compared to adults without ASD (Pines et al., 2011). A study by (E. R. Williams et al., 
2001) found high prevalence of anxiety and depressive disorders among frequent attenders of 
ED. Substance abuse also influences ED use over a period of time for adults with other 
psychiatric illness (OR = 4.9, 95% CI = 3.5–6.9) (G. M. Curran et al., 2003). In addition, some 
studies have shown that many patients (as high as 24%) with depressive disorders (comorbid or 
not) present to the ED for traumatic physical injuries/self-inflicted injuries (Doshi, Boudreaux, 
Wang, Pelletier, & Camargo, 2005; Richmond et al., 2007). This indicates that adults with ASD 
may have a higher risk of injuries not only because of their own behavioral tendencies but also 
because of high prevalence of comorbid depression (Lugnegard et al., 2011a; Lunsky et al., 
2009).  A very recent study by Croen and colleagues (Croen et al., 2015) showed that adults with 
ASD are also more likely to have greater prevalence of non-psychiatric comorbidities such as 
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diabetes, cardiovascular conditions, and high cholesterol, which may also be contribute to an 
increase in ED use and worsen ED experiences for adults with ASD.  
Disruptive Behaviors and Injuries 
Individuals with ASD are affected by challenging behaviors such as aggression, 
destruction, self-inflicted injuries, and other disruptive behaviors (Matson & Rivet, 2008) that 
many a time require emergent care. (Doshi et al., 2005) used the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) to examine the ED visit patterns for attempted suicide and 
self-inflicted injuries which accounted for more than 400,000 ED visits per year (0.4% of all ED 
visits).  The most common cases in the ED were treated for poisoning (28% by unspecified drugs 
or medicinal substances, 27% tranquilizers and other psychotropic agents and 25% by 
analgesics/antipyretics/anti-rheumatics) followed by cutting or piercing. Knowing that 
individuals with ASD frequently engage in disruptive behaviors (Matson & Rivet, 2008), it is 
very likely that they may present to ED with extreme self-inflicted injuries. Since, some adults 
with ASD have communication difficulties, providing care in ED for injuries, may also be a 
bigger challenge for ED primary care providers.  
Paucity of Trained Professionals 
Lack of trained psychiatrists and other mental health professionals that can manage 
individual ASD issues in specialty or primary care settings may also lead to greater ED use. (E. 
R. Williams et al., 2001) found that individuals with severe mental illness such as schizophrenia, 
bipolar disorder, and other psychosis who were frequent attenders of ED lacked a coordinated 
community program involving mental health, primary care, and ED.  In addition, it was found 
that ED visits related to mental health, in many cases, could have been handled well in an 
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outpatient primary setting due to the non-urgent nature of the complaint (Sills & Bland, 2002; 
Soto et al., 2009).  Thus, sometimes an ED becomes a source of primary care for those with 
psychiatric needs such as ASD due to the lack of access to mental health facilities in the 
community and lack of trained professionals who are able to provide ASD care (Bruder et al., 
2012).   
The current study aims to address the gaps in literature on ED utilization among adults 
with ASD.  The study compares the trends in ED rates for adults with ASD across a span of six 
years using the Nationwide Emergency Database Sample (NEDS) 2006-2011 (Healthcare Cost 
and Utilization Project (HCUP), 2011).  We also determine the differences in rates of specific 
ED visits such as psychiatric, non-psychiatric, and injury visits across adults with and without 
ASD.  Examination of ED use will help highlight the deficits (if any) in quality of care/care 
coordination for adults with ASD provided in the primary care setting that possibly contributes to 
greater ED use and inpatient hospitalizations (Soto et al., 2009; E. R. Williams et al., 2001).  Due 
to the rise in adult ASD cases (Brugha et al., 2011) and with greater number of individuals 
receiving ASD diagnoses than ever before, we hypothesized that rates of ED visits with ASD 
diagnosis will increase over the six year period. In addition, we also expected that adults with 
ASD will be more likely to have psychiatric, non-psychiatric, as well as an injury visit as 
compared to adults without ASD. 
   




Study Population & Design 
Any ED visits among adults aged 22-64 years was the study population. A cross-sectional 
matched case-control design was used. Trend analyses was conducted with each year selected as 
a distinct data point in the study (2006-2011). For objectives other than trends, a pooled sample 
was used.  If any variable had missingness ≥0.5%, we created a missing indicator to account for 
any differences caused by missingness in our major independent variables. 
Data Source 
We used the Nationwide Emergency Database Sample (NEDS)  2006- 2011, largest all 
payer ED database including national estimates for hospital based ED data visits created for the 
Healthcare Cost and Utilization Project, Agency of Healthcare and Research Quality (Healthcare 
Cost and Utilization Project (HCUP), 2011). NEDS compiles discharge data collected from 
hospital billing records from both state emergency department databases (SEDD) and state 
inpatient databases (SID). The SID contains information on patients initially seen in the ED and 
then admitted to the same hospital. The SEDD capture information on ED visits that do not result 
in an admission (i.e., treat-and-release visits and transfers to another hospital).  
The NEDS is built using a 20% stratified sample of institutions and collects data from 
951 hospitals located in 30 states with an unweighted 30 million discharges each year. The 
NEDS presents rich information on type of ED visits (psychiatric, injury, etc.) along with up to 
15 diagnoses associated with each visit, geographic information, hospital characteristics, and 
total charges for each ED visit. We expect that high proportion of adults with ASD will present 
to the ED, utilize ED services frequently, and are possibly associated with an increased risk of 
subsequent hospitalizations as compared to adults without ASD. Using a database such as NEDS 
PhD Dissertation Chapter 3 
93 
 
not only helps understand the extent and patterns of ED use among adults with ASD but also 
provides additional information on reasons for these visits such as type of injuries (which has not 
been previously reported in any study on adults with ASD), primary diagnosis for the ED visit, 
and the outcome(s) of the ED visits (e.g. treated and released, transfer to home health, or 
inpatient hospitalizations etc.).  
Dependent Variables 
Psychiatric visit (yes/no) 
A psychiatric visit was identified by an ED visit with a principal diagnosis of a psychiatry 
disorder, other than ASD. The NEDS includes the single level clinical classification software 
(CCS) provided by Agency for Healthcare Research and Quality (Healthcare Cost and 
Utilization Project (HCUP), 2011) (https://www.hcup 
us.ahrq.gov/toolssoftware/CCS/AppendixASingleDX.txt) to categorize diagnosis and procedure 
codes to clinically meaningful categories. We used nine broad categories of psychiatric 
disorders: adjustment disorders (CCS code: 650), alcohol use disorders (AUD; CCS code: 660), 
anxiety disorders (CCS code: 651), attention deficit disorders & conduct behavior disorders 
(ADD; CCS code: 652), developmental disorders (CCS code: 654), mood disorders including 
depressive disorders and bipolar disorder (CCS code: 6571,6572), personality disorders (CCS 
code: 658), schizophrenia & other psychotic disorders (CCS code: 659), and substance use 
disorders (SUD; CCS code: 661).  
Non-psychiatric visit (yes/no) 
A non-psychiatric visit was identified as an ED visit with a principal diagnosis of a non-
psychiatric disorder. We used six broad categories of non-psychiatric disorders some of which 
have been found to be very common among adults with ASD in a recent study (Croen et al., 
2015): cancer (CCS code: 11-37, 39, 40-43), cardiovascular disease (CCS code: 100, 101, 105, 
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106, 108, 53, 98, 99, 109, 110-112), diabetes (CCS code: 49, 50), epilepsy (CCS code: 83), 
gastrointestinal disease (CCS code: 138-140, 141), and respiratory disease (CCS code: 125-128, 
132-134).  
Injury visit (yes/no) 
NEDS 2006-2009 reported external causes of injuries in form of CCS ecodes (4 possible 
ecodes on each record), but 2009 onwards the NEDS reported injuries as a separate variable 
(injury on principal diagnosis, injury on other diagnoses, and no injury). Each type of injury was 
identified using CCS ecodes/ICD-9-CM codes prior to 2009 and by an injury variable after the 
year 2009 to create a single binary indicator for any injury (yes/no). Any visit with a record of 
the following codes qualified as an injury visit: cutting (CCS ecode: 2601), drowning (CCS 
ecode: 2602), fall (CCS ecode: 2603), fire (CCS ecode: 2604), machinery (CCS ecode: 2606), 
poison (CCS ecode: 2613), struck (struck by lightning or an object; CCS ecode: 2614), and 
suffocation (CCS ecode: 2615). Additional critical injury characteristics such as assault (by 
intent; yes/no), self-harm (by intent; CCS ecode: 662 excluding V6284), and suicidal ideation 
(ICD9-CM code: V6284) are also included in the study.  We also report the severity of injury 
associated with an ED visit by examining presence of multiple cause of injuries (none or one, 2 
or more), which indicates the total number of external cause of injury ecodes (valid and invalid).  
Total ED Charges  
The edited total charges for ED services associated with each visit was used to identify 
economic burden of ED visits. Total ED charges included both “treat and release” ED visits as 
well as ED visits that led to a hospitalization in the same hospital. The total ED charges were 
expressed in constant dollars to adjust for inflation over the period of six years. “Medical care 
services” part of the annual consumer price index (CPI) was utilized to transform/convert total 
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charges to 2011 constant dollars. The CPI was obtained from the Bureau of Labor Statistics 
(Bureau of Labor Statistics, US Department of Labor, 2014).  
Independent variables 
ASD (yes/no) 
The NEDS provides up to 15 possible diagnoses recorded on each ED visit. Adults with 
ASD were identified using an ICD-9-CM diagnosis code in any position for: 299.xx (which 
includes autistic disorder, Asperger’s syndrome, and other pervasive developmental disorders).  
Other independent variables  
Age (22-40, 41-54, and 55-64) and gender (male and female) were included as 
demographic characteristics. The socio-economic status was described using median household 
income for patient’s zip code which was assigned as quartiles by the HCUP for each year (For 
e.g. in the 2011 NEDS, the median income was divided into: $1 - $38,999, $39,000 - $47,999, 
$48,000 - $63,999, and $64,000 or more). We used the median household income for patient’s 
zip code and categorized it into four major quartiles (Q1, Q2, Q3, Q4, and missing). Health 
insurance coverage selected as a primary payer for the ED visit was categorized into: public 
(Medicare/Medicaid), private, self-pay/other/no charge. Hospital characteristics included region 
(Northeast, Midwest, South, and West) and hospital location (rural, urban, and missing). Patient 
disposition characteristics included the type of ED event (treat and release, inpatient admission, 
transfer to another short term hospital/home health, and died/other). A mortality event was 
defined as any record of patient death reported on the ED visit (yes/no).  
Matching 
The ASD cases (1) and no ASD controls (3) were matched by age and gender using 
propensity score matching method with GREEDY algorithm. Predicted probabilities from a 
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multivariate logistic regression analysis on ASD status (yes, no) were used to identify and match 
the “nearest neighbor” with an ASD to a visit with no ASD.  
Statistical Analyses 
We conducted two sample chi-square tests to present trends in ED use and multivariate 
logistic and linear regressions to assess the significance of trends. The weighted rates (number 
per 100,000 admissions) are presented in form of graphs. Weighted rates for adults with ASD 
were calculated using number of ED visits with any ASD diagnosis (numerator) and total 
number of ED visits in the sample (denominator).  Weighted rates for specific ED visits, for 
example psychiatric visits were calculated using number of psychiatric ED visits with any ASD 
diagnoses (numerator) and total number of psychiatric ED visits in the sample (denominator). 
For examining sub-group differences across adults with and without ASD in the pooled sample, 
bivariate analyses were conducted (Chi-square for categorical and t-tests for continuous 
variables). Numbers and weighted percentages are reported for each type of visit by ASD status. 
Unadjusted and multivariate adjusted logistic regressions were run for binary dependent 
variables (psychiatric, non-psychiatric, and injury visits). All procedures accounted for NEDS 
complex survey design. For all analyses, SAS v9.4 was used. 
  




Trend Analyses (Figure 1 and 2) 
 Rates of ED visits for adults with ASD (Figure 1) increased from 10,047 to 23,992 per 
every 100,000 ED visits from the years 2006 to 2011. Psychiatric visit rates for adults with ASD 
exhibited the steepest rise from 9,576 to 24,948 per every 100,000 psychiatric visits as compared 
to all other specific ED visits. Despite the actual rise in rates for all, psychiatric, non-psychiatric, 
and injury visits, none of the trends were significantly different from trends for adults without 
ASD.  Figure 2 shows the change in mean total charges for all, psychiatric, non-psychiatric, and 
injury visits with ASD over a period of six years. The mean total ED charges were found to 
decrease significantly among adults with ASD for all other types of ED visits, except for 
psychiatric visits (p>0.05). However, the decline in mean total charges over the 6 year period 
was not very substantial (0.02%, 0.21%, and 0.18% for all, injury, and non-psychiatric visits 
respectively).  
Pooled Study Sample (table not shown here) 
In the pooled study sample 25,257 ED visits were among adults with ASD (0.4% in 
unmatched sample). The ED visits were primarily among male gender (67%) and age group 22-
40 years (72%). Most of the ED visits in the sample were treat and release (86%) and 0.3% visits 
were associated with a mortality event. Most common ED visits in the pooled sample were 
associated with an injury (n = 27,193, 26%), followed by a non-psychiatric disorder (n = 14,574, 
14%), and a psychiatry disorder (n = 7,005, 7%).   
Sample Description by ASD status (Table 1) 
Around 80% of adults with ASD had public health insurance as a primary payer as 
compared to only 26% adults without ASD.  One-third of ED visits among adults with ASD led 
to an inpatient admission (34%) as compared to one-tenth of ED visits among adults without 
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ASD.  Approximately one percent of adults with ASD had a mortality event after an ED visit as 
compared to 0.3% adults without ASD. 
Type of ED Visits by ASD status (Table 2) 
Fifteen percent of adults with ASD had a psychiatric visit as compared to 4.2% adults 
without ASD.  Proportion of adults with ASD with an injury visit was significantly less as 
compared to adults without ASD (23.7%ASD vs. 27.7%NoASD).  However, non-psychiatric visits 
(16.1%) were much more common among adults with ASD as compared to adults without ASD 
(13.6%).  Within psychiatric visits, a majority of adults with ASD came to ED with a principal 
diagnosis of: schizophrenia (3.8%), followed by bipolar disorder (3.2%), depression (2.5%), and 
intellectual disabilities (1.6%). Even though the rates of injury visits were much lower among 
adults with ASD as compared to adults without ASD, there were certain injuries that were more 
common in the former group. Adults with ASD had higher rates of injuries due to falls (6.5%ASD 
vs. 5.0%noASD), poisoning (1.4%ASD vs. 0.8%noASD), self-harm (1.9%ASD vs. 0.5%noASD), and 
suicidal ideation (2.6%ASD vs. 0.9%noASD).  Adults with ASD also had significantly greater rates 
of non-psychiatric visits with a principal diagnosis of cancer (0.3%ASD vs. 0.2%noASD), diabetes 
(1.1%ASD vs. 0.8%noASD), and epilepsy (8.8%ASD vs. 1.0%noASD). 
In the adjusted logistic regression analyses, adults with ASD were found to be more 
likely to have a psychiatric visit (AOR = 2.63, 95% CI = 2.41-2.88), a non-psychiatric visit 
(AOR = 1.07, 95% CI = 1.01-1.14), as well as an injury visit (AOR = 1.10, 95% CI = 1.04-1.16) 
as compared to adults without ASD.  However, they were significantly less likely to have a 
psychiatric visit with AUD (AOR = 0.22, 95% CI = 0.16- 0.29) and SUD (AOR = 0.19, 95%CI = 
0.14 -0.26).  Adults with ASD were also significantly more likely to have injury visits due to 
falls (AOR = 1.48, 95% CI = 1.34-1.62), self-harm (AOR = 2.95, 95% CI = 2.33-3.75), and 
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suicidal ideation (AOR = 1.88, 95% CI = 1.56-2.26) as compared to adults without ASD. In 
addition, adults with ASD were more likely to have multiple cause of injuries as compared to 
adults without ASD (AOR = 1.12, 95% CI = 1.04-1.19).  Although non-psychiatric ED rates for 
certain visits were lower among adults with ASD, they were seven times more likely to have an 
ED visit with a principal diagnosis of epilepsy, as compared to adults without ASD (AOR = 
7.15, 95% CI = 6.28-8.13).  
Mean Total Charges (Table 1 and 6) 
Mean total ED charges for adults with ASD were significantly higher as compared to 
adults without ASD (meanASD= $14,289, SE = $418 vs. meannoASD = $6,196, SE = $165).  Table 
6 shows the means and standard errors (SE’s) for mean total ED charges among adults with and 
without ASD by type of ED visits.  The mean total charges for a psychiatric visit among adults 
with ASD were significantly higher as compared to adults without ASD (meanASD= $12,506, SE 
= $559vs. meannoASD= $7,238, SE = $359, p<0.001). Despite a lower proportion of adults with 
ASD having a non-psychiatric visit in the sample, their associated mean total charges were 
significantly higher (meanASD= $13,662, SE = $681 vs. meannoASD= $9,521, SE = $454, p<0.001) 
when compared to adults without ASD.  Injury visits also costed more for adults with ASD as 
compared to adults without ASD (meanASD= $12,912, SE = $715 vs. meannoASD= $5,842, SE = 
$345, p<0.001).  
One of the highest costing ED visit for both adults with (mean = $75,352, SE = $10,528) 
and without ASD (mean = $67,434, SE = $7,907) was an ED visit with a primary diagnosis of 
cancer.  However, ED visit with a cardiovascular disease had higher mean total ED charges for 
adults with ASD (mean = $ 39,432, SE = $3,671) as compared to adults without ASD (mean = 
$27,181, SE = $1,893). Mean total ED charges for schizophrenia, which was the costliest 
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psychiatric ED visit among adults with ASD (mean = $20,336, SE = $1,168), were significantly 
greater than mean charges for adults without ASD (mean = $12,183, SE = $1,088). Injury visits 
such as those associated with self-harm also had greater mean total ED charges for adults with 
ASD (mean = $13,001, SE = $1,106) as compared to adults without ASD (mean = $11,560, SE = 
$1,810), even though the difference did not reach statistical significance.  Falls among adults 
with ASD were also associated with significantly greater mean total ED charges (mean = 








Our study is a unique contribution to the literature providing information on extent and 
types of ED use among adults with ASD along with their ED costs. A very recent study showed 
that an ASD diagnosis was very strongly associated with frequent ED use as well as hospital 
readmissions (Smith et al., 2015), therefore we expected that the trends of ED visits among 
adults with ASD will increase. The rates of ED visits with an ASD diagnosis more than doubled 
in a period of six years in the current study, highlighting a rise in resource utilization among 
adults with ASD. However, there was a simultaneous decline in mean total ED charges for adults 
with ASD during this period. The introduction of states mental health parity act was found to be 
associated with a greater out of pocket spending for individuals with mental health issues such as 
ASD until 2011 and greater proportion of inpatient admissions spending was shared by the 
patients during the 2006-2011 period (Carolina-Nicole, John, & Gregory, 2013). Since the NEDS 
does not provide information on non-covered charges, the trends in mean total ED charges may 
not reflect the cost burden of each ED visit to the patient.  
In the pooled study sample, ED visits with ASD formed 0.4% of the total study sample 
(unmatched). There were two critical findings in the descriptive analyses: 1) Majority (80%) of 
adults with ASD were covered by a public health insurance as compared to one-quarter (25%) 
adults without ASD. This finding reflects that public payers still account for covering ED and 
inpatient services among majority of adults with mental health issues such as ASD, consistent 
with a few previous studies (Ruble et al., 2005; Semansky et al., 2011a); and 2) Another 
intriguing observation in the study was the difference in rates of inpatient admissions after an ED 
use among adults with and without ASD. Around one-third of ED visits among adults with ASD 
led to an inpatient admission as compared to one-tenth of adults without ASD. This indicates that 
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higher ED use among adults with ASD may also lead to greater hospitalizations which is 
associated with high hospitalization costs (Lokhandwala et al., 2012).  
ED visits 
The second part of our study focused on identifying the common ED visits among adults 
with ASD and compare their occurrences to adults without ASD. We found that non-psychiatric 
(16%) and psychiatric (15%) visits were more common among adults with ASD as compared to 
adults without ASD.  The most commonly associated reasons for ED visits among adults with 
ASD included: epilepsy (8.8%), falls (6.5%), schizophrenia (3.8%), respiratory disorders (3.8%), 
bipolar disorders (3.2%), and depression (2.5%).  These rates support the findings regarding 
comorbid diagnoses among adults with ASD from many other studies (Ahmedani & Hock, 2012; 
Leyfer et al., 2006; Maski et al., 2011; Simonoff et al., 2008; White, Oswald, Ollendick, & 
Scahill, 2009; Zafeiriou, Ververi, & Vargiami, 2007).  
Psychiatric visit 
It is well known that adults with ASD are extensively affected by psychiatric 
comorbidity, with 90% reporting at least one DSM-IV psychiatric disorder and our findings 
indicate that 15% of adults with ASD are visiting ED due to psychiatric reasons (Leyfer et al., 
2006; Lunsky et al., 2009; Palucka & Lunsky, 2007; Simonoff et al., 2008). Some psychiatric 
visits were less common among adults with ASD as compared to adults without ASD.  These 
visits were associated with behavioral disorders such as AUD (0.4%ASD vs. 1.5%noASD) and SUD 
(0.3% ASD vs 0.9% noASD). Literature has shown that usually individuals with ASD are less prone 
to use of drugs/alcohol, however, individuals on the higher functioning spectrum may frequently 
engage in alcohol consumption to help alleviate the social difficulties they experience (Santosh 
& Mijovic, 2006; Sizoo et al., 2009). Although the prevalence of SUD in our study and in a 
previous study by Santosh & Mijovic was low (0.3%), another study by (Sizoo et al., 2009) has 
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shown a higher prevalence rate (30%) of substance abuse among adults with ASD.  Since SUD is 
associated with greater healthcare resource utilization and worse outcomes (Smith et al., 2015), 
greater attention and monitoring may be needed to identify SUD among adults with ASD so that 
timely counseling can be provided.  
Non-psychiatric visit 
Fewer adults with ASD had a non-psychiatric visit with cardiovascular disease (1.4%), 
gastrointestinal disease (0.8%), and respiratory disorder (3.8%) as compared to adults with ASD. 
On the other hand, significantly greater proportion of adults with ASD came to the ED with a 
principal diagnosis of diabetes (1.1%), epilepsy (8.8%), and cancer (0.3%). Our findings indicate 
that adults with ASD if not more likely, are at least equally likely to have non-psychiatric needs 
as compared to adults without ASD when presenting to the ED. Other than epilepsy, most non-
psychiatric disorders among adults with ASD have received little attention, especially in the ED 
settings. Additional healthcare needs associated with non-psychiatric disorders will only increase 
the healthcare needs, utilization, and expenditures of adults with ASD.  
Injury visit 
Adults with ASD had lower rates of injury visits as compared to adults without ASD. 
Nonetheless, a few specific injury visits were more common in the ASD group. For example, 
significantly greater proportion of adults with ASD had an injury visit with poisoning (1.4%ASD 
vs. 0.8%noASD), self-harm (1.9% ASD vs. 0.5% noASD), and suicidal ideation (2.6% ASD vs.0.9% 
noASD). This finding is complementary to our hypothesis that some of the major reasons for ED 
use among adults with ASD are disruptive behaviors and self-inflicting injuries. Even after 
adjusting for other study variables, adults with ASD were more likely to visit ED with a fall 
injury (AOR = 1.5), self-harm (AOR = 2.95), and suicidal ideation (AOR = 1.88).  Most studies 
have examined injuries, especially falls among patients with developmental disabilities (DD), 
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where the prevalence of injuries have ranged from 11%-20% (Finlayson, Morrison, Jackson, 
Mantry, & Cooper, 2010; Hsieh, Heller, & Miller, 2001). The primary risk factors for an injury 
among adults with DD are higher frequency of seizures, destructive behaviors, and use of 
antipsychotic drugs.  Knowing that adults with ASD may be at a greater risk of all the above 
factors (Billstedt et al., 2007; Esbensen et al., 2009; Levy et al., 2010), their probability of a fall 
injury and a subsequent ED visit is also very high. 
In the current study, although the rates of injuries due to assault were lower among adults 
with ASD as compared to adults without ASD, further investigation is needed to corroborate this 
finding using other data (for e.g., police records). This is a critical type of injury especially for 
adults with ASD who many a time have difficulty communicating their needs and experiences 
resulting in frustration, anger, aggression, and self-injurious behaviors. Future studies should 
focus on examining the gravity of such communication impediments on both self-inflictions as 
well as receipt of aggression by others during ED visits and hospitalizations.  
Total ED Charges 
Our study also compared mean total ED charges for adults with and without ASD. Adults 
with ASD, in general had higher ED costs compared to adults without ASD (ratio of meansASD vs. 
NoASD = 2.30, p<0.001). The ratio of meansASD vs. NoASD for specific ED visits (psychiatric 
disorders = 1.7; non-psychiatric disorders = 1.4; and injuries = 2.2) indicated that the biggest 
difference in mean total ED charges between ASD and no ASD group was attributed to injuries. 
Mean charges of injuries due to falls among adults with ASD was almost double the costs for 
falls among adults without ASD (p<0.001). Mean charges of ED visit with suicidal ideation, 
which is a common diagnosis among adults with ASD, was also significantly higher among the 
ASD group as compared to the no ASD group (ratio of meansASD vs. NoASD = 1.56, p<0.001). 
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These findings indicate that injuries are common among adults with ASD (Kato et al., 2013) and 
are associated with high ED utilization and costs. Since, one-third of adults with ASD in the 
sample had an inpatient admission after using ED, the higher mean total ED charges not only 
reflect outpatient ED costs, but also indicate costs contributed by hospitalizations. 
Implications 
The current study has implications for policy discussions related to quality of care and 
care coordination in a primary care/specialty care setting for adults with ASD.  Our study sheds 
light on the need for better guidelines and greater support for incorporating ASD related training 
of physicians and other healthcare providers who usually report lack of self-perceived 
competency in treating and diagnosing adults with ASD (Bruder et al., 2012; Golnik et al., 2009; 
Oskoui & Wolfson, 2012). (Miller, 2015) examined the extent of ASD knowledge among nurses 
working in an ED and found that more than half of ED nurses surveyed reported having accurate 
knowledge, correctly identified causes of visit and comorbidities, and chose appropriate 
interventions for ASD cases. However, nurses still reported having limited knowledge and 
resources available to them and felt a need for ASD education early on in their training. This 
perceived need to overcome gaps in ASD related care among nurses may also be true for 
physicians and other healthcare providers. Future studies should examine the association of 
quality and consistency of care received by adults with ASD in the primary setting with a 
patient’s subsequent ED use, frequency of ED use, hospital admissions, and healthcare costs.  
  




Despite many advantages, the NEDS data is limited by use of a discharge level rather 
than a person level data. Therefore, multiple visits by a much sicker population could not be 
distinguished. Similar to Kalb et al. (2012) who utilized the NEDS for examining ED visits 
among children with ASD, we defined ASD as any of the 15 possible diagnoses rather than a 
primary diagnosis. However, this algorithm has not been validated in survey research and may 
have its own drawbacks.  In this study we also assumed that ED visits with a primary psychiatric 
disorder and non-psychiatric disorder was actually correlated with a patient’s psychiatric and 
non-psychiatric needs at the time of the visit. It is quite possible that the reason(s) for an ED visit 
might have been completely different than the principal diagnosis on the record, which could 
have been used purely for billing purposes.  
The data allowed only for capturing the total ED charges for the services used/billed. We 
could not manipulate the data to deliver cost/expenditure, which is a better and a more 
meaningful concept. However, the requirement of the study was to identify the excess healthcare 
utilization and total charges for the ASD group as compared to the no ASD group and using 
charges sufficed the need of the current study goals. We also could not account for the charges 
that were not included in the ED and inpatient charges (such as professional fees), expenditures 
paid by the payer, and/or out of pocket expenditures for the patients, which would provide the 
cost sharing burden among patients with or without ASD. The data also was limited by the 
absence of patient reported health behaviors (such as smoking, tobacco use, and drug abuse), 
physician review charts, and other additional information that could help validate the reasons for 
ED visits.  Finally, racial/ethnic differences could not be accounted for in the study due to the 
lack of information on race in the available data.  




Rates of ED visits among adults with ASD are on the rise. Adults with ASD use ED for 
different reasons which are not restricted to psychiatric needs, but also extend to non-psychiatric 
needs and injuries. ED visits among adults with ASD are also associated with significantly 
greater hospitalization rates as compared to adults without ASD.  Mean total ED charges for 
adults with ASD are almost twice as high as charges for adults without ASD. Prevalence, risk 
factors, and burden of ED utilization among adults with ASD is understudied and future studies 
should examine the impact of such ED utilization on long term healthcare costs. 
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Figure 1. Number of ED visits with ASD per every 100,000 ED admissions for all, psychiatric, non-
psychiatric, and any injury ED visits.  
Trend analyses examined change in rates of ED visits associated with ASD as compared to ED visits 
without ASD from 2006 to 2011. In the logistic regression analyses, the trends were adjusted for hospital 
region, urban/rural status, median annual household income, and primary payer. 
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Figure 2. Mean inflation adjusted total ED charges for ASD visits for all, psychiatric, non-psychiatric, and 
any injury ED visits. 
Trend analyses examined the change in inflation adjusted mean total ED charges for ED visits associated 
with ASD as compared to ED visits without ASD from 2006 to 2011.In the linear regression analyses, the 
trends were adjusted for age, gender, hospital region, urban/rural status, median annual household 
income, and primary payer. 
 
Trend for mean total charges for psychiatric ED visits with ASD was insignificant at p≤0.05 level.  
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Description of Pooled Study Sample Characteristics by ASD status 
Adults with and without ASD matched on age and gender  
2006-2011 Nationwide Emergency Department Sample (n =102,108) 
      ASD No ASD Sig. 




%   
Sex        
 Male  19,286 75.5 57,858 75.7 ns 
 Female  6,241 24.5 18,723 24.3  
Age (in years)       
 22-40  17,961 70.2 53,883 70.3 ns 
 41-54  5,575 21.8 16,725 21.9  
 55-64  1,991 8.0 5,973 7.8  
Income Groups (quartiles)      *** 
 Q1  5,364 21.2 24,787 32.4  
 Q2  6,230 24.5 20,783 27.2  
 Q3  6,590 25.8 16,848 21.9  
 Q4  6,612 25.8 12,119 15.8  
 Missing  731 2.8 2,044 2.7  
Primary Payer       *** 
 Public  20,483 80.4 19,496 25.7  
 Private  3,764 14.7 25,938 34.3  
 Self-Charge  807 3.2 23,934 31.1  
 No Charge/Other  424 1.7 6,763 9.0  
Hospital Region      *** 
 North-east  7,453 29.6 15,211 20.5  
 Mid-west  6,446 27.0 16,366 23.5  
 South  7,476 27.1 32,132 38.8  
 West  4,152 16.3 12,872 17.2  
Hospital Location       
 Rural  945 4.0 5,345 7.3 *** 
 Urban  24,459 95.5 70,503 91.8  
 Missing  123 0.5 733 1.0  
ED Event       *** 
 Treat and release  16,340 64.0 66,751 87.1  
 Inpatient admission  8,651 33.9 8,136 10.6  
 Transfer   326 1.3 804 1.1  
 Died/other  210 0.8 890 1.2  
Mortality Events  181 0.7 16,186 0.3 *** 
Total ED charges mean (SE)   $14,289 ($418) $6,196 ($165) *** 
The estimates are provided from NEDS representing ED visits with adults aged 22-64 years from the 
years 2006-2011; ED visits with and without ASD were matched on age and gender; 
Col. Wt. %: Column weighted percentages; SE: Standard errors; ns: not significant at p<0.05 level. 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05.  




Type of  ED Visits in the Pooled Study Sample by ASD Status 
Adults with and without ASD matched on age and gender  
2006-2011 Nationwide Emergency Department Sample (n =102,108) 
    ASD No ASD Sig. 
    N Col. Wt.% N Col. Wt.%   
Psychiatric Visit 3,831 15.1 3,174 4.2 *** 
 ADD/ADHD 328 1.3 27 0.0 *** 
 Adjustment Disorders 137 0.5 91 0.1 *** 
 Anxiety Disorders 376 1.5 675 0.9 *** 
 AUD 97 0.4 1,099 1.5 *** 
 Bipolar Disorder 825 3.2 326 0.4 *** 
 Depression 608 2.5 717 1.0 *** 
 Intellectual Disabilities 399 1.6 22 0.0 *** 
 Personality Disorders 113 0.4 11 0.0 *** 
 Schizophrenia 971 3.8 619 0.8 *** 
 SUD 74 0.3 686 0.9 *** 
Injury Visit§§ 6,076 23.7 21,117 27.7 *** 
 Assault€§ 146 0.9 901 1.9 *** 
 Cut 346 1.3 2,270 3.0 *** 
 Drown 5 0.0 6 0.0 nc 
 Fall 1,655 6.5 3,751 5.0 *** 
 Fire 52 0.2 323 0.4 *** 
 Machinery 1 0.0 177 0.2 nc 
 Poison 368 1.4 567 0.8 *** 
 Self-harm§§ 475 1.9 371 0.5 *** 
 Struck 832 3.3 3,337 4.4 *** 
 Suffocation 66 0.3 24 0.0 *** 
 Suicidal Ideation§§ 650 2.6 683 0.9 *** 
 Multiple Injuries§§ 3,754 14.7 12,180 16.3 *** 
 Non-psychiatric Visit 4,130 16.1 10,444 13.6 *** 
 Cancer 70 0.3 147 0.2 ** 
 Cardiovascular Disease 369 1.4 1,867 2.5 *** 
 Diabetes 274 1.1 628 0.8 ** 
 Epilepsy 2,253 8.8 793 1.0 ** 
 Gastrointestinal Disease 188 0.8 765 1.0 ** 
 Respiratory Disease 976 3.8 6,244 8.1 ** 
The estimates are provided from NEDS representing ED visits with adults aged 22-64 years from the years 2006-
2011; ED visits with and without ASD were matched on age and gender; 
nc: Not conclusive. Tests not feasible due to low cell sizes;  
ADD/ADHD: Attention deficit disorders/attention deficit hyperactivity disorders; AUD: Alcohol use disorders; 
SUD: Substance use disorders.  
Col. Wt. %: Column weighted percentages. Represents percentages within ASD and no ASD ED visits that were 
associated with each individual diagnoses. The denominator is the total number of ED visits with an ASD 
diagnosis (n = 25,527) and without an ASD diagnosis (n =76,581). 
§§Not included as part of an injury visit. 
€Data on assault intent was only available for the years 2009-2011. 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05.  




Odds Ratios and Confidence Intervals from Multivariate Logistic Regressions for Psychiatric Visits 
Adults with and without ASD matched on age and gender 
2006-2011 Nationwide Emergency Department Sample (n =102,108) 
  OR 95% CI Sig. AOR 95% CI Sig. 
Any  4.03 ( 3.74 ,  4.34) *** 2.63 ( 2.41 ,  2.88) *** 
Schizophrenia 4.77 ( 4.17 ,  5.46) *** 1.90 ( 1.61 ,  2.23) *** 
ADD/ADHD 38.64 (25.96 , 57.51) *** 33.82 (22.01 , 51.97) *** 
Adjustment Disorders 4.33 ( 3.25 ,  5.77) *** 4.04 ( 2.62 ,  6.23) *** 
Anxiety 1.70 ( 1.46 ,  1.99) *** 1.93 ( 1.58 ,  2.36) *** 
AUD 0.26 ( 0.20 ,  0.33) *** 0.22 ( 0.16 ,  0.29) *** 
Bipolar Disorders 7.84 ( 6.71 ,  9.16) *** 3.83 ( 3.15 ,  4.66) *** 
Depression 2.57 ( 2.24 ,  2.96) *** 1.86 ( 1.54 ,  2.24) *** 
Intellectual Disabilities 54.12 (35.24 , 83.12) *** 41.31 (24.56 , 69.48) *** 
Personality Disorders 30.55 (16.02 , 58.24) *** 24.57 (11.22 , 53.80) *** 
SUD 0.30 ( 0.24 ,  0.40) *** 0.19 ( 0.14 ,  0.26) *** 
The estimates are provided from NEDS representing ED visits with adults aged 22-64 years from the years 
2006-2011; ED visits with and without ASD were matched on age and gender;  
ADD/ADHD: Attention deficit disorders/attention deficit hyperactivity disorders; AUD: Alcohol use 
disorders; SUD: Substance use disorders.  
OR: Odds ratios; AOR: Adjusted odds ratios; CI: Confidence Intervals. 
Multivariate logistic regressions were adjusted for sex, age, NEDS year, income groups, primary payer, 
hospital region, hospital location, and ED event. 





Odds Ratios and Confidence Intervals from Multivariate Logistic Regressions for Non-Psychiatric Visits 
Adults with and without ASD matched on age and gender  
2006-2011 Nationwide Emergency Department Sample (n =102,108) 
  OR 95% CI Sig. AOR 95% CI Sig. 
Any 1.22 ( 1.16 ,  1.29) *** 1.07 ( 1.01 ,  1.14) * 
Cancer 1.50 ( 1.11 ,  2.02) ** 0.65 ( 0.46 ,  0.91) * 
Cardiovascular Disease 0.58 ( 0.51 ,  0.66) *** 0.39 ( 0.33 ,  0.45) *** 
Diabetes 1.32 ( 1.10 ,  1.57) ** 0.75 ( 0.61 ,  0.93) ** 
Epilepsy 9.26 ( 8.36 , 10.27) *** 7.15 ( 6.28 ,  8.13) *** 
Gastrointestinal Disease 0.76 ( 0.64 ,  0.91) ** 0.66 ( 0.54 ,  0.82) *** 
Respiratory Disease 0.45 ( 0.41 ,  0.49) *** 0.53 ( 0.48 ,  0.58) *** 
The estimates are provided from NEDS representing ED visits with adults aged 22-64 years from the years 
2006-2011; ED visits with and without ASD were matched on age and gender; 
OR: Odds ratios; AOR: Adjusted odds ratios; CI: Confidence Intervals. 
Multivariate logistic regressions were adjusted for sex, age, NEDS year, income groups, primary payer, 
hospital region, hospital location, and ED event. 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. 





Odds Ratios and Confidence Intervals from Multivariate Logistic Regressions for Injury Visits 
Adults with and without ASD matched on age and gender  
2006-2011 Nationwide Emergency Department Sample (n =102,108) 
  OR 95% CI Sig. AOR 95% CI Sig. 
Any§§ 0.81 ( 0.78 ,  0.85) *** 1.10 ( 1.04 ,  1.16) *** 
Assault 0.47 ( 0.38 ,  0.57) *** 0.61 ( 0.49 ,  0.77) *** 
Cut 0.44 ( 0.38 ,  0.50) *** 0.75 ( 0.65 ,  0.86) *** 
Fall 1.33 ( 1.23 ,  1.44) *** 1.48 ( 1.34 ,  1.62) *** 
Poison 1.91 ( 1.66 ,  2.20) *** 1.21 ( 1.00 ,  1.46) ns 
Self-harm 3.90 ( 3.30 ,  4.60) *** 2.95 ( 2.33 ,  3.75) *** 
Struck 0.74 ( 0.67 ,  0.82) *** 1.10 ( 0.99 ,  1.22) ns 
Suicidal Ideation 2.96 ( 2.59 ,  3.40) *** 1.88 ( 1.56 ,  2.26) *** 
Multiple Injuries 0.89 ( 0.84 ,  0.95) *** 1.12 ( 1.04 ,  1.19) ** 
The estimates are provided from NEDS representing ED visits with adults aged 22-64 years from 
the years 2006-2011; ED visits with and without ASD were matched on age and gender; 
OR: Odds ratios; AOR: Adjusted odds ratios; CI: Confidence Intervals. 
Multivariate logistic regressions were adjusted for sex, age, NEDS year, income groups, primary 
payer, hospital region, hospital location, and ED event. 
§§ Any injury visit variable does not include assault, self-harm, suicidal ideation, and multiple injuries. 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. ns: not significant   




Type Of  Visits And Mean Total ED Charges in the Pooled Study Sample 
Adults with and without ASD matched on age and gender 
2006-2011 Nationwide Emergency Department Sample (n =102,108) 
    ASD No ASD Sig. 
    Mean SE Mean SE  
Psychiatric Visit $12,506 $559 $7,238 $359 *** 
 ADD/ADHD $4,963 $1,341 $1,510 $267 * 
 Adjustment Disordersa $10,362 $3,583 $4,119 $562 ns 
 Anxiety Disorders $5,651 $1,481 $2,217 $184 * 
 AUD $14,486 $3,324 $6,462 $555 * 
 Bipolar Disorder $15,576 $876 $10,136 $1,069 *** 
 Depression $10,241 $616 $5,582 $366 *** 
 Intellectual Disabilities $3,759 $418 $3,061 $787 ns 
 Personality Disorders $9,078 $2,350 $3,299 $931 * 
 Schizophrenia $20,336 $1,168 $12,183 $1,088 *** 
 SUD $11,581 $1,384 $8,523 $789 * 
Injury Visit $12,912 $715 $5,842 $345 *** 
 Assault§ $8,174 $1,872 $8,836 $1,218 ns 
 Cut $4,953 $944 $2,221 $135 ** 
 Drowna $17,044 $1,155 $2,534 $759 ** 
 Fall $11,230 $934 $5,880 $475 *** 
 Firea $20,605 $8,333 $2,890 $558 * 
 Machineryb $18,562 $0 $5,248 $528 nc 
 Poison $11,790 $1,252 $13,201 $1,451 ns 
 Self-harm $13,001 $1,106 $11,560 $1,810 ns 
 Struck $3,672 $406 $3,087 $390 ns 
 Suffocationa $53,110 $6,129 $42,061 $17,630 ns 
 Suicidal Ideation $12,579 $701 $8,013 $481 *** 
Non-psychiatric Visit $13,662 $681 $9,521 $454 *** 
 Cancer $75,352 $10,528 $67,434 $7,907 ns 
 Cardiovascular Disease $39,432 $3,671 $27,181 $1,893 ** 
 Diabetes $19,574 $2,194 $16,146 $1,955 ns 
 Epilepsy $9,551 $553 $6,238 $435 *** 
 Gastrointestinal Disease $16,224 $2,263 $7,032 $568 *** 
  Respiratory Disease $5,431 $745 $2,455 $135 *** 
The estimates are provided from NEDS representing ED visits with adults aged 22-64 years 
from the years  2006-2011; ED visits with and without ASD were matched on age and gender; 
aRelative standard errors >30%. Estimates may not be precise. 
 bOnly 1 individual with ASD reported having machinery associated injury.  
§Data on assault intent was only available for the years 2009-2011. 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. 
nc: not conclusive. Tests are not feasible because of low numbers. 
ns: not significant
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Background: Lack of absolute gold standard ASD treatment, approved guidelines, and strong 
evidence based treatments lead to greater off label prescribing with no information on the long 
term effects of high prescription drug use among individuals with ASD. Extent of general (six or 
more drug classes in a year) and psychotropic (three or more psychotropic drug classes within a 
period of 90 days) polypharmacy among adults with ASD has not been studied till date.  
Aim: 1) To examine and compare the types of prescription drug use and rates of general and 
psychotropic polypharmacy among adults with and without ASD; 2) To examine predictors of 
polypharmacy among adults with ASD.  
Method: A retrospective cross sectional study using claims data from three state Medicaid 
Analytic eXtract was conducted. Adults aged 22-64 years with ASD (ICD9-CM code: 299.xx) 
who were continuously enrolled between January 1, 2000 to December 31, 2008 were identified. 
ASD cases were 1:3 matched to no ASD controls by age, sex, and race using propensity score 
matching. Rates of different prescription drug classes, general polypharmacy, and psychotropic 
polypharmacy among adults with and without ASD were compared using chi-square tests. T-
tests were conducted to examine the differences in mean annual number of claims for specific 
drug classes between adults with and without ASD. Multivariate multinomial logistic regressions 
were run to examine the likelihood of general and psychotropic drug polypharmacy among 
adults with ASD as compared to adults without ASD, after adjusting for identification year, 
patient socio-demographics, county characteristics, and number of comorbidities.  
Results: Almost 70% of adults with ASD had more than 25 prescription drug (Rx) claim in the 
identification year as compared to 28% of adults without ASD. Around 85% of adults with ASD 
used psychotropic drugs as compared to 42% of adults without ASD. The rates of specific 
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psychotropic drug classes were: antipsychotics (66%ASD vs. 20%noASD), anticonvulsants (59%ASD 
vs. 20%noASD), antidepressants (37%ASD vs. 26%noASD), anxiolytics/hypnotics/sedatives (21%ASD 
vs. 11%noASD), and CNS stimulants (1.9%ASD vs. 1%noASD). Around half of adults with ASD used 
six or more Rx classes per year as compared to one-third of adults without ASD.  Among adults 
with ASD who used six or more Rx classes per year, the most common classes were: 
antipsychotics (78%), anticonvulsants (75%), antimicrobials (67%), dermatologic agents (64%), 
respiratory agents (59%), and gastrointestinal agents (52%). A substantial proportion of adults 
with ASD (19%) also engaged in psychotropic polypharmacy as compared to adults without 
ASD (6%). After adjusting for selected characteristics, adults with ASD were 17% more likely 
and 40% more likely to engage in general and psychotropic polypharmacy, respectively, as 
compared to adults without ASD.   
Conclusion: Prescription drug use, general polypharmacy, and psychotropic polypharmacy is 
significantly and substantially higher among adults with ASD than adults without ASD. Half of 
adults with ASD use six or more drug classes in a year and 19% of them use three or more 
psychotropic drug classes within a 90 day period. Higher prescription drug use among adults 
with ASD was not restricted to psychotropic drugs, but extended to prescriptions alleviating 
other medical needs including dermatologic agents, respiratory agents, cardiovascular agents, 
gastrointestinal agents, antiparkinsonian agents, and many others. The study highlights 
considerable pharmaceuticals use by adults with ASD as well as practice of off-label 
prescriptions for adults with ASD by healthcare providers. Even though various clinical trials 
have provided with off-label options for pharmacological treatment of adults with ASD, such 
treatments should still be administered based on case by case analysis with due consideration for 
risk-benefit ratios.  




Individuals with autism spectrum disorders (ASD) often have characteristic behavioral 
problems such as aggression, irritability, and self- injury (Jang et al., 2011; Matson & Rivet, 
2008; Matson, Wilkins, & Macken, 2009; Murphy et al., 2005), along with multiple medical and 
psychiatric comorbidities (Buie et al., 2010; Kohane et al., 2012; McElhanon et al., 2014; 
Simonoff et al., 2008; van Steensel et al., 2013). Management of such behavioral issues and 
comorbid conditions are usually pharmacological (LeClerc & Easley, 2015) and lead to 
substantial medication use (Baribeau & Anagnostou, 2014; Matson, Sipes, Fodstad, & 
Fitzgerald, 2011; Myers, 2007; Volkmar et al., 1999). Till date, there are no prescription drugs 
that treat core ASD symptoms, but the US Food and Drug Administration approved risperidone 
(2006) and aripiprazole (2009) to be used primarily for symptoms of irritability, hyperactivity, 
and aggression associated with ASD (Warren et al., April 2011). Pharmacological treatment is 
clinically essential or warranted in most cases, yet there are reasons why high prescription drug 
use, especially psychotropic drugs as well as polypharmacy (use of more than a single class of 
drug) may be of concern: 
Lack of evidence base  
There is a lack of strong evidence for safety and efficacy of prescription drugs that are 
used off-label (where physicians often prescribe non-indicated medications, in a trial-and-error 
fashion to help manage troublesome symptoms in patients, especially if other treatments are 
failing) among adults with ASD (Warren et al., April 2011). Increasing number of studies are 
documenting the practice of off-label prescriptions by physicians to manage cases where the 
approved medications are either not available or not considered an adequate treatment option for 
individuals with ASD (Dalsgaard, Nielsen, & Simonsen, 2013; Frazier et al., 2011b; Zito et al., 
2008). A Danish study using a national registry indicated a 4.7 fold increase in prescription of 
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atomoxetine, methylphenidate, and dexamphetamine to children with ASD from 2003-2010 
(Dalsgaard et al., 2013). This practice also extends to psychotropic drug prescriptions including 
selective serotonin reuptake inhibitors (SSRI’s) (Baribeau & Anagnostou, 2014) for repetitive 
behaviors, stimulant medications for ADHD type symptoms (Barnard-Brak, Davis, Schmidt, & 
Richman, 2014) and anti-epileptic medications such as valproate for behavioral symptoms in 
ASD (Hirota, Veenstra-Vanderweele, Hollander, & Kishi, 2014). 
Effectiveness vs. side effects 
Aripiprazole and risperidone display medium level effectiveness but are associated with 
substantial adverse effects (Warren et al., April 2011). (Dove et al., 2012) conducted a 
systematic review to find the evidence base for treatment for adults and adolescents (13-30 
years) with ASD. The study concluded a moderate evidence for risperidone as a medication for 
controlling aggression in this population and mentioned a weak evidence for any other treatment 
option.  However, the study also underlined a strong evidence base for adverse events associated 
with use of risperidone (such as sedation, obesity, and tardive dyskinesia).  Risperidone is also 
known to cause increased appetite, fatigue, drowsiness, dizziness, and drooling in children with 
ASD (McCracken et al., 2002).  Use of aripiprazole is associated with weight gain, sedation, and 
sialorrhea (Blankenship et al., 2010; Ching & Pringsheim, 2012; M. P. Curran, 2011; Marcus et 
al., 2009; Owen et al., 2009). A medical chart review study (Adler et al., 2014) showed that 40% 
of patients with ASD required medication adjustment despite previous trials of risperidone and 
aripiprazole or combinations of these together for ASD symptoms.  
Other medications such as antidepressants and mood stabilizers also cause significant 
tolerability issues. A recent systematic review on clinical trials examining the efficacy of SSRI’s 
(fluoxetine, fluvoxamine, fenfluramine, and citalopram) reported no significant improvements in 
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ASD symptoms but rather posed additional risk of harm (K. Williams et al., 2010). Use of 
antidepressants is also associated with behavioral activation (hyperactivity and agitation), 
aggression, and suicidal ideation in children and adolescents with ASD (West et al., 2009).There 
is a lack of robust information on long term effects of use of multiple drug classes in adults with 
ASD along with paucity of trials examining risk-benefit analyses of prescribing medications off-
label (Lake, Balogh, & Lunsky, 2012; LeClerc & Easley, 2015).  
Statement of Problem 
Majority of the published literature is limited and provides scattered information on 
overall prescription drug and polypharmacy use among individuals with ASD.  In addition, 
studies that have examined and reported rates of prescription drug utilization, have focused 
primarily on pediatric or adolescent populations of ASD (Armand-Branger, Poisson, Gaudoneix-
Taieb, & Ramos, 2009; Buck et al., 2014b; Esbensen et al., 2009; Lake et al., 2012; Logan et al., 
2012; Mandell et al., 2008a; Oswald & Sonenklar, 2007a; Rosenberg et al., 2010a). Many of 
these studies among individuals with ASD indicated that increasing age was associated with 
greater likelihood of prescription drug use (Khanna et al., 2013; Mandell et al., 2008a; 
Rosenberg et al., 2010b). A report published by (Esbensen et al., 2009) on assessment of 
medication use at baseline and follow up period among 286 adolescents and adults with ASD 
(average age 21 years), showed that on an average individuals with ASD who were using 1-2 
medications at baseline increased to 2-3 medications per person by the end of the follow up 
period. A majority of the studies examining polypharmacy among individuals with ASD are 
limited to psychotropic polypharmacy, which is found to be prevalent among 10-20% of children 
with ASD (Coury et al., 2012a; Frazier et al., 2011b; Gerhard, Chavez, Olfson, & Crystal, 2009; 
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Logan et al., 2012; Mandell et al., 2008a; Oswald & Sonenklar, 2007a; Oswald & Sonenklar, 
2007b; Spencer et al., 2013).  
The current study will focus on identifying the most common therapeutic classes of drugs 
used by adults aged 22-64 years with and without ASD enrolled in Medicaid fee for service 
program. Since recently it has been shown that adults with ASD have significantly higher rates 
of medical conditions such as metabolic disorders, immune system dysfunctions, gastrointestinal 
issues, and eating disorders as compared to adults without ASD (Croen et al., 2015), it is critical 
to examine the burden of other medications in this population. A few previous studies have 
examined specific types of prescription drug use (mostly psychotropic) among younger and older 
youth with ASD (Buck et al., 2014a; Esbensen et al., 2009; Khanna et al., 2013).  (Esbensen et 
al., 2009) focused on the use of psychotropic (such as antipsychotics and anti-depressants) and 
non-psychotropic medications (such as anti lipimic, GI medications, and other drugs) among 
adolescents and adults with ASD (average age 21 years) via longitudinal (4.5 years) contingency 
analyses and found that both types of prescription drug use among adults with ASD is very high. 
Using literature support of such studies, we hypothesize that adults with ASD will have a higher 
use of psychotropic as well as other therapeutic drug classes as compared to adults without ASD.  
The current study will also compare the rates of general polypharmacy (use of six or 
more unique classes of prescription drugs in a year) and psychotropic polypharmacy (concurrent 
use of 3 or more psychotropic drug classes within a 90 day period after the first prescription fill 
for a psychotropic drug) among adults with and without ASD.  We expect greater rates of 
general and psychotropic polypharmacy among adults with ASD as compared to adults without 
ASD. This may be due to paucity of clinical trials for most prescription drugs among adults with 
ASD, lack of training of healthcare providers in terms of treatment guidelines (Bruder et al., 
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2012; Golnik et al., 2009; Heidgerken et al., 2005; Oskoui & Wolfson, 2012), greater risk for 
adults with ASD to use psychotropic medications than their younger counterparts (Esbensen et 
al., 2009; Khanna et al., 2013), and low likelihood of discontinuation of a medication once 
started at a younger age (Esbensen et al., 2009).  
Our study will use three state Medicaid administrative claims data (IL, NY, and TX; 
2000-2008) to determine the rates of overall prescription drug use, specific prescription drug use, 
general polypharmacy, and psychotropic polypharmacy among adults with and without ASD in a 
1:3 matched cohort (age, gender, and race).  Although, prescription drug coverage is an optional 
benefit under federal Medicaid law, all state Medicaid programs provide coverage for outpatient 
pharmacy prescription drugs to eligible individuals. Medicaid plays a significant role in 
prescription drug coverage for individuals with mental health and substance abuse issues 
(Schubart et al. 2014). Many studies have utilized Medicaid claims databases to examine the 
rates of psychotropic polypharmacy among children with ASD (Frazier et al., 2011a; Logan et 
al., 2012; Mandell et al., 2008b).  Thus, using this database will help provide a comprehensive 
understanding of prescription drug use among adults with ASD.  
  





Administrative health insurance claims data from three state Medicaid programs (IL, NY, 
and TX) were extracted from the 2000-2008 Centers for Medicare and Medicaid Services 
Medicaid analytic eXtract (MAX) data files. We selected IL, NY, and TX because of lower 
managed care penetration rates and greater fee-for-service enrollment during the study period 
(The Henry J Kaiser Family Foundation, 2013). The MAX files provide diagnosis codes, service 
use, demographic characteristics, and state of residence. Separate files received from CMS can 
be linked based on beneficiaries’ unique identification number.  
For the current study we used the personal summary file (provides information on 
Medicaid eligibility, enrollment type, and demographics), other therapy file (provides 
information on two possible diagnoses, utilization of outpatient services such as clinical services, 
physician services, procedures, home health, and lab services), inpatient file (provides 
information on nine possible diagnoses, hospitalizations, procedures, and length of stays), and 
the prescription drug file (national drug codes (NDC), prescription fill date, and days of supply).  
County level variables were obtained from the area resource file (ARF) (Quality Resource 
Systems, 2006) which provides information on type of health facilities, number and type of 
health professions, resource scarcity measures, health status, economic activities, health training 
programs, and socioeconomic and environmental characteristics. The Medicaid files were linked 
with ARF files with a five digit county identification variable.  
Study Population and Design 
A retrospective cross-sectional matched cohort study among adults aged 22-64 years with 
and without ASD was conducted. Adults with any ASD (at least 1 inpatient or 2 outpatient 
PhD Dissertation Chapter 4 
129 
 
claims on separate service dates with an ICD9-CM code: 299.xx in any position) and 
continuously enrolled in a fee for service (FFS) program from 2000-2008 were matched (1:3) 
with adults without ASD by age, gender, and race using propensity score matching method with 
GREEDY (1:8) algorithm. Adults without ASD were selected only if they had at two least 
medical claims on separate dates of service (either inpatient or outpatient). We excluded 
enrollees who were: a) dual Medicaid/Medicare eligible; b) Managed care enrollees; c) dead; and 
d) did not have a medical claim (outpatient/inpatient services). Due to the low number of FFS 
enrolled adults with ASD in the year 2008, their data was merged with the adults with ASD 
identified in the year 2007. The baseline characteristics (patient’s socio-demographic 
information, comorbidities, drug use, and polypharmacy) were extracted from the identification 
year (first medical claim year with any ASD diagnosis).   
Variables 
Socio-demographic Characteristics 
 Age (22-40 and 41-64 years), sex (male and female), race (White, African-American, and 
Other), state (IL, NY, and TX), identification cohort (before and after 2004), and Medicaid 
eligibility by cash and medical needs (yes/no) were extracted from the MAX personal summary 
file.   
County Characteristics 
We used various contextual variables from the ARF file such as county metro status 
(urban/rural), primary care shortage area (yes/no), mental health specialist shortage area (yes/no), 
psychiatrist density (high/low), median household income level (quartiles: q1, q2, q3, and q4), 
and high school education and above density which is a measure of county education status 
(quartiles: q1, q2, q3, and q4). These were used as proxy measures of access to services.  




We included both number (none, one, two, three or more) and types of comorbid 
conditions (either 1 inpatient or 2 outpatient claims on separate service dates with a diagnosis in 
any position for a psychiatric or a non-psychiatric disorder). Variable representing number of 
comorbidities was created as a sum of any psychiatric disorder, any non-psychiatric disorder, and 
other relevant health conditions which were found to be of significant prevalence in both ASD 
and no ASD groups (epilepsy, thyroid disorders, lipid metabolism disorders, pancreatic 
disorders, fluid and electrolyte disorders, jaw and teeth disorders, genitourinary disorders, skin 
disorders, and infections).  
We used the single level clinical classification software (CCS) provided by Agency for 
Healthcare Research and Quality (https://www.hcup 
us.ahrq.gov/toolssoftware/CCS/AppendixASingleDX.txt) to categorize diagnosis codes to 
clinically meaningful categories. A psychiatric comorbidity included: adjustment disorders (CCS 
code: 650), alcohol/substance use disorders (AUD; CCS code: 660,661), anxiety disorders (CCS 
code: 651), attention deficit disorders & conduct behavior disorders (ADD; CCS code: 652), 
developmental disorders (CCS code: 654), mood disorders including depressive disorders and 
bipolar disorder (CCS code: 6571,6572), personality disorders (CCS code: 658), and 
schizophrenia & other psychotic disorders (CCS code: 659). A non-psychiatric comorbidity 
included: cancer (CCS code: 11- 37, 39-43, 46, 47) cardiovascular disease (CCS code: 96-108), 
diabetes (CCS code: 49, 50), muscoskeletal disorders (CCS code: 201-212), gastrointestinal 
disease (CCS code: 138-151, 153-155), and respiratory disease (CCS code: 125-128, 132-134). 
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Types of Prescription Drugs 
 The study examined use of any prescription drug class as well as the use of specific drug 
classes. We examined the proportion of adults using specific drug classes as well as the mean 
number of Rx claims per year for the following drug classes: respiratory agents (antihistamines, 
bronchodilators, inhaled corticosteroids, respiratory inhalants, leukotriene modifiers etc.), 
antimicrobials (amebicides, anthelmintics, antifungals, antibiotics, antiviral, antituberculosis etc.) 
anticancer (antineoplastics, radiologics, and biologicals), immunologics (immunoglobulins and 
immune-suppressives/stimulants),  cardiovascular agents (antiadrenergics, ACE inhibitors, beta 
blockers, antiarrythmics, diuretics, vasodilators, etc.) analgesics,  blood modifiers (antiplatelet 
agents, anticoagulants, and other coagulants)  hormone modifiers/steroids (glucocorticoids, sex 
hormones, thyroid hormones, other adrenal corticoids, etc.), statins/other antihyperlipidemics,  
antidiabetics, dermatologic agents, alternative medicine/nutritional supplements,  gastrointestinal 
agents,  CNS agents (excluding stimulants), antiparkinsonian agents, and other metabolic agents. 
These agents were identified using drug database from Multum® Lexicon 2014 (Cerner Multum, 
Inc., Denver, CO), which provides national drug codes or NDC’s (eleven digit code). Such 
NDC’s represents unique prescription drugs that are assigned drug categories which can be 
classified further into meaningful therapeutic drug classes and can be linked with the MAX 
pharmacy file.  
Polypharmacy  
 We defined general polypharmacy (yes, no, no Rx claim) as use of six or more unique 
classes of prescription drugs in a year. General polypharmacy may include but is not restricted to 
prescription drug classes such as antipsychotics, antidiabetics, antihyperlipidemics, 
antineoplastics, antibiotics, gastrointestinal agents, respiratory agents, and many other classes of 
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drugs. The psychotropic drug polypharmacy (yes, no, no Rx claim) was defined as use of three 
or more unique classes of psychotropic drugs within a 90 day period after the first occurring 
prescription fill date of any psychotropic drug. A similar definition of psychotropic 
polypharmacy in claims database analyses has been previously used by (Spencer et al., 2013) 
among children with ASD. The psychotropic drug classes in the current study included: 
antidepressants, antipsychotics, anticonvulsants, CNS stimulants, and 
anxiolytics/sedatives/hypnotics. For converting the national drug codes to therapeutic drug 
classes, we used drug database from Multum® Lexicon 2014 (Cerner Multum, Inc., Denver, CO) 
and Healthcare Effectiveness Data and Information Set (HEDIS) NDC 2015 lists (National 
Committee for Quality Assurance, 2015).  
Statistical Analyses 
Bivariate analyses such as chi-square tests of associations for categorical variables and t-
tests for continuous variables were conducted to assess the sub-group and mean differences 
between adults with and without ASD. To examine and compare the likelihood of general and 
psychotropic polypharmacy we conducted a multinomial logistic regression among adults with 
and without ASD.  For predictors of polypharmacy within adults with ASD, the multinomial 
variable was converted to a binary indicator (polypharmacy vs. no polypharmacy). Numbers, 
percentages, means and standard deviations, adjusted odds ratios (AOR) along with 95% 
confidence intervals (CI) are reported. Mean number of Rx claims per year for each therapeutic 
drug class are presented for the entire sample as well as among users only. Analyses were 
adjusted for socio-demographics, county characteristics, and number of comorbidities. Findings 
with cell sizes that were 11 or less are suppressed in accordance with CMS data user agreement. 
All analyses were conducted using SAS v9.4. 




Study sample had 1,772 adults with ASD, most of them being male (71%), aged 22-40 
years (86%), and under a cash assistance program (82%). Rates of psychiatric (81%ASD vs. 
41%noASD) and non-psychiatric comorbidity (40%ASD vs. 45%noASD) were significantly higher 
among adults with ASD as compared to adults without ASD. Around 4% of adults with ASD 
were Medicaid eligible by medical needs as compared to 17% of adults without ASD. About 
82% of adults with ASD were Medicaid eligible by cash assistance as compared to 60% of adults 
without ASD.  
Types of Prescription Drugs (Table 1) 
 Almost 95% of adults with ASD had at least one Rx claim in the identification year as 
compared to 87% of adults without ASD. A significantly greater proportion of adults with ASD 
used dermatologic agents (48%ASD vs. 32%noASD), respiratory agents (38%ASD vs. 34%noASD), 
gastrointestinal agents (32%ASD vs. 23%noASD), alternative medicine/nutritional supplements 
(25%ASD vs. 18%noASD), cardiovascular agents (23%ASD vs. 19%noASD), antiparkinsonian agents 
(23%ASD vs. 10%noASD), statins/other antihyperlipidemics (7.3%ASD vs. 5%noASD), immunologics 
(2%ASD vs. 0.7%noASD), and other metabolic agents (1.4%ASD vs. 1.1%noASD). Any psychotropic 
drug use was also significantly higher among adults with ASD (85%) as compared to adults 
without ASD (42%). The rates of specific psychotropic drug use among adults with and without 
ASD were: antidepressants (37%ASD vs. 26%noASD), antipsychotics (66%ASD vs. 20%noASD), 
anticonvulsants (59%ASD vs. 20%noASD), CNS stimulants (1.9%ASD vs. 1%noASD), and 
anxiolytics/hypnotics/sedatives (21%ASD vs. 11%noASD).   
PhD Dissertation Chapter 4 
134 
 
Number of Prescription Drug Claims (Table 2a and 2b) 
 On the average, adults with ASD had a significantly higher number of prescription drug 
claims per year (48ASD vs. 21noASD claims). The mean number of Rx claims per year for some 
specific therapeutic classes were also significantly higher in the ASD group as compared to no 
ASD group. Examples of such therapeutic classes were: gastrointestinal agents (4ASD vs. 1noASD 
claims), antiparkinsonian agents (2ASD vs. 0.5noASD claims), dermatologic agents (3ASD vs. 1noASD 
claims), respiratory agents (3ASD vs. 2noASD claims), alternative medicines/nutritional supplements 
(2ASD vs. 1noASD claims), hormone modifiers/steroids (2ASD vs. 1noASD claims), cardiovascular 
agents (3ASD vs. 2noASD claims), statins/other antihyperlipidemics (1ASD vs. 0.3noASD claim), and 
other metabolic agents (0.15ASD vs. 0.05noASD claims). The mean number of psychotropic drug 
claims per year for adults with ASD were four times the number of psychotropic drug claims for 
adults without ASD (25ASD vs. 6noASD claims). The difference in mean number of psychotropic 
drug claims between adults with and without ASD were highest for anticonvulsants (10ASD vs. 
1noASD claims), followed by antipsychotics (10ASD vs. 2noASD claims), antidepressants (4ASD vs. 
2noASD claims), anxiolytics/sedatives/hypnotics (1ASD vs. 0.5noASD claims), and CNS stimulants 
(0.1ASD vs. 0.05noASD claims).  Among users of specific drug classes, a similar pattern of higher 
average number of claims was observed for adults with ASD as compared to adults without ASD 
(Table 2b).  
General Polypharmacy (Six or more drug classes per year; Table 1 and Table 3) 
The rate of general polypharmacy was 48% among adults with ASD as compared to 32% 
among adults without ASD. The most common drug classes used among adults with ASD who 
used six or more drug classes in a year were: antipsychotics (78%), anticonvulsants (75%), 
antimicrobials (67%), dermatologic agents (64%), respiratory agents (59%), and gastrointestinal 
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agents (52%). The most common drug classes used among adults without ASD who used six or 
more drug classes in a year were: antimicrobials (84%), analgesics (77%), respiratory agents 
(67%), dermatologic agents (60%), gastrointestinal agents (52%), and antidepressants (50%). In 
an adjusted logistic regression analyses, adults with ASD were more likely to use six or more 
drug classes in a year as compared to adults without ASD (AOR = 1.17, 95% CI = 1.03-1.33), 
even after adjusting for the number of comorbidities.  
The number of adults with ASD with general polypharmacy increased significantly and 
consistently from 2000 (42%) to 2007 (64%). Significantly greater proportion of females with 
ASD (55%) used six or more drug classes in a year as compared to males with ASD (45%). 
Higher general polypharmacy rates for adults with ASD were observed in 41-64 age group 
(46%) as compared to the 22-40 age group and Whites (54%) as compared to African Americans 
(47%) and other race (44%). Adults with ASD residing in counties with primary care provider 
shortage (47%) and mental health specialist shortage (47%) had lower rates of general 
polypharmacy as compared to adults with ASD residing in counties with no workforce shortage. 
Around 52% of adults with ASD and a psychiatric comorbidity used six or more drug classes in 
a year as compared to 32% of adults with ASD but no psychiatric comorbidity. The highest use 
of general polypharmacy among adults with ASD was seen for those who had personality 
disorders (80%), schizophrenia (66%), and mood disorders (65%). Adults with ASD and a non-
psychiatric disorder also had significantly high rates of general polypharmacy (68%). Highest 
rates of general polypharmacy among adults with ASD were observed for those who had a 
gastrointestinal disorder (78%), cardiovascular/cerebrovascular disorders (74%), respiratory 
disorder (71%), muscoskeletal disorders (68%), and diabetes (64%).  Number of comorbidities 
was also associated with greater general polypharmacy rates among adults with ASD, where 
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65% of adults with three or more comorbid conditions, 41% of adults with two comorbid 
conditions, and 27% of adults with one comorbid condition had general polypharmacy. Around 
21% of adults with ASD with no comorbidity had general polypharmacy.  
Psychotropic Polypharmacy (Three or more psychotropic drug classes within a 90 day period; 
Table 1 and 3) 
Psychotropic polypharmacy was prevalent among 19% of adults with ASD as compared 
to 6% of adults without ASD. Adults with ASD were also more likely to use three or more 
psychotropic drug classes in a year as compared to adults without ASD in a multivariate logistic 
regression analyses (AOR = 1.40, 95% CI = 1.17-1.68).  Among adults with ASD, White race 
had significantly greater psychotropic polypharmacy rate as compared to African American and 
Other race.  Adults with ASD and a psychiatric comorbidity such as adjustment disorders (26%), 
mood disorders (31%), and schizophrenia (32%) had significantly higher rates of psychotropic 
polypharmacy. A little more than 24% of adults with ASD and epilepsy had psychotropic 
polypharmacy. The number of comorbidities was also associated with greater psychotropic 
polypharmacy rates among adults with ASD, where 24% of adults with three or more comorbid 
conditions, 17% of adults with two comorbid conditions, and 15% of adults with one comorbid 
condition used three or more psychotropic drug classes within a 90 day period.  Around 12% of 
adults with ASD with no comorbidity used psychotropic polypharmacy.  
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Predictors of polypharmacy among adults with ASD (Table not shown) 
 General Polypharmacy was significantly more likely to be prevalent among adults with 
ASD after 2004 as compared to before 2004 (AOR = 1.30, 95% CI = 1.01-1.68). Male adults 
with ASD were significantly less likely to use six or more drug classes per year as compared to 
female adults with ASD (AOR = 0.63, 95% CI = 0.50-0.80).  Adults with ASD residing in 
counties with lower education status were less likely to have general polypharmacy as compared 
to adults with ASD residing in counties with higher education status (q1 vs. q4; AOR = 0.43, 
95% CI = 0.27-0.66).  Adults with ASD who were either African American (AOR = 0.50, 95% 
CI = 0.34-0.72) and other race (AOR = 0.71, 95% CI = 0.53-0.96) were significantly less likely 
to have psychotropic polypharmacy as compared to Whites.  The number of comorbidities was 
strongly associated with greater likelihood of both general and psychotropic polypharmacy. 
Adults with ASD and three or more comorbidities were 12 times likely to use general 
polypharmacy (AOR = 11.14, 95% CI = 7.05-17.6) and three times likely to use psychotropic 
polypharmacy (AOR = 3.03, 95% CI = 1.76-5.22) as compared to adults with ASD but no 
comorbidity.  
  




 The burden of prescription drug use among Medicaid enrolled adults with ASD is 
substantially and significantly higher than adults without ASD.  The higher medication burden 
was not only restricted to greater proportion of adults with ASD using a prescription drug as 
compared to adults without ASD, but also extended to higher number of claims for prescription 
drugs. Adults with ASD use considerable number of prescriptions drugs that focus on psychiatric 
symptoms such as antipsychotics, antidepressants, anxiolytics/sedatives, as well as prescription 
drugs that alleviate medical issues including respiratory agents, gastrointestinal agents, 
cardiovascular agents, statins, and many others. Another notable finding of this study was that 
adults with ASD are more likely to use multiple drug classes as compared to adults without 
ASD. Almost half of the adults with ASD used six or more drug classes in a year and 19% of 
adults with ASD used three or more psychotropic drug classes within a 90 day period as 
compared to adults without ASD.  
With the rising concerns of off-label use and potential risks associated with multiple drug 
use among individuals with ASD (LeClerc & Easley, 2015), our study provides essential and 
timely information on prescription practices and the patterns of drug utilization among adults 
with ASD. Various studies in the past have focused on examining extent of medication use and 
polypharmacy among children and adolescents with ASD (Baribeau & Anagnostou, 2014; 
Barnard-Brak et al., 2014; Buck et al., 2014b; Coury et al., 2012a; Frazier et al., 2011b; Hirota et 
al., 2014; Logan et al., 2012; Oswald & Sonenklar, 2007a; Schubart, Camacho, & Leslie, 2014; 
Spencer et al., 2013), but this study is the first large sample study using real world data which 
has established rates of prescription drug use, types of prescription drugs, and the extent of 
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polypharmacy among adults with ASD as compared to a age, gender, and race matched sample 
of adults without ASD.  
Overall and Specific Prescription Drug Use 
 Almost 95% of adults with ASD had at least one prescription drug claim in a year as 
compared to 87% of adults without ASD.  A large majority of adults with ASD (85%) used a 
psychotropic drug which was significantly higher as compared to adults without ASD (42%). 
Within psychotropic drugs, the most common drug classes used by adults with ASD were 
antipsychotics (66%), followed by anticonvulsants (59%), and antidepressants (37%). As 
compared to previous studies (Esbensen et al., 2009; Lake et al., 2012) on psychotropic 
medication and polypharmacy use among adults with ASD, our psychotropic drug use was much 
higher than their rates of 64% (Lake et al. 2012) and 57% (Esbensen et al. 2009). Unlike the 
study by (Esbensen et al., 2009) which focused on a younger age group of 10-48 years old with 
ASD, our study included adults up till 64 years of age which could have been the reason for 
elevated rates of the medication use. The study by (Lake et al., 2012), even though informative, 
was restricted by the clinical settings, staff reports of medication use, and a low sample size 
which may not be representative of community dwelling adults with ASD. Nonetheless, the 
psychotropic drug use rate in our study was much higher than rates among children with ASD 
(27-64%), as observed in previous studies (Coury et al., 2012b; Khanna et al., 2013; Oswald & 
Sonenklar, 2007a; Spencer et al., 2013).  
Other than psychotropic drug use, this study also indicates that significantly higher 
proportion of adults with ASD use non-psychotropic drugs such as dermatologic agents (48%), 
respiratory agents (38%), gastrointestinal agents (32%), alternative medicine/nutritional 
supplements (25%), cardiovascular agents (23%), antiparkinsonian agents (23%), and 
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statins/other antihyperlipidemics (7.3%) as compared to adults without ASD. This is a critical 
finding, since most of the literature in the past focused on psychiatric needs of adults with ASD 
and utilization of psychotropic drugs (Baribeau & Anagnostou, 2014; Barnard-Brak et al., 2014; 
Buck et al., 2014b; Coury et al., 2012a; Frazier et al., 2011b; Hirota et al., 2014; Logan et al., 
2012; Oswald & Sonenklar, 2007a; Schubart et al., 2014; Spencer et al., 2013).   
A recent study by (Croen et al., 2015) using claims data from the Northern California 
Kaiser Permanente program showed a considerable and higher prevalence of non-psychiatric 
comorbidities such as immune conditions, gastrointestinal disorders, dyslipidemia, hypertension, 
and diabetes among adults with ASD as compared to adults without ASD. In fact, adults with 
ASD also had a higher prevalence of rare disorders such as stroke and Parkinsonism. Recently, a 
study by (Starkstein, Gellar, Parlier, Payne, & Piven, 2015) showed a 20% prevalence of 
Parkinsonism among a small sample of middle aged and older adults (49 years and above) with 
ASD. (Hollander, Wang, Braun, & Marsh, 2009) published a review on links between 
Parkinsonism and ASD which may have overlapping phenomenology such as repetitive 
behaviors and a common underlying involvement of the basal ganglia leading to symptoms that 
require similar medication management. Thus, our study findings support and extend the 
findings of Croen et al. (2015), underlining that adults with ASD have similar or higher non-
psychiatric needs which transforms into higher prescription drug use as well. Use of additional 
prescription drugs other than psychotropic drugs may be of bigger concern in a scenario where 
numerous medications are used off-label with no information on their benefit-risk ratios, limited 
data on beneficial effects of psychotropic drugs other than risperidone and aripiprazole (Warren 
et al., April 2011), and lack of well-designed clinical trials with large cohorts of adult ASD 
population (LeClerc & Easley, 2015).  
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Adults with ASD also had a significantly greater mean number of drug claims per year. 
For example, the mean number of claims per year for gastrointestinal agents and 
statins/antihyperlipidemics among adults with ASD were four times and almost three times, as 
that for adults without ASD respectively. Adults with ASD also had four times the mean number 
of drug claims for a psychotropic drug as compared to adults without ASD.  For some drug 
classes such as anticonvulsants, the mean number of claims per year were as high as 11 claims 
per year for adults with ASD as compared to a mean of 2 claims per year for adults without 
ASD. Such findings were consistent when restricted to users only, where adults with ASD still 
had higher mean number of claims in a year for most drug classes. Thus, adults with ASD may 
tend to use greater quantity of drugs in a year and may have considerably higher prescription 
drug needs and lead to greater prescription drug costs. (Croen et al., 2006) found that on an 
average Medicaid enrolled children with ASD have six drug prescriptions per year, and our study 
shows a rate eight times higher of 48 prescription encounters per year among adults with ASD.  
These results support findings from a study by (Esbensen et al., 2009) which found that young 
adults are less likely to discontinue medications and more likely to add medications over the 
course of the ASD treatment as they age. Such high prescription use among adults with ASD 
should be addressed by healthcare providers, policymakers, and state health insurance programs 
to determine their use justification and effectiveness.  
General Polypharmacy  
 In our study cohort, almost half of the adults with ASD used six or more drug classes in a 
year as compared to one-third of adults without ASD. One of the interesting findings in our study 
was the consistent increase (22% rise) in the proportion of adults with ASD with general 
polypharmacy from 2000 to 2007. The past decade was a critical transition period for ASD 
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awareness and better diagnoses (Autism Speaks, 2015), better Medicaid policies for prescription 
drug coverage (Arjun et al., 2011; Mauch et al., 2011) for individuals with mental health issues 
such as ASD, and increased mental health workforce could have been associated with better 
access to medications which may have resulted in number of individuals getting access to 
prescription drugs. Adults with ASD living in counties with workforce shortage of primary care 
and mental health specialty providers had lower rates of general polypharmacy as compared to 
those living in counties with no workforce shortage, underlining the important role of healthcare 
providers in access to prescription drugs for adults with ASD and emphasizing the need for 
better pharmacological guidelines to help providers to care for adults with ASD, and reduce 
excess prescription drug use whenever risks outweigh benefits.   
Among predictors of general polypharmacy for adults with ASD, female gender and 
older age was significantly associated with greater rates as compared to male gender and younger 
age group respectively. Even though not fully established, a few studies have shown that females 
with ASD are less likely to have repetitive behaviors but have a higher prevalence of other 
disorders such as intellectual disabilities, anxiety, schizophrenia, depression, bipolar disorders, 
cancer, diabetes, and some neurological disorders, putting them at a greater risk of using multiple 
classes of drugs (Croen et al., 2015; Rubenstein, Wiggins, & Lee, 2015). More than half of the 
adults with ASD and a psychiatric comorbidity used six or more drug classes in a year and the 
highest general polypharmacy rates were observed among those with comorbid schizophrenia 
(66%) and mood disorders (65%). Adults with ASD and a non-psychiatric comorbidity were also 
highly likely to use general polypharmacy (68%), with those with gastrointestinal disorders 
being associated with the highest rate of general polypharmacy at 78%, followed by 
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cardiovascular/cerebrovascular disorders (74%), and respiratory disorders (71%). Around 21% 
of adults with ASD but no comorbidity used six or more drug classes per year. 
Psychotropic Polypharmacy 
Psychotropic polypharmacy was observed among 19% of adults with ASD as compared 
to only 6% of adults without ASD. This rate of psychotropic polypharmacy was lower than that 
reported by (Lake et al., 2012) of 29%. This may be because we defined psychotropic 
polypharmacy as use of three or more drug classes within a period of 90 days after the first 
prescription fill. Nevertheless, the rate of 20% was still higher as that reported by studies among 
children with ASD (Coury et al., 2012b; Spencer et al., 2013). Adults with ASD who had 
adjustment disorders (26%), ADD/ADHD (30%), mood disorders (31%), schizophrenia (32%), 
and epilepsy (24%) had greater psychotropic polypharmacy rates as compared to adults with 
ASD but no respective comorbidities. Around 12% of adults with ASD but no comorbidity used 
three or more psychotropic drugs in a 90 day period. This finding shows that physicians 
frequently follow off label prescription practices without strong evidence for drugs such as 
selective serotonin reuptake inhibitors and drugs such as memantine for improvements in autistic 
symptoms such as irritability, hyperactivity, and aggression (Croen et al., 2015; Rubenstein et 
al., 2015). In addition, use of multiple classes of drugs at one time also increases the risks of 
adverse events such as tardive dyskinesia, a strong and lethal consequence of risperidone 
therapy, as well as cause weight gain, gastrointestinal issues, and increased self-injurious and 
extreme behaviors that further worsen ASD symptoms (Myers, 2007). This worsening of 
symptoms may contribute to greater use of emergency departments and hospitalizations and 
higher costs of healthcare for adults with ASD (Kato et al., 2013; Myer et al., 2013; Myers, 
2007).  




Our study is the first study to examine the extent of prescription drug use and 
polypharmacy rates among adults with ASD using a large population based setting and real 
world data. We used three state Medicaid database, a program that provides extensive pharmacy 
services and home and community based waivers to individuals with ASD (Ruble et al., 2005; 
Semansky, Xie, & Mandell, 2011b). Unlike a few other studies that have provided estimates of 
polypharmacy among very restricted number of adults with ASD in clinical settings, our study 
utilized a large sample of adults with ASD and provide estimates that are not restricted to 
psychotropic polypharmacy use. The current study is also the first study to estimate the average 
number of claims per year for specific therapeutic classes among adults with ASD and compare 
the rates with a matched sample of adults without ASD. State Medicaid programs have made 
consistent efforts to reduce prescription drug use and costs since early 2000’s (National 
Conference of State Legislatures, 2014) and our study highlights that adults with ASD, despite 
having many medical necessities, have substantial and/or off label use of prescription drugs as 
compared to other Medicaid beneficiaries.  
Limitations 
Despite the various strengths, our study was limited in some ways. Our study period was 
restricted and definition of ASD and many drug related policies/rebate programs have changed 
after 2008. In addition, the list of drug classes coded using NDCs may not have been exhaustive 
and some drugs which are provided in intravenous form (e.g. anticancer therapies) or via 
inpatient pharmacy are not reflected in the findings. We required adults with ASD to be 
continuously enrolled during the study period to allow capturing their full prescription drug 
utilization date, which could have excluded many individuals with sporadic Medicaid 
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enrollment. We did not match the ASD cases and no ASD controls on their enrollment period, 
which could have created certain baseline differences in the two groups. A majority of adults in 
the study were eligible by cash assistance indicating that our sample was primarily from low 
income and/or had high needs, thus rates of drug use may be overrepresented for both ASD and 
no ASD groups. Definitions of polypharmacy have varied substantially across studies but we 
used definitions that were most relevant to our population of interest. The rate of psychotropic 
polypharmacy may have been underestimated because we did not include patients with a 
psychotropic polypharmacy with any 90 day period in the year, rather restricted it to 90 days 
after the first prescription fill for a psychotropic drug.   
Conclusion 
Prescription drug, general polypharmacy, and psychotropic polypharmacy use among 
adults with ASD is significantly and substantially higher than adults without ASD. Half of adults 
with ASD use six or more drug classes in a year and almost 20% of them use three or more 
psychotropic drug classes within a 90 day period. Higher prescription drug use among adults 
with ASD was not restricted to psychotropic drugs, but extended to prescriptions alleviating 
other medical needs including cardiovascular agents, statins, immunologics, gastrointestinal 
agents, antiparkinsonian agents, and many others. The study highlights considerable 
pharmaceutical needs of adults with ASD as well as the practice of off-label prescription use for 
adults with ASD by healthcare providers. Even though various clinical trials have provided off-
label options for pharmacological treatment of adults with ASD, such treatments should still be 
administered based on case by case analysis with due consideration for risk-benefit ratios. 
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Table 1. Description of type of prescription drugs and polypharmacy by ASD status 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
    ASD No ASD   
Rx type    N Col% N Col % Sig. 
    1,772 100.0 5,320 100.0   
Any prescription drug     *** 
 >25 Rx claims 1,230 69.4 1,486 27.9  
 <=25 Rx claims 448 25.3 3,137 59.0  
 no Rx claim 94 5.3 697 13.1  
Dermatologic agents 850 48.0 1,711 32.2 *** 
Respiratory agents 679 38.3 1,821 34.2 *** 
Gastrointestinal agents 560 31.6 1,235 23.2 *** 
Alternative medicine/nutritional supplements 437 24.7 964 18.1 *** 
Cardiovascular agents 411 23.2 1,026 19.3 *** 
Antiparkinsonian agents 401 22.6 523 9.8 *** 
Statins/other antihyperlipidemics 129 7.3 266 5.0 *** 
Immunologics 35 2.0 37 0.7 *** 
Other metabolic agents 25 1.4 57 1.1 *** 
Antimicrobials 822 46.4 2,913 54.8 *** 
Analgesics  503 28.4 2,615 49.2 *** 
Hormone modifiers/steroids 281 15.9 909 17.1 *** 
CNS agents (excluding stimulants) 74 4.2 540 10.2 *** 
Antidiabetics 62 3.5 262 4.9 *** 
Blood modifiers 44 2.5 219 4.1 *** 
Anticancer§   13 0.7 121 2.3  
Psychotropic medications 1,510 85.2 2,254 42.4 *** 
Antipsychotics 1,170 66.0 1,072 20.2 *** 
Anticonvulsants 1,048 59.1 1,042 19.6 *** 
Antidepressants 652 36.8 1,361 25.6 *** 
Anxiolytics/Hypnotics/Sedatives 380 21.4 587 11.0 *** 
CNS stimulants  33 1.9 54 1.0 *** 
Polypharmacy           
General polypharmacy (>=6 classes) 856 48.3 1,727 32.5 *** 
Psychotropic polypharmacy (>=3 classes) 337 19.0 312 5.9 *** 
ASD vs. no ASD OR (95% CI ) AOR (95% CI)   
>=6 classes vs. <6 classes 1.74*** (1.56,1.95) 1.17*  (1.03,1.33)  
>=3 vs. <3 psychotropic classes 1.65*** (1.39,1.96) 1.40*** (1.17,1.68)   
Note: Based on chi-square estimates for fee for service enrolled individuals aged 22-64 years with no Medicare 
coverage and alive in IL, NY, and TX Medicaid from 2000-2008. ASD: Autism Spectrum Disorders; Rx: 
Prescription Drug; Col %: Column percentages; Fischer exact tests were conducted for variables with expected cell 
count <5. §Chi-square test was not conducted due to very low cell sizes. OR: Odds ratio; represents estimates from 
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multinomial logistic regression analyses using ASD status. AOR: Adjusted odds ratio; represents estimates from 
multinomial logistic regression analyses respectively after adjusting for cohort (before/after 2004), state, eligibility, 
county characteristics (metro status, median household income, above high school education, PCP shortage area, 
mental health specialist shortage area, and psychiatrist density), and number of comorbidities. Sig.: ***P < 0.001; 
**0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05.  
 
  




Table 2a. Mean number of claims for specific Rx classes per year 
Adults with and without ASD matched on age, race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
 
  ASD No ASD     
  Mean (SD) Mean (SD) 
Ratio of Means 
ASD vs. No ASD Sig. 
Any prescription drug 48.15 (37) 21.36 (29) 2.25 *** 
Respiratory agents 2.50 (6) 1.85 (6) 1.35 ** 
Antimicrobials 1.34 (3) 2.79 (8) 0.48 *** 
Anticancer 0.07 (2) 0.03 (1) 0.00  
Immunologics 0.02 (0) 0.03 (1) 0.00  
Cardiovascular agents 2.77 (7) 1.77 (6) 1.56 *** 
Analgesics 0.85 (2) 2.11 (5) 0.40 *** 
Blood modifiers 0.20 (1) 0.23 (2) 0.00  
Hormone modifiers/steroids 1.44 (4) 0.78 (3) 1.85 *** 
Statins/other antihyperlipidemics 0.74 (3) 0.27 (2) 2.74 *** 
Antidiabetics 0.40 (3) 0.50 (3) 0.80  
Dermatologic agents 2.83 (6) 1.16 (3) 2.44 *** 
Alternative medicine/nutritional 
supplements 2.38 (6) 0.87 (3) 2.74 *** 
Gastrointestinal agents 3.52 (8) 1.16 (4) 3.03 *** 
CNS agents (excluding stimulants) 0.37 (2) 0.35 (2) 1.00  
Antiparkinsonian agents 1.86 (4) 0.48 (2) 3.88 *** 
Other metabolic agents 0.15 (1) 0.05 (1) 3.00 *** 
Psychotropic medications 25.51 (21) 6.26 (12) 4.08 *** 
Antidepressants 3.93 (6) 1.79 (4) 2.20 *** 
Antipsychotics 9.90 (10) 2.04 (6) 4.85 *** 
Anticonvulsants 10.28 (14) 1.84 (6) 5.59 *** 
CNS stimulants 0.14 (1) 0.05 (1) 2.80 *** 
Anxiolytics/Hypnotics/Sedatives 1.25 (3) 0.54 (2) 2.31 *** 
Based on t-test estimates for fee for service enrolled individuals aged 22-64 years with no Medicare 
coverage and alive in IL, NY, and TX Medicaid from 2000-2008. Sig.: ***P < 0.001; **0.001 ≤ P < 
0.01; *0.01 ≤ P < 0.05.  
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Table 2b. Mean number of claims for specific Rx classes per year for users€ 
Adults with and without ASD matched on age ,race, and gender (n = 7,092) 
Medicaid Analytic Extract 2000-2008 (IL,NY, and TX) 
  ASD No ASD     
  Mean (SD) Mean (SD) 
Ratio of Means ASD 
vs. No ASD Sig. 
Any prescription drug 50 (36) 25 (30) 2.00 *** 
Respiratory agents 7 (8) 5 (8) 1.40 ** 
Antimicrobials 3 (3) 5 (10) 0.60 *** 
Anticancer 10 (17) 6 (7) 1.66  
Immunologics 1 (0) 4 (6) 0.25 *** 
Cardiovascular agents 12 (9) 9 (10) 1.33 *** 
Analgesics 3 (3) 4 (6) 0.75 *** 
Blood modifiers 8 (6) 6 (6) 1.33  
Hormone modifiers/steroids 9 (6) 5 (5) 1.80 *** 
Statins/other antihyperlipidemics 10 (5) 5 (4) 2.00 *** 
Antidiabetics 12 (8) 10 (9) 1.20  
Dermatologic agents 6 (7) 4 (5) 1.50 *** 
Alternative medicine/nutritional 
supplements 10 (8) 5 (6) 2.00 *** 
Gastrointestinal agents 11 (10) 5 (6) 2.20 *** 
CNS agents (excluding stimulants) 9 (7) 3 (4) 3.00 *** 
Antiparkinsonian agents 8 (6) 5 (5) 1.60 *** 
Other metabolic agents 10 (5) 5 (4) 2.00 *** 
Psychotropic medications 30 (20) 15 (16) 2.00 *** 
Antidepressants 11 (6) 7 (6) 1.57 *** 
Antipsychotics 15 (9) 10 (10) 1.50 *** 
Anticonvulsants 17 (14) 9 (9) 1.88 *** 
CNS stimulants 7 (6) 5 (4) 1.40 ** 
Anxiolytics/Hypnotics/Sedatives 6 (5) 5 (5) 1.20 ** 
Based on t-test estimates for fee for service enrolled individuals aged 22-64 years with no Medicare coverage 
and alive in IL, NY, and TX Medicaid from 2000-2008.  
€Only among those who used specific drug classes. 
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05.  
  




Table 3. Description of Sample by General  and Psychotropic Polypharmacy Among Adults 
with ASD (n = 1,772) 





(6 or more)   
Psychotropic 
Polypharmacy (3 or 
more)   
    N Row% Sig. N Row%   
ALL   856 48% *** 337 19% Sig. 
Identification year   ***     
 2000 260 42.1  110 17.8  
 2001 113 45.2  48 19.2  
 2002 82 44.3  31 16.8  
 2003 81 50.0  27 16.7  
 2004 86 52.8  27 16.6  
 2005 68 52.7  30 23.3  
 2006 54 58.7  24 26.1  
 2007 112 64.4  40 23  
Sex    ***    
 female 281 55.5  101 20  
 male 575 45.4  236 18.6  
Age    ***    
 22-40 700 46.1  282 18.6  
 41-64 156 61.2  55 21.6  
Race    ***   *** 
 White 358 54.4  166 25.2  
 African American 172 47.3  50 13.7  
 Other 326 43.5  121 16.1  
Eligibility    **   ** 
 Cash 681 46.8  259 17.8  
 No cash 175 55.4  78 24.7  
    **    
 Medically needy 50 64.9  19 24.7  
  
Not medically 
needy 806 47.6  318 18.8   
County 
Characteristics              
Metro          
 yes  686 47.3  264 18.2  
 no 170 52.8  73 22.7  
PCP shortage area       
 yes 753 47.8  304 19.3  
 no 103 52.3  33 16.8  
Mental health specialist shortage area    
 yes 682 47.6  268 18.7  




Table 3. Description of Sample by General  and Psychotropic Polypharmacy Among Adults 
with ASD (n = 1,772) 





(6 or more)   
Psychotropic 
Polypharmacy (3 or 
more)   
    N Row% Sig. N Row%   
ALL   856 48% *** 337 19% Sig. 
 no 174 51.5  69 20.4  
Psychiatrists density       * 
 high 622 47.0  234 17.7  
 low 234 52.0  103 22.9  
 Median household income level *    
 q1 148 51.7     
 q2 31 44.9     
 q3 184 54.4     
 q4 493 45.7     
HS education and above  *   ** 
 q1 494 46.1  185 17.3  
 q2 34 42.5  10 12.5  
 q3 130 53.3  62 25.4  
  q4 198 52.5  80 21.2  
Comorbidities             
Psychiatric Comorbidity  ***     * 
 yes 750 52.1  289 20.1  
 no 106 31.9  48 14.5  
Adjustment Disorders      
 yes 26 44.8  15 25.9  
 no 830 48.4  322 18.8  
Anxiety       * 
 yes 117 54.2  53 24.5  
 no 739 47.5  284 18.3  
ADD/ADHD   *   *** 
 yes 82 56.2  43 29.5  
 no 774 47.6  294 18.1  
Intellectual Disabilities  *    
 yes 627 50.9  224 18.2  
 no 229 42.3  113 20.9  
Mood Disorders   ***   *** 
 yes 165 64.5  79 30.9  
 no 691 45.6  258 17  
       
       




Table 3. Description of Sample by General  and Psychotropic Polypharmacy Among Adults 
with ASD (n = 1,772) 





(6 or more)   
Psychotropic 
Polypharmacy (3 or 
more)   
    N Row% Sig. N Row%   
ALL   856 48% *** 337 19% Sig. 
Schizophrenia   ***   *** 
 yes 194 66.0  20 45.5  
 no 662 44.8  317 18.3  
Non-Psychiatric Comorbidity ***    
 yes 481 67.9  137 19.4  
 no 375 35.2  200 18.8  
Gastrointestinal Disorders  ***    
 yes 173 77.6  48 21.5  
 no 683 44.1  289 18.7  
Respiratory Disorders  ***    
 yes 190 71.2  57 21.3  
 no 666 44.3  280 18.6  
Muscoskeletal Disorders  ***    
 yes 147 68.1  35 16.2  
 no 709 45.6  302 19.4  
Cardiovascular/Cerebrovascular Disorders ***    
 yes 179 74.0  50 20.7  
 no 677 44.2  287 18.8  
Diabetes    *    
 yes 40 63.5  
- 
 
 no 816 47.7   
Epilepsy    ***   ** 
 yes 255 63.3  98 24.3  
 no 601 43.9  239 17.5  
Number of comorbidities  ***   *** 
 None 33 20.6  19 11.9  
 1 101 27.3  53 14.3  
 2 151 41.3  61 16.7  
  3 or more 571 65.2   204 23.3   
Note: Based on chi-square estimates for fee for service enrolled individuals aged 22-64 years with no 
Medicare coverage and alive in IL, NY, and TX Medicaid from 2000-2008.ASD: Autism Spectrum 
Disorders; Rx: Prescription Drug; PCP: Primary Care Provider; HS: High School. Fischer exact tests were 
conducted for variables with expected cell count <5.  
Chi-square tests were not conducted and findings are not presented for cell sizes ≤11  
Sig.: ***P < 0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P < 0.05. 
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In the past decade, awareness about autism spectrum disorders (ASD) has increased 
(Autism Speaks, 2015) and more efforts are being put towards providing quality care to 
individuals affected by this condition. Even though vast number of studies have been conducted 
on health services utilization, health economics, and outcomes about children with ASD, there is 
extant literature on healthcare utilization and expenditures about adults with ASD. In addition, 
most existing studies on adults with ASD are restricted to small sample sizes, clinical or 
specialty settings which doesn’t allow generalizability. The current dissertation research aimed to 
examine the burden of healthcare needs, healthcare utilization, and expenditures among adults 
with ASD as compared to a matched sample of adults without ASD. Considering the increasing 
prevalence of ASD in children and as large numbers of children with ASD transition to adults 
(Brugha et al., 2011; Developmental Disabilities Monitoring Network Surveillance Year 2010 
Principal Investigators & Centers for Disease Control and Prevention (CDC), 2014), our study is 
timely and critical for understanding the scope and nature of healthcare utilization and costs 
related to adults with ASD. In general, all three studies conducted as part of this research 
highlighted that adults with ASD are an at-risk population with high healthcare needs which 
transforms into substantial use of healthcare services and expenditures.  
Our first study examined the prevalence of psychiatric, non-psychiatric comorbidities, 
other health conditions, healthcare utilization, and expenditures among adults with ASD as 
compared to adults without ASD enrolled in a fee for service Medicaid programs from 2000-
2008. The study findings included: 1) Psychiatric comorbidities such as depression, anxiety, 
schizophrenia, and attention deficit disorders are higher among adults with ASD as compared to 
adults without ASD, an observation similar to children with ASD, which has been shown in few 
small sample studies (Lugnegard et al., 2011a; Lunsky et al., 2009; Unenge Hallerback et al., 




2012); 2) Adults with ASD have lower yet modestly similar rates of non-psychiatric 
comorbidities as adults without ASD, except for gastrointestinal conditions which were 
significantly greater in the ASD group; 3) Adults with ASD also exhibit a significantly higher 
prevalence of other co-occurring conditions such as epilepsy, thyroid disease, lipid metabolism 
disorders, genito-urinary disorders, skin disorders, and infections as compared to adults without 
ASD, similar to findings of recent study by (Croen et al., 2015); 4) The burden of healthcare use 
such as average number of outpatient visits and prescription drug claims per year for adults with 
ASD were significantly greater as compared to adults without ASD; 5) Average number of 
emergency room visits per year were not significantly different and hospitalizations per year 
were lower among adults with and without ASD; 6) Adults with ASD have a higher total and 
specific expenditures for outpatient office visits, emergency room visits, and prescription drugs; 
and 7) The presence of a psychiatric and/or a non-psychiatric comorbidity may not contribute 
highly to the differences in healthcare utilization and expenditures between an age, gender, and 
race matched cohort of adults with and without ASD, but have a significant contribution to 
higher healthcare utilization and expenditures among adults with ASD.  
 Our second study examined the trends and rates of all and specific emergency department 
(ED) visits among adults with and without ASD. The main study findings were: 1) The number 
of adults with ASD using ED over time increased as shown in the 6 year trend; 3) Public payers 
including Medicaid/Medicare account for 80% of insurance coverage for ED use among adults 
with ASD; 3) For one-third of adults with ASD using the ED resulted in an inpatient hospital 
admission as compared to one-tenth of adults without ASD; 4)  Both psychiatric and non-
psychiatric ED visits are more common among adults with ASD as compared to adults without 
ASD; 5) Overall, any injury visits were much less prevalent in adults with ASD as compared to 




adults without ASD; 6) The most commonly associated reasons for ED visits among adults with 
ASD included: epilepsy, falls, schizophrenia, respiratory disorders, bipolar disorders, and 
depression; 7) A significantly greater proportion of adults with ASD reported self-harm, 
poisoning, and suicidal ideation during the ED visits as compared to adults without ASD; 8) 
Adults with ASD had 2.3 times the mean total ED costs for adults without ASD; and 9) The 
mean ED costs for psychiatric, non-psychiatric, as well as an injury visit was significantly higher 
for adults with ASD as compared to adults without ASD.  
 The third study of this three part research assessed the medication burden among adults 
with and without ASD. This study focused on examining the extent of prescription drug use and 
polypharmacy use among adults with and without ASD and the findings included: 1) Almost 
95% of adults with ASD had at least one prescription drug claim with a mean of 48 unique drug 
claims per year; 2) Psychotropic drug use among adults with ASD was extremely high (85%), 
with the highest use of antipsychotics, followed by anticonvulsants, antidepressants, and 
anxiolytics/sedatives/hypnotics; 3) Use of prescription drug classes among adults with ASD were 
not restricted to psychiatric needs and a high proportion of adults with ASD also had drug claims 
for respiratory agents, immunologics, cardiovascular agents, hormone modifiers/steroids, 
statins/antihyperlipidemics, dermatologic agents, alternative medicines/supplements, 
gastrointestinal agents, and antiparkinson agents; 4) The mean number of prescription drug 
claims for such drug classes were higher among adults with ASD as compared to adults without 
ASD; 5) Rates of general (48%) and psychotropic polypharmacy (19%) among adults with ASD 
were high and they were more likely to use at least six or more prescription drug classes in a year 
and 3 or more psychotropic drug classes in a 90 day period as compared to adults with ASD; 6) 
From 2000 to 2008, the proportion of adults with ASD who used general polypharmacy showed 




a sustained and significant rising trend; 7) Female adults with ASD were found to be more likely 
to have general polypharmacy as compared to male adults with ASD; 8) Number of comorbid 
conditions was the most critical and significant determinant of general and psychotropic 
polypharmacy in a specified period of time. 
 There are several themes that emerge from the findings of our three part research: 
1. Unlike most previous studies which have reported high prevalence of psychiatric 
comorbidities among individuals with ASD, our study showed that adults with ASD have 
similar rates of non-psychiatric needs such as gastrointestinal disorders ,cardiovascular 
disorders, diabetes, lipid disorders, respiratory disorders, and many others as compared to 
adults without ASD. This finding was consistent in all three studies where adults with 
ASD showed high prevalence of these comorbidities, visited ED for such reasons, and 
also showed a higher prescription drug use for similar drug classes as compared to adults 
without ASD.  A recent study by (Croen et al., 2015) indicated a similar pattern where 
adults with ASD were not only afflicted by psychiatric comorbid conditions but also had 
a high occurrence of other health conditions.  
2. Injurious behaviors have long been reported among individuals with ASD (Adler et al., 
2014; Matson & Rivet, 2008), but very few studies have examined the actual implication 
of such behaviors. Our second study on ED use among adults with ASD showed that 
adults with ASD have a high degree of self-harm behaviors and suicidal ideation which 
leads to ED visits and possibly higher hospitalization rates.  
3. Healthcare services use and costs among children with ASD have been established to be 
extremely high to the society as well as individuals with ASD (Croen et al., 2006; 
Lokhandwala et al., 2012; Wang & Leslie, 2010a; Wang et al., 2012). However, there is 




no current literature about the healthcare utilization and costs among adults with and 
without ASD.  Our three part research is the first of its kind to report a high healthcare 
utilization and expenditures in a large sample of adults with ASD. The total mean 
Medicaid expenditures for adults with ASD were 1.6 times higher than adults without 
ASD.  There have been previous studies that have shown increasing Medicaid 
expenditures for individuals with ASD (Mandell et al., 2006; Mandell, 2008a; Rosenberg 
et al., 2010a; Semansky et al., 2011a). With the increasing concern of rising Medicaid 
expenditures, our study provides substantial evidence about the overall and specific cost 
burden on Medicaid of providing healthcare services to adults with ASD.   
4. Multiple medication use or polypharmacy is a critical issue among individuals with ASD 
due to lack of gold standard treatments and use of off-label prescription drugs (Dalsgaard 
et al., 2013; Frazier et al., 2011a; Warren et al., April 2011; Zito et al., 2008). Our study 
on medication burden among adults with ASD showed that there might not only be 
multiple classes of drugs used in a year, which many a time is a necessity, but 
psychotropic medication use among adults with ASD is very high which is of concern, 
since other than risperidone and aripiprazole (new generation antipsychotics), most of the 
psychotropic drugs are used off-label. This was evident in our study when individuals 
with ASD but no psychiatric or non-psychiatric comorbidity used three or more 
psychotropic drugs concurrently. Other than off-label use, side effects of psychotropic 
drugs such as risperidone which can cause serious adverse events is also a concern for 
adults with ASD. The effectiveness of these drugs have also received only medium to 
low level rating of evidence (Warren et al., April 2011). This highlights a great need for 
appropriate pharmacological guidelines for the treatment of adults with ASD.   





Adults with ASD have high healthcare needs attributed to their core ASD symptoms as 
well as high prevalence of comorbid conditions. The implications of such needs are well 
reflected in our study findings where adults with ASD were shown to have higher healthcare 
utilization and expenditures as compared to adults without ASD.  As noted in many previous 
studies (Heidgerken et al., 2005; Imran et al., 2011; Liptak et al., 2006; Miller, 2015; Piven et al., 
2011), ASD knowledge and training among physicians and other specialty care providers have 
been reported to be low, and there is a lack in self-reported confidence among providers in being 
able to correctly identify ASD, understand their symptoms and pharmacological needs, and 
provide quality care that improves disease prognosis and reduce morbidity. In a scenario where 
there is no standard cure and two approved medications have only medium to low level 
effectiveness (Warren et al., April 2011), greater focus is needed to provide easy access to early 
behavioral intervention services, which have been shown to significantly improve prognosis of 
this condition (Autism Speaks, 2013; Bailey et al., 2004; Reichow, 2012). In addition, further 
studies are needed to address the poor rating of patient provider communication and greater 
unmet healthcare needs that have been reported by adults with ASD in a few studies (Magiati et 
al., 2014; Nicolaidis et al., 2013). 
 Medicaid coverage of healthcare services for adults with ASD is substantial and state 
programs bear the high costs of such services. Care should be directed towards managing both 
psychiatric and non-psychiatric needs of adults with ASD in the primary as well as specialty care 
settings. Future interventions must focus on better ASD training and education of healthcare 
providers as well as guidelines for treatment that assure quality and well-coordinated care for 
adults with ASD.  (Miller, 2015) examined the extent of ASD knowledge among nurses working 
in an ED and found that more than half of ED nurses surveyed reported having accurate 




knowledge, correctly identified causes of visit and comorbidities, and chose appropriate 
interventions for ASD cases. However, nurses still reported having limited knowledge and 
resources available to them and felt a need for ASD education early on in their training. This 
perceived need to overcome gaps in ASD related care among nurses may also be true for 
physicians and other healthcare providers. Future studies should examine the association of 
quality and consistency of care received by adults with ASD in the primary care setting with a 
patient’s subsequent ED use, frequency of ED use, hospital admissions, and healthcare costs.  
Future Research 
The area of health outcomes for adults with ASD requires further investiagtion that will 
help establish the varying healthcare needs of this population and their health related quality of 
life. Currently, there are no epidemiological studies on prevalence of ASD in adults in the US, 
leaving little information on the exact burden of this condition in the older population. In 
addition, bigger clinical trials and more advanced research is needed to develop interventions 
that work on addressing the ASD core symptoms and improve daily functioning and 
productivity.  As a follow up to our findings on psychotropic drug use among adults with ASD, 
future studies should examine the long term association of psychotropic drug use among adults 
with ASD on development of new conditions such as obesity, diabetes, and psychiatric 
conditions which are caused by high use of antipsychotics. More studies are needed to identify 
the employment opportunities for adults with ASD and state and federal policies that support 
such plans. There is also very little information on the distribution of patients with ASD across 
rehabilitation hospitals, residential facilities and intermediate care facilities that undermine their 
reported healthcare utilization, overall expenditures, and lifetime costs when analyzing a single 
data source such as state Medicaid database.  





 Our three part research have provided very useful insights on healthcare needs, 
utilization, and expenditures among adults with ASD. The current dissertation study utilized 
secondary databases such as the Nationwide Emergency Database Sample (NEDS) by Agency of 
Healthcare and Research Quality (AHRQ) and three-state Medicaid databases, both of which 
have significant policy implications. Our study not only provided an exploratory analysis of the 
prevalence of health conditions among adults with ASD, but also tested the association between 
comorbidities and healthcare utilization and expenditures. The three studies have filled some of 
the gaps in the literature and provide information about the healthcare needs of adults with ASD.  
Limitations 
 The current research work did not provide a patient reported needs, and thus may not 
include needs of home based care, daily functioning, and access to services other than healthcare. 
In addition, we did not include patients who were using home and community based waivers, 
were part of residential facilities, and/or intermediate care facilities, who may be much sicker 
and have worse outcomes than adults with ASD who are able to use Medicaid covered services 
through caretakers or on their own. This research was primarily cross sectional and we could not 
assess the longitudinal healthcare utilization and expenditures. The current research also did not 
assess costs including indirect costs and costs due to lost productivity which contribute highly to 
the substantial lifetime costs of individuals with ASD.  
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